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ABSTRACT 
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I Abstract 
The development of a therapeutic human papillomavirus (HPV) vaccine is important to cure people 
that are already infected with HPV. However, multiple immune evasion mechanisms have been 
described for HPV-induced malignancies, including altered expression of antigen processing 
machinery (APM) components. These changes are able to directly influence epitope presentation and 
thus hamper CD8 T cell responses and are therefore regarded as considerable challenges in the 
development of a therapeutic vaccine.        
 Until now, no systematic analysis of the APM had been performed in a large array of different 
HPV-positive tumor samples. Therefore, a systematic analysis of APM component expression on the 
mRNA level was performed in a comprehensive collection of HPV16-positive tumor cell lines in this 
study. The experiments revealed an upregulation of several APM components, which were 
subsequently investigated on the protein level. This analysis showed that the only component that was 
consistently upregulated in HPV16-positive tumor cells was the endoplasmic reticulum 
aminopeptidase 1 (ERAP1). Immunohistochemistry revealed that ERAP1 was more highly expressed 
in cervical intraepithelial lesions and cervical cancer than in nonmalignant cervical epithelium. 
Mechanisms that could account for ERAP1 overexpression were investigated. Single nucleotide 
polymorphisms (SNPs) of ERAP1 were analyzed in selected HPV-negative and HPV16-positive cell 
lines. Further, knockdown of HPV16 E6 and E7 was performed to investigate whether HPV 
oncogenes may influence ERAP1 expression levels. However, no influence of SNPs or the HPV 
oncogenes could be observed.         
 ERAP1 plays a key role in editing the human leukocyte antigen (HLA) class I epitope 
repertoire. Therefore, we further focused on the question whether ERAP1 overexpression influences 
HPV16 E6 and E7 epitope presentation. To do so, an ERAP1 siRNA-mediated knockdown approach 
was established. HPV16-positive cells lines with attenuated ERAP1 expression or normal 
(over)expression were compared. To assess epitope presentation, a panel of HPV16-derived epitopes 
was analyzed using mass spectrometry. Additionally, T cell lines were generated from healthy donors, 
who showed memory responses against HPV16 epitopes. T cell lines were used to investigate the 
influence of ERAP1 expression levels in target cells on HPV16-specific CD8 T cell-mediated 
cytotoxicity. Mass spectrometry revealed that ERAP1 attenuation had no influence on presentation of 
the selected epitopes. Conversely, T cell assays showed that cytotoxicity against some HPV16-derived 
epitopes is influenced by ERAP1 expression levels, including one T cell line that showed enhanced 
killing towards HPV16-positive cells upon ERAP1 attenuation.     
 Taken together, ERAP1 was observed to be highly expressed in HPV-induced malignancies. It 
was shown that ERAP1 influences the presentation of some, but not all, HPV16 E6 and E7-derived 
epitopes in an epitope-specific and tumor-specific way. In conclusion, ERAP1 overexpression can 
inhibit some HPV16-specific CD8 T cell responses and thus possibly represents a novel immune 
evasion mechanism of HPV-induced malignancies. 
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II Zusammenfassung 
Die Entwicklung eines therapeutischen Impfstoffes gegen das humane Papillomvirus (HPV) ist 
wichtig um Menschen zu heilen, die bereits mit HPV infiziert sind. Für HPV-induzierte bösartige 
Tumore wurden jedoch mehrere Mechanismen der Umgehung einer Immunantwort beschrieben. Dazu 
zählt die veränderte Expression von Komponenten der Antigenprozessierung. Diese Veränderungen 
können die Präsentation von Epitopen und daher CD8 T-Zell-Antworten direkt hemmen und werden 
als erhebliche Herausforderung in der Entwicklung eines therapeutischen Impfstoffes betrachtet. 
 Bis heute wurde keine systematische Analyse von Komponenten der Antigenprozessierung in 
einer großen Anzahl von verschiedenen HPV-positiven Tumorproben durchgeführt. Daher wurde in 
dieser Arbeit eine systematische Analyse der Expression von Komponenten der Antigenprozessierung 
auf Ebene der mRNA in einer umfassenden Sammlung von HPV16-positiven Tumorzelllinien 
ausgeführt. Generell zeigen die Experimente eine Hochregulierung von mehreren Komponenten, die 
darauffolgend auf Proteinebene untersucht wurden. Diese Analyse zeigte, dass die einzige 
Komponente, die in HPV16-positiven Tumorzellen konsistent hochreguliert war, die 
Endoplasmatische Retikulum Aminopeptidase 1 (ERAP1) ist. In immunhistochemischen Färbungen 
von prämalignen Zervix-Läsionen und Zervixkarzinomen war ERAP1 höher exprimiert als im nicht 
veränderten Zervixepithel. Es wurden Mechanismen untersucht, die für eine Überexpression von 
ERAP1 verantwortlich sein könnten. Einzelnukleotid-Polymorphismen von ERAP1 wurden in 
ausgewählten HPV-negativen und HPV16-positiven Zellen analysiert. Außerdem wurde ein 
Knockdown von HPV16 E6 und E7 durchgeführt, um zu untersuchen, ob HPV-Onkogene einen 
Einfluss auf die Expressionsstärke von ERAP1 haben. Es wurde jedoch kein Einfluss von 
Einzelnukleotid-Polymorphismen oder HPV-Onkogenen beobachtet.     
 ERAP1 spielt eine Schlüsselrolle im Editieren des Epitop-Repertoires, das auf humanen 
Leukozytenantigen (HLA) Klasse I-Molekülen präsentiert wird. Aus diesem Grund haben wir uns auf 
die Frage konzentriert, ob die Überexpression von ERAP1 die Präsentation von HPV16 E6- und E7-
Epitopen beeinflusst. Um diese Frage zu beantworten, wurde ein siRNA-vermittelter Knockdown von 
ERAP1 etabliert. HPV16-positive Zelllinien mit abgeschwächter ERAP1-Expression wurden mit 
Zellen mit für sie normaler Überexpression verglichen. Um die Epitop-Präsentation zu untersuchen, 
wurde eine Gruppe von HPV16 E6- und E7-Epitopen durch Massenspektrometrie analysiert. Zudem 
wurden T-Zelllinien von gesunden Spendern generiert, die immunologische Gedächtnisantworten 
gegen HPV16-Epitope zeigten. T Zelllinien wurden verwendet, um den Einfluss der Expressionsstärke 
von ERAP1 in Zielzellen auf HPV16-spezifische CD8 T-Zell vermittelte Zytotoxizität zu untersuchen. 
Die Massenspektrometrie ergab, dass eine geringere ERAP1-Expression keinen Einfluss auf die 
Präsentation der ausgewählten Peptide hatte. Im Gegensatz dazu war die Zytotoxität gegen HPV16-
Epitope von der Expressionsstärke von ERAP1 beeinflusst. Eine T Zelllinie wies verstärkte 
Zytotoxizität gegen HPV16-positive Zielzellen mit verringerter ERAP1 Expression auf.  
 Zusammenfassend wurde beobachtet, dass ERAP1 stark in HPV-induzierten Tumoren 
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exprimiert wird. Es wurde gezeigt, dass ERAP1 die Präsentation von manchen, aber nicht allen, 
HPV16 E6- und E7-Epitopen in einer epitopspezifischen und tumorspezifischen Art beeinflusst. Die 
Überexpression von ERAP1 kann manche HPV16-spezifische CD8 T Zell-Antworten hemmen und 
stellt daher einen möglichen neuen Mechanismus von HPV-induzierten Tumoren zur Umgehung der 
Immunantwort dar.  
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1 Introduction 
1.1 The immune system 
Every day, we are surrounded by viruses, bacteria, parasites and fungi and many of these have the 
potential to cause disease. The immune system has evolved from simplicity in invertebrates to 
complexity in vertebrates as the body’s defense against infection. Vaccinology has its roots in the 18th 
century when Edward Jenner investigated the disease smallpox. He observed that inoculation of 
individuals with a moderate disease, cowpox, conferred protection to infection with smallpox and he 
called this procedure “vaccination” for the first time in history (1).     
 The immune system is composed of primary and secondary lymphoid organs. In the primary 
lymphoid organs, the thymus and the bone marrow, leukocytes are generated. In secondary lymphoid 
organs, the lymph nodes, the spleen and the mucosal lymphoid tissue in the nasal, respiratory and 
urogenital tract, the gut and other mucosae, leukocytes are maintained and immune responses are 
initiated. Protection of our body by immunological recognition is carried out by the two branches of 
the immune system: the innate immune system and the adaptive. Usually, the innate immune system is 
the first barrier that provides a fast response. Cells of the innate immune system express several 
pattern recognition receptors (PRR) and each receptor recognizes a feature shared by many pathogens. 
The adaptive immune system has a delayed response during infection, but it is very specific and able 
to establish long term protection, which is called immunological memory (1). Both the innate and the 
adaptive branch of the immune system have cellular and humoral effector systems. 
 
1.1.1 The adaptive immune system 
The adaptive immune response takes longer to form, because for its induction antigen uptake by 
antigen presenting cells (APCs) in secondary lymphoid organs is needed. Mostly, these APCs are 
dendritic cells (DCs) (see 1.1.2). APCs take up antigens, degrade them intracellularly and present 
protein fragments, i.e. peptides, derived from for instance a pathogen, on their surface. Antigen 
recognition is conducted by T cells which express antigen receptors that have been rearranged during 
their maturation in the thymus. The adaptive immune system has another powerful subset of antigen 
recognizing cells, B cells. These cells mature in the bone marrow and also undergo receptor gene 
rearrangements. The receptor gene rearrangements are called V(D)J recombination. In each human 
individual, there are lymphocytes of at least 108 different specificities highlighting the huge repertoire 
that, in theory, can recognize virtually any antigen (1).     
 When a B or a T cell recognizes its antigen it undergoes clonal expansion in order to produce 
many identical cells to fight the infection. These activated and proliferating cells are called effector 
cells. T and B cells operate in a different way. B cells differentiate into plasma cells and produce 
antibodies, which are the secreted form of their antigen receptor, known as adaptive humoral 
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immunity. On the contrary, T cells develop into different subsets and produce specific cytokines and 
cytotoxic effector functions, known as adaptive cell-mediated immunity. Depending on their cell 
surface proteins, T cells are classified into CD4 and CD8 T cells. In general, CD4 T cells are destined 
to become T helper cells (Th) which recognize antigens derived from extracellular pathogens that have 
been taken up by APCs and presented on the major histocompatibility complex class II (MHC II). 
Additionally, Th cells help B cells to produce antibodies and cytotoxic T cells (CTLs) to mature. The 
majority of CD8 T cells become CTLs and respond to an MHC I presented antigen which is derived 
from cytosolic proteins (1).  
 
1.1.2 Antigen presenting cells 
APCs are crucial to induce cell-mediated immunity by T cells. There are three professional antigen 
presenting cell types: DCs, macrophages and B cells. Of these cell types, DCs are most important in 
vertebrates in orchestrating an effective immune response (2). However, macrophages and B cells are 
also able to present antigens and activate T cells, but they do not have the potential to guide the 
direction of an immune response. Thus, this section will focus on the description of DCs.   
 DCs as highly phagocytic sentinel cells have the unique ability among APCs to not only sense 
pathogens and to process them into peptides for T cell recognition, but also to direct the specificity, 
magnitude and polarity of immune responses. These specialized cells can be found in the blood, 
epithelia and lymphoid tissues (2). Ralph Steinmann discovered and named this unique cell type in the 
1970s (3). Importantly, DCs form the interface between innate and adaptive immunity and they confer 
peripheral tolerance to self-peptides, which can be derived from engulfed dead cells (4). DCs can 
differentiate between self and non-self antigens depending on the context of uptake. Quiescent DCs 
take up soluble proteins or apoptotic bodies from cellular turnover and since these uptakes do not 
activate DCs, they do not express co-stimulatory molecules and induce either deletion or anergy of 
autoreactive T cells (5). However, DCs express PRRs such as toll-like receptors (TLRs) to sense non-
self antigens. PRRs recognize, for instance, lipopolysaccharides (LPS) found in the outer membrane of 
gram-negative bacteria or double stranded RNA (dsRNA) of viruses. When these receptors get 
triggered, DCs undergo maturation, upregulate MHC molecules and co-stimulatory molecules and 
secrete pro-inflammatory cytokines such as interleukin (IL)-1α, IL-1β, IL-6 and interferon (IFN)α (1). 
 DCs are also specialized in antigen processing because they are capable of presenting 
endogenous and exogenous antigens on both MHC I and MHC II molecules, respectively. 
Furthermore, they can cross-present antigens, which means that an exogenously derived antigen is 
presented on MHC I (6). Cross-presentation is crucial in immune responses directed against 
extracellular pathogens. It is important to note that cross-presentation also works the other way around 
with endogenous antigens that are presented on MHC II (7). Both types of cross-presentation are under 
intensive investigation (8). Recently, Alloatti and colleagues observed that efficient cross-presentation 
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only takes place when the activating TLR ligand and sufficient antigen were engulfed simultaneously 
(9). This reflects the natural situation in which DCs only become activated and induce immune 
responses when pathogens are present.        
 The activation of a naïve T cell only happens if three signals, coming from the same DC, are 
delivered to a T cell (Figure 1.1 A) (1). The first signal is antigen specific and results from the binding 
of the cognate peptide:MHC complex to the T cell receptor (TCR) with help of the co-receptor CD4 or 
CD8. Signal 2 is delivered by molecules belonging to the B7 family on the APC and CD28 on the T 
cell. This second signal is also called the co-stimulatory signal and is crucial for clonal expansion 
(Figure 1.1 B). It also triggers the production of the T cell growth factor, IL-2. T cells secrete this 
cytokine themselves and it drives their proliferation and differentiation. Finally, the third signal is a 
cocktail of instructing cytokines that together influence the fate of the activated T cell, in particular 
differentiation into the various CD4 T cell types. It is important to point out that this crosstalk between 
a T cell and a DC is bidirectional, because T cells expressing CD40L support DC maturation, thus 
boosting the immune response (10).  
 
 
Figure 1.1: Antigen presenting cells deliver three signals to naïve T cells, thereby activating them. A. The induction of 
T cell-mediated immunity needs three kinds of signals provided by APCs. The first signal is the encounter of the cognate 
peptide:MHC with the T cell receptor (TCR), which causes G1 phase entry of the T cell. Signal 2, called co-stimulatory 
signal, is conducted by molecules of the B7 family. The third signal is secretion of a specific cytokine cocktail which 
determines the direction of T cell differentiation, particularly different subsets of effector CD4 T cells. B. Mature dendritic 
cells express high levels of co-stimulatory B7 molecules. Upon binding, naïve CD8 T cells are activated and undergo clonal 
expansion and differentiation into cytotoxic T cells. Taken from (1).  
 
1.1.3 T lymphocytes  
Immunity mediated by T lymphocytes involves three steps: priming/activation of naïve T cells, 
activated T cells performing effector functions and establishment of long-term T cell memory. There 
are two major T cell subsets having different TCRs (11). The majority is known as the αβ T cell 
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subset, while a minority of T cells expresses γδ TCRs. Those γδ T cells are less heterogenic and reside 
in the skin and mucosal surfaces. This section will focus on the αβ T cell subset bearing a diverse 
repertoire of antigen receptors. T cells mature in the thymus, but only a small number of them leaves it 
again. The major part of T cells is eliminated because either they are not able to properly bind to MHC 
molecules (positive selection) or they are self-reactive (negative selection). Hence, the thymus 
represents the first layer of T cell tolerance, called central tolerance (1). Each individual T cell has a 
unique TCR, which can recognize a peptide only in the context of a MHC complex. This phenomenon 
is called MHC restriction.  
 Mature T cells that leave the thymus are called naïve, because they have not yet seen their 
cognate antigen and have not been activated. They circulate in the blood, the lymphatic system and 
secondary lymphoid organs, always on the mission to encounter their cognate peptide bound to MHC 
on an APC (12). Naïve T cells express L-selectin (CD62L), the CC chemokine receptor 7 (CCR7) and 
leukocyte function antigen (LFA)-1 (12, 13). These surface molecules, also known as “homing 
molecules”, enable the T cells to travel through high endothelial venules localized in lymphoid tissues. 
In lymphoid tissues, they bind to APCs, mostly DCs. Upon high-affinity interaction of the TCR with 
the cognate peptide:MHC complex, the immunological synapse between the APC and the T cell is 
formed and the T cell becomes primed (see 1.1.2). The immunological synapse is composed of the 
TCR:peptide:MHC interaction, co-receptors (CD4 and CD8), accessory molecules (e.g. LFA-1 and 
CD2) that stabilize the cellular contact, and co-stimulatory molecules (e.g. CD28), all of which have 
corresponding ligands on the APC (14). During T cell activation, the T cell undergoes phenotypical 
changes such as the expression of CD69, CD25 (the α-chain of the IL-2 receptor) and CD40 (1). In 
addition, CD28-related proteins such as the inducible T cell co-stimulator (ICOS) and cytotoxic T 
lymphocyte associated antigen (CTLA)-4 are found on activated T cells. ICOS is especially important 
for proper CD4 T cell function and does not trigger IL-2 production like CD28, but rather stimulates 
the production of IL-4 and IFNγ (15, 16). On the contrary, CTLA-4 inhibits T cell activation and IL-2 
production (17). Thus, this molecule is seen as an “immunological break” since it limits the 
proliferative T cell response which is a crucial negative feedback loop. Moreover, tumor necrosis 
factor (TNF) family members like CD27, 4-1BB and OX40 (and their matching ligands on the APC) 
transmit further co-stimulatory signals. With regard to adhesion molecules, activated T cells lose 
CD62L and express an integrin, very late antigen (VLA)-4, which allows them to enter inflammation 
sites through vascular epithelium (1). Eventually, activated T cells differentiate into effector T cells 
that do no longer need a co-stimulatory signal, leading to their capability of immediate action.  
 After activation, the CD4 T cell subset differentiates into six functional classes: Th1, Th2, 
Th9, Th17, T follicular helper cells (TFH) and regulatory T cells (Treg). While Th1 cells mainly drive a 
pro-inflammatory response by secreting IFNγ, IL-2 and TNFα, Th2 cells promote non-inflammatory 
responses and secrete IL-4 and IL-5. Th1 and Th2 mediated immune responses are mutually 
antagonistic. A Th1-driven immune response involves cell-mediated immunity by macrophages and 
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CTLs, whereas Th2-driven immune responses control parasites by eosinophils and IgE production by 
B cells. In addition, Th2 cells are involved in allergic immune reactions (1). Recently, a new T cell 
subset - Th9 cells - specifically secreting IL-9 was identified. Th9 cells are implicated in the 
immunopathology of allergy and autoimmunity. Furthermore, they were shown to support immunity 
against worms in the intestine and against melanoma (18). The Th17 subset is characterized by the 
secretion of IL-17 and IL-22. This subset plays a pivotal role in combating infections with 
extracellular bacteria and fungi, together with the participation of neutrophils (1). TFH cells are 
distinguished by the expression of CXCR5 and their localization in lymphoid follicles where they 
promote B cell mediated immunity (19, 20). The last CD4 T cell subset, the Tregs, has 
immunosuppressive functions by secreting tumor growth factor (TGF)β, IL-10 and IL-35 as well as by 
expressing CTLA-4 on the surface (21). Their pivotal role is the prevention of autoimmunity and they 
serve to control the amplitude of immune responses. About 10% of CD4 T cells are natural Tregs 
(nTreg) which express CD25 and the transcription factor forkhead box p3 (Foxp3). They develop in 
the thymus as a part of central tolerance. There is also a small proportion known as induced Treg 
(iTreg), which develops in the periphery as a result of a particular immunosuppressive environment or 
in the absence of co-stimulation. This type of Tregs belongs to peripheral tolerance and complements 
central tolerance (21). Of note, there are also experimental models demonstrating an important role of 
CD8 Tregs (22, 23), but so far more is known about the CD4 Treg population.   
 In general, naïve CD8 T cells differentiate into CTLs, which can directly kill target cells 
infected with an intracellular pathogen, such as a virus, or malignant cells. CD8 T cells need more co-
stimulatory signals than CD4 T cells. In many cases, co-stimulation provided by mature DCs is not 
enough and additional support by CD4 effector T cells is needed. CD4 effector T cells bind to their 
cognate peptide:MHC II complex on the APC and induce them to increase levels of co-stimulatory 
molecules. Additionally, CD4 effector T cells produce IL-2. Together, this activates the naïve CD8 T 
cell recognizing its cognate peptide:MHC I complex. The additional need for CD4 T cell help may be 
due to the extremely damaging effects of CTLs (1). Cytotoxicity mediated by CTLs happens by two 
pathways. On the one hand, lytic granules consisting of granzymes and perforins are released. Perforin 
supports the transport of granzymes through the plasma membrane of the target cell. Granzymes are 
serine proteases that can induce apoptosis (24) via the caspase-dependent and -independent pathway. 
On the other hand, CTLs express CD95L (FasL), a member of the TNF receptor family, that induces 
Fas-mediated apoptosis (25). The binding of FasL to Fas on the target cell triggers the intracellular 
“death” domain leading to caspase-mediated apoptosis.      
 The end of an immune response is characterized by apoptosis of the majority of effector T 
cells (26). Only a small population survives and forms the immunological memory. When the body is 
challenged again with the same pathogen, memory T cells can act immediately with a reduced need for 
co-stimulation. T cell memory is composed mainly of central memory T cells (TCM) and effector 
memory T cells (TEM). TCM cells are found in the blood and lymphoid tissues. Upon recognition of 
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their cognate antigen they rapidly proliferate and gain effector functions. On the contrary, TEM cells 
circulate in non-lymphoid tissues and can directly execute effector functions (27).  
 
1.1.4 Antigen processing and presentation on MHC I 
Antigen processing and presentation on MHC I is a fundamental process needed for all CTL-mediated 
immune responses. The processing of antigens into peptides and their presentation on the cellular 
surface is a multistep pathway involving the following steps: 1) peptide generation/trimming; 2) 
peptide transport into the ER; 3) MHC I assembly/peptide loading and 4) peptide:MHC I presentation 
(28). Whereas MHC II is mainly expressed by APCs, MHC I is expressed on all nucleated cells, thus 
enabling the immune system to detect viral infections and malignant cells (characterized e.g. by 
mutated proteins) (29). The structure and peptide-binding preferences of the two MHC types (Figure 
1.2) are different. MHC I is composed of an α-chain and a non-covalently associated β2-microglobulin 
chain. The binding cleft is closed and binds peptides in their elongated form with a length of 8-11 
amino acids. On the contrary, MHC II molecules are heterodimers composed of an α- and β-chain with 
an open peptide-binding cleft. Thus, peptides of up to 25 amino acids are able to bind (30).  
 
 
Figure 1.2: Schematic illustration of the MHC I and II molecules. MHC I consists of an α-chain that is anchored in the 
plasma membrane and has three immunoglobulin domains (α1-3). The β2-microglobulin chain is non-covalently bound. The 
peptide-binding groove is closed which limits the length of binding peptides to 8-11 residues. MHC II consists of two 
transmembrane chains (α and β) each composed of two immunoglobulin domains. The peptide-binding groove is open at 
both ends, enabling binding of peptides of differing lengths up to 25 residues.  
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MHC I presents self- and non-self peptides. The presentation of self-peptides contributes to 
tolerance, whereas non-self peptides derived from viruses or mutated proteins in malignant cells 
induce an immune response. Antigen generation starts in the cytosol (Figure 1.3). Here, proteins are 
degraded by the ubiquitin-proteasome pathway, which controls normal physiological protein turnover. 
Other proteins that get degraded by the proteasome are either short-lived regulatory proteins, damaged 
or misfolded proteins (31) including defective ribosomal products (DRiPs), which are degraded within 
minutes after their synthesis (32, 33). In the ubiquitin-proteasome pathway, proteins are tagged by 
covalent linkage of a polyubiquitin chain (34, 35). These proteins are destined for degradation by the 
proteasome, which is constitutively expressed in all cells. The proteasome is a barrel-shaped, 
multimeric protein complex composed of a catalytic core, the 20S proteasome, and two regulatory 
particles, the 19S proteasomes, functioning as proteasome activators (28, 35). The 20S proteasome is a 
stack of four heptameric rings with a central opening. The two outer rings consist of seven α-subunits 
(PSMA1-7) and the two adjacent inner rings consist of seven β-subunits (PSMB1-7). All α- and β-
subunits are structurally similar but have different functions. Three β-subunits, PSMB5, 6 and 7, have 
threonine-protease catalytic activities and hydrolyze peptide bonds at the C-terminus. PSMB5 is 
associated with a chymotrypsin-like activity (hydrolysis after hydrophobic residues), PSMB6 with a 
caspase-like activity (hydrolysis after acidic residues) and PSMB7 with a trypsin-like activity 
(hydrolysis after basic residues) (36, 37). The catalytic core is usually capped on one or both sites by 
the 19S activator, which identifies an ubiquitin-tagged protein, removes polyubiquitin chains, unfolds 
the protein and transfers it into the catalytic core by opening the α-ring (38). Of note, six subunits of 
the activator are ATPases, since these processes are dependent on energy.    
 Upon exposure of the cell to IFNγ, the three catalytic subunits of the 20S core are replaced by 
functionally different subunits (PSMB8, 9 and 10). Also another activator, composed of PSME1 and 2, 
is expressed in this context, forming a proteasome which is called immunoproteasome. This name has 
been chosen because in comparison to the constitutive proteasome, immunoproteasomes assemble in a 
type I IFN (α and β) and type II IFN (γ) containing milieu (39, 40). Interestingly, they are 
constitutively expressed in lymphoid organs. Immature DCs express equivalent amounts of 
proteasomes and immunoproteasomes, but only immunoproteasomes when they are mature (41, 42). 
The exact role of immunoproteasomes in immunity is still under extensive investigation, but it is 
known that they change the MHC I epitope repertoire. It is generally thought that immunoproteasomes 
have a positive effect on MHC I antigen presentation by producing CD8 T cell epitopes more 
efficiently (43). A major breakthrough in analyzing the mechanism of the immunoproteasome 
activator has been achieved by Raule and colleagues. They showed that the immunoproteasome 
activator does not increase the rate of substrate turnover but reduces size and increases hydrophilicity 
of peptide products (44).        
 Peptides released from the proteasome have a length between 2 and 25 amino acids (28) with 
variation in terms of sequence and quantity depending on the presence of proteasomes or 
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immunoproteasomes. In the cytosol, peptides can be further cleaved by peptidases such as nardilysin, 
thimet oligopeptidase (TOP), tripeptidyl peptidase II (TPPII) and insulin-degrading enzyme. There is 
experimental evidence that a minority of epitopes depends on cleavage by one or two of these 
peptidases (45, 46). However, these peptidases are mainly associated with destruction rather than 
generation of MHC ligands (47-49) rendering the cytosol an unfavorable environment for MHC I 
ligands. To continue antigen processing, peptides have to be transported into the endoplasmic 
reticulum (ER) by the transporter associated with antigen processing (TAP). TAP is a transmembrane 
pore composed of two parts, TAP1 and TAP2, which can switch between an open and a closed state in 
an ATP dependent way (50) and mainly transports peptides with a length of 8-12 residues and 
hydrophobic or basic C-termini. Thus, TAP preferentially transports peptides that bind to MHC I (51). 
Inside the ER, peptides are trimmed by ER aminopeptidases (ERAP1 and ERAP2) (49). ERAPs 
contribute fundamentally to the generation of MHC I ligands (see 1.1.4.1). Notably, DCs also bear the 
insulin-regulated aminopeptidase (IRAP), an endosomal protease, which has been demonstrated to 
play an important role in cross-presentation (52). Optimal MHC I ligands are loaded onto MHC 
molecules by the help of the chaperones calnexin, calreticulin and tapasin. The thiol oxidoreductase 
protein disulfate isomerase A3 (PDIA3 or ERp57) is also assisting this process (28). Together these 
proteins form the peptide loading complex (PLC). Together, calnexin and PDIA3 ensure the correct 
folding and oxidative state of the nascent MHC I molecule until β2-microglobulin can bind. Further, 
calreticulin supports the “open” form of the MHC I molecule which is now prepared to be loaded with 
a peptide (53). Tapasin functions as a bridge between TAP and MHC I, thus ensuring that imported 
peptides can bind (54). Once an optimal peptide binds to MHC I, the complex becomes stabilized, 
released from the PLC and is transported via the Golgi apparatus to be presented on the cellular 
surface.  
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Figure 1.3: Antigen processing and presentation via the classical MHC class I pathway. Antigen processing starts with 
the destruction of ubiquitinated proteins by the constitutive proteasome or the immunoproteasome, which is inducible by 
IFNγ, but also by type I interferons. The peptides that leave the proteasome can be further cleaved by peptidases in the 
cytosol and are actively transported into the ER by the TAP transporter. In the ER, peptides are cleaved by aminopeptidases 
so that they perfectly fit into the MHC I peptide-binding groove. The peptide loading complex, a complex of three 
chaperones (calreticulin, calnexin and tapasin) and the thiol oxidoreductase PDIA3, ensures correct folding and stabilization 
of the nascent MHC I molecules. Upon binding of a high-affinity peptide, the MHC complex is stabilized and transported via 
the Golgi apparatus to the plasma membrane of the cell. Modified from (29) and (43).  
 
The antigen processing machinery is tightly regulated, as productive antigen processing is 
crucial to elicit specific and robust CTL responses against viruses and also cancer. Thus, it is not 
surprising that there is considerable experimental evidence for alterations in the APM in viral 
infections and tumors (28, 55, 56).  
1.1.4.1 Endoplasmic reticulum aminopeptidase 1 
The first time ERAP1 has been cloned and characterized was in 1999 (57). The gene is located on 
chromosome 5 in humans and chromosome 13 in mice, where it is frequently called ERAAP (ER 
aminopeptidase associated with antigen processing). ERAP1 is an ER resident zinc 
metalloaminopeptidase and belongs to the M1 protease family. Together with ERAP2, which is absent 
in mice, and IRAP these three enzymes have been classified into the oxytocinase subfamily of M1 
proteases (58). ERAP1 and ERAP2 are highly homologous and have a sequence identity of 50%. The 
current opinion is that ERAP2 has evolved by an evolutionary recent gene duplication event of ERAP1 
(59) explaining why there are no analogues in rodents. Notably, a minor allele of ERAP2 has a single 
nucleotide polymorphism (SNP) that results in alternative splicing and degradation by nonsense 
mediated decay. Hence, approximately 25% of the population do not express ERAP2 at all, 
highlighting the pivotal role of ERAP1. Nevertheless, it has been proposed that ERAP1 and ERAP2 
form heterodimers because both enzymes can be co-immunoprecipitated from cells (60). However, 
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direct experimental evidence for a heterodimer from crystallization studies is still missing. 
 Multiple functions have been attributed to ERAP1, including antigen processing, post-natal 
angiogenesis, shedding of several cytokine receptors (e.g. TNFR1), and blood pressure regulation. The 
latter effect is mediated by a secreted form of ERAP1 (61). This and the following section focus on the 
role of ERAP1 in antigen processing. The structure of ERAP1 has been solved and has essentially 
facilitated the understanding of the mode of action of this enzyme (62). ERAP1 is composed of four 
domains. The catalytic site with the zinc atom is located within domain II, which is capped by domain 
I. Domain III has the role of a hinge between domain II and IV and is thought to enable 
conformational changes between an “open” and a “closed” state (Figure 1.4). Domain IV has a 
concave shape and its orientation relative to domain I and II is changing during conformational 
changes. During the “open” state of ERAP1, the protein exposes a cavity, because domain IV is 
orientated away from domain II. In this state, elongated peptides can enter the cavity of ERAP1. The 
peptide is then trapped inside of the enzyme since domain IV is placed alongside of domain I and II. 
Next, the active site is activated and can trim peptides at their N-terminus. ERAP1 controls antigenic 
peptide generation by both generating and destroying MHC I ligands (63), thereby editing the 
antigenic peptide repertoire and immunodominance hierarchy of peptides (64, 65). The unique 
biological role of ERAP1 is attributed to its ability to spare shorter peptides (8-9 residues) and to 
prefer longer peptides (9-16 amino acids) (66). This length dependence of ERAP1 is called “the 
molecular ruler” property and is essential for its role in trimming MHC I ligands. Additionally, 
ERAP1 prefers substrates with several positively charged amino acids, hydrophobic C-termini and it 
preferentially removes hydrophobic residues (e.g. leucine, methionine, and phenylalanine) (66). The 
strong association of ERAP1 with immune responses is stressed by the fact that it is inducible by IFNγ 
(67).  
 
Figure 1.4: The molecular ruler mechanism of ERAP1. ERAP1 has two conformations, an “open” (left) and a “closed” 
(right) conformation. In the closed state, the active site of the enzyme is active and the interface is structured like a molecular 
ruler. The elongated peptide binds with its N-terminus facing the active site. Adapted from (49). 
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After the identification of ERAP1, its biological function in the immune system has been 
studied in ERAAP knockout mice by several groups independent of each other (reviewed in (61)). It 
has been observed that the loss of ERAAP moderately reduced MHC I molecules on the surface, 
ranging from 20-40% for the mouse MHC I molecules Kb and Db. Moreover, it was reported that 
transfer of splenocytes from wild type mice into ERAAP knockout mice led to CTL responses, 
confirming that ERAP1 has a quantitative and qualitative effect on epitope generation as the wild type 
splenocytes were recognized as foreign. Experiments exploiting peptide-specific CD8 T cell 
hybridomas demonstrated that ERAAP loss had a neutral effect on some epitopes. However, other 
epitopes were either lacking or were upregulated, reflecting the chemical preferences of the peptidase.  
1.1.4.2 ERAP1 in health and disease  
There is abundant experimental evidence that ERAP1 is associated with different diseases, namely 
infection, autoimmune diseases and cancer. In an infection model of LCMV (lymphocytic 
choriomeningitis virus), the investigators observed that in mice lacking ERAP1 CD8 T cell responses 
to LCMV peptides were altered in regard to magnitude, confirming that ERAP1 is a key player in the 
immunodominance hierarchy of epitopes (64). Further, escape mutations of the human 
immunodeficiency virus (HIV) alter HIV epitope processing dependent on ERAP1 (68). One such 
mutation was a change from alanine to proline at residue 146 in the HIV Gag protein immediately 
before the N-terminus, inhibiting trimming by ERAP1 and reducing CTL responses. In 2011, the first 
evidence of ERAP1 as a direct target of a human cytomegalovirus (HCMV)-encoded microRNA (miR-
US4-1) was reported (69). This microRNA downregulated the expression of ERAP1, which rendered 
HCMV infected cells less susceptible to CTLs, representing a novel immune evasion mechanism. 
 ERAP1 is a polymorphic gene and naturally occurring SNPs have been shown to be associated 
with susceptibility for several autoimmune diseases (70). In recent years, it has become clear that 
HLA-B27 and the ERAP1 variant K528R predispose to develop ankylosing spondylitis (AS) (71-73). 
Interestingly, AS-associated ERAP1 allotypes have altered trimming activities in vitro, which has a 
negative impact on peptide presentation by HLA-B27. In general, a pathogenesis mechanism for AS 
was characterized by very active or hypoactive ERAP1 variants that overtrimmed or undertrimmed 
their substrates (73). A recent study demonstrated that ERAP1 variants profoundly shape the HLA-
A29:02 peptidome, suggesting that ERAP1 SNPs influence the susceptibility to Birdshot 
Chorioretinopathy (74). In addition, SNPs of ERAP1 in combination with certain HLA class I alleles 
are also associated with psoriasis (75) and Behçets disease (76).      
 The expression of ERAP1 has been studied in a panel of different cancers compared to normal 
counterparts. These studies revealed that ERAP1 was expressed at highly varying levels in all 
examined samples, including melanoma, leukemia-lymphomas, carcinoma of breast, colon, lung, skin, 
chorion, cervix, prostate, kidney and bladder (61, 77-79). In 12 cervical cancer samples, ERAP1 was 
found to be expressed at normal (7 out of 12), high (3 out of 12) and low (2 out of 12) levels compared 
to normal tissue, which was shown by the Human Protein Atlas project available from 
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www.proteinatlas.org (80). Another study of cervical cancer tissue observed a downregulation of 
ERAP1 in 15% of more than 100 investigated samples (81). ERAP1 variants were correlated with 
increased metastases and decreased survival in this disease (81, 82). Interestingly, SNPs in the 
polymorphic ERAP1-127 locus, which is coding for the M1 peptidase domain, were associated with a 
bad prognosis. So far, only a few studies could directly show that ERAP1 expression affects the 
presentation of a specific epitope. The attenuation of ERAP1 expression in tumor entities where 
ERAP1 overexpression was reported showed increased anti-tumor immune responses against a 
colorectal carcinoma epitope and a melanoma epitope (83, 84). Taken together, all these studies show 
that ERAP1 is a key determinant of the MHC I epitope repertoire. For this reason, several groups are 
working on the identification of a specific chemical inhibitor for ERAP1. However, due to the 
similarity of ERAP1 to ERAP2 and IRAP, the inhibitors still exhibit cross-reactivity (85, 86). Whether 
ERAP1 drives destruction or generation of a peptide is dependent on the ERAP1 variant, the 
presenting MHC I allele and the specific peptide and has to be tested in each individual setup. 
 
 
1.2 Human Papillomavirus  
Papillomaviruses (PVs) have evolved successfully over millions of years to propagate in most 
mammals and birds. The papillomavirus group has two distinctive characteristics, which are the strict 
genotype-specific host-restriction and the epithelial tropism. Today, more than 300 PVs have been 
identified and sequenced, including over 200 human papillomaviruses (HPVs) (87). HPV is the most 
common sexually transmitted agent in the world. Harald zur Hausen postulated the connection 
between cervical cancer and HPV for the first time in the 1970s (88, 89). From the 80s on, when 
HPV16 and HPV18 were first isolated (90-92), the viruses have been investigated intensively. 
 HPVs are grouped into different genera, species and types (Figure 1.5). HPVs from the alpha 
genus are classified into low-risk and high-risk types (Figure 1.5) depending on the oncogenic 
potential. Notably, most high-risk types belong to the alpha9 species. While low-risk types cause 
benign ano-genital and skin warts, a persistent infection with a high-risk type can cause ano-genital 
cancer, such as cervical, vaginal, penile and anal cancer as well as a certain subset of head and neck 
cancer, namely oropharyngeal cancer (93-97). Of note, the low-risk types can also cause problematic 
diseases such as recurrent respiratory papillomatosis (RRP), which is associated with HPV11 (98). 
Every HPV type has a different pathology. For instance, HPV6 shows a preference for genital sites 
whereas HPV11 is the most prominent type at oral sites (99). Additionally, HPV16 is associated with 
cervical cancer ten times stronger than HPV31 and HPV35, and of these three types HPV16 is the only 
one that has been found in oropharyngeal tumors (99). To date, these subtle tropism differences cannot 
be explained, but they may be controlled at the level of viral gene expression by regulatory elements 
(100). The two high-risk types HPV16 and HPV18 mediate approximately 70% of all cervical cancers. 
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In virtually all other cervical cancers, DNA derived from other high-risk types can be found (101). To 
stress the importance of HPV research one should note that almost every sexually active individual 
will acquire at least one high-risk type infection during their lifetime (102). Usually, HPV infections 
are cleared by the immune system within 6 to 18 months (103, 104). In the minority of cases, less than 
5%, a persistent infection establishes which is necessary for subsequent malignant transformation. 
Interestingly, a latent papillomavirus infection remains to be convincingly validated in humans, but 
experiments in animal models suggest that also this is likely (99). 
 
Figure 1.5: Human papillomavirus types fall into five genera. Types from the alpha genus are classified into low-risk 
cutaneous (brown), low-risk mucosal (yellow) or high-risk (pink). High-risk types highlighted in red are reported to be 
carcinogenic and the other high-risk types are possible carcinogens. The phylogenetic tree was prepared according to 
alignments of the E1, E2, L1 and L2 genes. Taken from (99).  
 
1.2.1 HPV genome, viral life cycle and viral proteins 
PVs are small (50-60nm diameter), non-enveloped and double-stranded DNA viruses with an 
icosahedral capsid illustrated in Figure 1.6 A. The circular DNA genome of HPVs comprises 
approximately 8,000 base pairs containing 8 or 9 open reading frames (ORFs) (105). Since the HPV 
genome is so small, the virus employs an elegant mechanism to make maximal use of its genome. The 
number of encoded proteins is increased, because gene expression involves the usage of many 
promoters and alternative splicing (106-108). The HPV genome encodes for early (E) and late (L) 
genes depending on their expression during the viral life cycle (Figure 1.6 B).   
 In general, the viral genome contains an upstream regulatory region (URR), comprising 
transcription factor binding sites and the replication origin, as well as the two ORFs encoding early 
and late genes. The early proteins (E1, E2, E4, E5, E6 and E7) are important for viral maintenance, 
replication and oncogenesis; whereas the late proteins (L1 and L2) are the capsid forming units. The 
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genes involved in replication (E1 and E2) and capsid formation (L1 and L2) are highly conserved 
among PVs, whereas the other genes (E4, E5, E6 and E7) have a greater diversity (109). The lack of 
an E3 ORF is attributed to an initial sequencing error in the bovine papillomavirus (BPV)1 genome 
(105).  
 
Figure 1.6: Viral particles and genome organization of HPV16. A. Negatively stained HPV16 particles photographed by 
electron microscopy. The particles are approximately 55nm in diameter and non-enveloped. The individual capsomeres of the 
capsid structure are clearly visible. Taken from (105). B. The HPV16 genome is circular and encodes for 6 early (blue) and 2 
late (green) proteins. Whereas the early proteins are important for viral replication, maintenance and oncogenesis, the late 
proteins form the viral capsid. The upstream regulatory region (URR) controls early gene expression and replication since it 
contains promoter and enhancer elements and the viral origin of replication (ORI). Taken from (108). AL = late 
polyadenylation signal, AE = early polyadenylation signal 
 
The viral life cycle of PVs is perfectly adapted to their host cells. PVs enter squamous 
epithelia of mucosa and skin through microabrasions, where they exclusively infect undifferentiated 
basal keratinocytes (Figure 1.7). Upon wound healing, cell proliferation is occurring, which is crucial 
for episomal maintenance of the viral genome and its entry into the nucleus (110). The cervical 
transformation zone is particularly susceptible for infections with high-risk HPV types. In this zone, 
squamous metaplasia occurs, which is the process of replacing the everted columnar epithelium on the 
ectocervix with a newly formed squamous epithelium from the sub-columnar reserve cells. The 
presence of cuboidal stem-like cells was suggested at the squamo-columnar junction, rendering this 
area prone to infection by high-risk types and susceptible to cancer progression (111). In addition, the 
incidence of infection is elevated during puberty since then metaplastic cells are present at this site 
(112). Of note, primary infections leading to malignant transformation have been observed mostly in 
the late teens or early twenties. The development from infection to persistent infection to late cervical 
intraepithelial lesion (CIN III) was estimated to be 7 to 15 years with a faster development following 
HPV16 and HPV18 infections (113).          
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Initially, virions bind to glycosaminoglycan (GAG) chains of heparan sulfate proteoglycan 
(HSPG) of the exposed basement membrane. This binding leads to a conformational change of the 
virion, exposing furin/proprotein convertase cleavage sites at the amino terminus of the virion coat 
protein L2 (105). Only after this conformational change basal keratinocytes can be infected. After 
infection, it is generally thought that an initial phase of genome amplification takes place before the 
viral episome is maintained at a low copy number within the basal cell. Here, E1, a DNA helicase, and 
E2, which binds to the non-coding region within the viral genome, initiate viral DNA replication. 
Laser capture methods (114) revealed that the episomal copy number in the infected cell is 50-100. For 
the initial genome amplification, E1 and E2 are essential, but E1 is dispensable for episomal 
maintenance when the copy number becomes constant. E2 is important for genome partitioning, 
replication and viral gene expression (105). Furthermore, E2 is repressing the expression of the 
oncogenes E6 and E7.          
 After cell division, one daughter cell moves to upper epithelial layers and starts differentiating, 
eventually leading to terminal differentiation (107). In an infected cell, terminal differentiation is 
prevented since the cell would enter cell cycle arrest, which would end viral replication. The 
transmembrane protein E5 has an important role in modulating cellular signaling by stabilizing the 
epidermal growth factor (EGF) receptor and enhancing mitogen-activated protein (MAP) kinase 
activity. This keeps the cell in a replicative state (115). Further, proliferation is mediated by E6 and 
E7, which allow expansion in lesion size. The role of E6 and E7 as key regulators of cell cycle 
progression is clearly defined for the high-risk types, whereas it is uncertain for the low-risk types that 
do not generally cause neoplasia. E7 promotes S-phase-entry by binding to the retinoblastoma protein 
(pRB), thereby activating the transcription factor E2F, which causes induction of S-phase genes such 
as cyclins (116, 117). Additionally, the binding of E7 to pRB leads to the upregulation of p16INK4A, a 
surrogate biomarker for HPV oncogene expression and regulator of active cyclin kinases. The 
expression of p16 is found in 86% of cervical intraepithelial lesions grade I (CIN I), 100% of CIN II 
and CIN III and in 97% of cervical carcinomas (118). Eventually, cell cycle progression mediated by 
E7 would result in apoptosis, as p53 increases. The virus uses the E6 protein to counteract apoptosis. 
E6 interacts with an E3-ubiquitin E6-associated protein (E6-AP), which results in polyubiquitination 
of p53 leading to its degradation by the proteasome. Until now, 14 additional possible binding partners 
carrying a PDZ domain (that is bound by E6), have been identified. The majority of those is implicated 
in cell polarity, cell adhesion and cell differentiation (105, 119). Moreover, E6 is required for episomal 
maintenance of HPV16 and HPV31 genomes in primary human keratinocytes. With regard to its 
mechanism it is believed that E6 is controlled by phosphorylation, and binding to its substrates reveals 
an alternative binding site for the ubiquitin ligase (105). Taken together, E6 and E7 have a very large 
number of targets within the cell. The targets vary between HPV high-risk and low-risk groups and 
even between different high-risk types.         
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The HPV life cycle is completed by the expression of minor coat protein (L2), major coat 
protein (L1) and cell cycle exit to allow genome packaging. 72 capsomers form the HPV virion with 
approximately 80% L1 and 20% L2, which is mainly located on the inside (120, 121). Virus 
maturation takes place in the terminally differentiated cell and virions are released by the natural 
process of epithelial shedding. It is supposed but not exactly defined that E4 amyloid fibers are 
supporting virion release.         
  
 
Figure 1.7: Viral life cycle of HPV16. The viral life cycle starts with the infection of a basal keratinocyte which is exposed 
by epithelial trauma. As the infected cell starts to differentiate and moves to upper layers of the epithelium, viral replication is 
triggered by the viral proteins E1 and E2. E6, E7 and E5 keep the cell in a proliferative state, but rising levels of E2 limit the 
expression of E6 and E7, allowing the cell to differentiate. The viral capsid proteins L1 and L2 are produced in the uppermost 
layer of the epithelium. Here, high levels of E4 enable virion release. Eventually, the virions are released during the normal 
process of epithelial cell shedding after the keratinocyte has undergone terminal differentiation. Modified from (107). 
 
In HPV-associated neoplasia, protein expression leading to virus maturation and release is 
disrupted. An important step towards cancer progression is the integration of high-risk HPV DNA into 
the host genome. This happens in premalignant lesions, CIN II or CIN III. The integration of the high-
risk type HPV genome happens in many cases via opening of the episome within the ORF of E2, 
which leads to the upregulation of the two oncoproteins E6 and E7. This scenario is often observed in 
late CIN II stages and the thus caused elevated proliferative phenotype of the cell favors the 
accumulation of genetic errors that contribute to cancer progression (122). Of note, E6 activates the 
human telomerase reverse transcriptase (hTERT) gene. A higher expression of hTERT results in 
telomerase activity, which adds hexamer repeats to the telomeric ends of chromosomes thereby 
immortalizing the cells (115). 
 
1.2.2 Immune responses to HPV and immune evasion by HPV 
The majority of HPV infections is cleared by the host immune system within 1-2 years after infection 
and only a minority of infected individuals develop HPV-mediated cancer (103). The natural immune 
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control of an HPV infection is achieved by innate and adaptive immune responses including specific 
antibodies and effector T cells (104). DCs within the dermis and Langerhans’ cells, which are 
immature DCs resident in the epidermis and superficial epithelial layers of the mucosa, induce the 
adaptive immune response by detecting viral structures by pattern recognition through their TLRs. A 
protective immunity against local reinfection is accomplished by neutralizing antibodies against HPV 
capsid proteins, though these antibodies do not help against infected cells and a subsequent infection 
with other HPV types and do not form in every individual (123). Thus, it has become clear that the 
induction of a T cell mediated immune response and T cell memory is essential for the effective 
clearance of HPV (108). However, many naturally exposed individuals have a poor anti-HPV humoral 
immunity and patients with high grade CIN have an impaired T cell immunity against the HPV 
proteins E2, E6 and E7, when compared to patients with regressed lesions (124). This is the result of a 
broad and very effective spectrum of immune evasion strategies of HPV. Immune evasion strategies 
can be classified into immunosuppressive mechanisms during infection and in HPV-driven tumors 
(125).            
 During HPV infection, the virus follows the principle of “staying invisible” which also leads 
to a slower clearance compared to other viruses. The viral life cycle by itself is already an immune 
evasion strategy, because the virus stays outside the basement membrane, has no secreted proteins, 
keeps protein expression at a low level and does neither induce host cell death nor inflammation. HPV 
only infects basal keratinocytes and does not cross the basement membrane or enter the blood stream 
(104, 125). Access of the immune system to these regions of the skin is limited and furthermore HPV 
can impair the attraction of APCs such as LCs and macrophages. It is thought that this is due to an E6-
mediated reduced E-cadherin expression on HPV-infected keratinocytes (105, 126) and a 
downregulation of macrophage inflammatory protein (MIP)-3α (127) in HPV16 E6 and E7 expressing 
keratinocytes. During normal physiologic conditions, LC trafficking is regulated by attaching to E-
cadherin expressed on keratinocytes, and macrophages are attracted to the site of infection by MIP-3α. 
Furthermore, viral early gene expression is kept at low levels controlled by E2 (see 1.2.1) in the basal 
and lower layers of the epithelium, and HPV proteins are non-secreted. These low levels of viral 
protein expression can hinder the activation of local APCs and thus the induction of a potent adaptive 
immune response against HPV infected cells. The highly immunogenic virions and a higher 
expression of viral proteins happen only in the upper epithelial layers. At this time point, infected 
keratinocytes have entered the terminal differentiation phase and virions will only be released by the 
natural process of cell shedding from the surface of the epithelium, away from circulating immune 
cells (108, 124).          
 In addition, HPV has evolved multiple strategies to reduce the sensitivity of infected cells to 
anti-viral responses. It has been reported that TLR9 signaling is impaired, which has been attributed to 
HPV16 E6 and E7 (125, 128), thereby hindering the recognition of unmethylated CpG sequences in 
viral DNA. Moreover, the production and signaling of type I IFNs (IFN-α, IFN-β and IFN-κ), which 
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act as a first line of immune response against viruses, can be directly modified by HPV16. The E6 
protein interferes with IFNα transcription by binding to the transcription activator interferon regulatory 
factor (IRF)3 and impairs IFNα signaling by inhibiting tyrosine kinase 2 (TYK2). Normally, TYK2 
binds to the intracellular site of the IFN receptor. IFNβ can also be targeted by E6 via the inhibition of 
IRF3 transactivation. Lately, there has been experimental evidence for an implication of E6 in the 
transcription of IFNκ, a type I IFN only expressed in keratinocytes and DCs. The study showed that 
E6 contributed to de novo methylation near the transcriptional site of IFNκ. Besides high-risk E6, 
high-risk E7 blocks IFNβ transcription by an interaction with IRF1, and IFNα by binding to IRF9 
(125, 129). In addition to the modulation of the IFN response, other cytokines are affected by HPV as 
well. IL-6, which is constitutively expressed by keratinocytes, and IL-1β have been found to be 
downregulated in a genome wide expression profiling array (130). Recently, the mechanism of IL-1β 
downregulation has been unraveled. IL-1β has been demonstrated to be degraded by the proteasome in 
HPV16 E6 expressing cells, which is caused by the ubiquitin-ligase E6-AP and p53 (131).  
 Most of the mechanisms explained above primarily affect inflammation and APC activation, 
the crucial link between the innate and the adaptive immune system. However, HPV has also evolved 
strategies to stay invisible for T cells. Inside the keratinocyte, HPV can perturb antigen processing and 
presentation (see 1.1.4) at multiple steps, thereby directly interfering with the effective generation of 
CTL epitopes. In the cytoplasm, the proteasome subunits PSMB8 and PSMB9 have a decreased 
expression in HPV16 infected cells (132). PSMB9 expression has been found to be repressed by 
HPV16 and HPV18 E7 (133), whereas the promoter of the PSMB8 gene has been observed to be 
highly methylated in HPV16-positive cervical cancer (134). At the membrane of the ER, the TAP 
transporter can also be affected by HPV. Both, TAP1 and TAP2 are expressed at lower levels in 
cervical cancer. TAP1 transcription can be inhibited by HPV16 E7 and additionally its promoter is 
highly methylated in HPV16-positive cervical cancer (132, 134). Furthermore, a loss or a partial loss 
of protein expression of MHC I, calreticulin, calnexin, ERAP1, PDIA3 and tapasin was described in 
cervical cancer (134). The expression of MHC I is impaired on the transcriptional level and during its 
presentation to the surface. E7 has been shown to directly block the MHC I heavy chain promoter 
(133). HLA-A and -B, but not HLA-C and -E, can be retained by an HPV16 E5-mediated mechanism 
within the cell (135). The E5 protein can interact with leucine pairs in the first transmembrane domain 
of the MHC I heavy chain. Alternatively, E5 keeps MHC I in the Golgi apparatus by vesicle 
alkalinization (136).           
 The combination of direct immune evasion, the lack of inflammation and a low level 
presentation of viral antigens rather favors immune tolerance than a potent T cell response that is able 
to quickly clear virus infected cells. For the effective clearance of HPV, a robust Th1 and CTL 
response is needed (125). Interestingly, it has been unraveled that HPV is also able to interfere with 
Th1/Th2 polarization of the immune response. In early HPV induced lesions, cytokines associated 
with a Th2-like immune response such as IL-6 and IL-10 are detected and only low or no IFNγ 
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mediated Th1 responses. On the contrary, high-grade epithelial lesions have upregulated TNFα and 
elevated levels of both Th1 and Th2 associated cytokines, reflecting an uncoordinated immune 
response in advanced disease. The shift from Th1 to Th2 during the early lesions may perturb proper 
virus immune recognition and thus promote disease persistence and progression (137, 138).  
 Besides the immune evasion strategies during infection, HPV-driven tumors employ 
additional strategies to hide from the host immune system. Almost all immune evasion strategies are 
present during infection as well as in HPV-driven tumors. In cancer, it is important to note that the 
expression of E6 and E7 is no longer attenuated, because E2 is lost when the HPV genome is 
integrated into the host genome (see 1.2.1). In order to evade immune recognition, HPV-driven tumors 
create an immunosuppressive environment similar to many other tumor types. Immunosuppressive cell 
types such as tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs) and 
Tregs are recruited to infiltrate the tumor (125). TAMs are a heterogeneous population of macrophages 
mostly with an M2-like phenotype that are known to inhibit antitumor T cell responses, attract Tregs 
and secrete the immunosuppressive cytokines IL-10 and TGFβ (139). MDSCs produce reactive 
oxygen species (ROS). Although the role of MDSCs in HPV-driven tumors has not been fully 
elucidated, it is believed that ROS cause inhibition of T cell activation by downregulating the CD3ζ-
chain of the TCR complex (140). In addition, Tregs, important players of peripheral tolerance, secrete 
immunosuppressive cytokines such as IL-10 and TGFβ and can directly inactivate T cells for example 
by surface-expressed CTLA-4 (see 1.1.3).        
 In summary, HPV is a very successful virus because it is able to stay invisible to the immune 
system by employing different immune evasion mechanisms already during early infection. This 
enables HPV to persist for a long time and increases the risk of lesion persistence and the onset of 
malignant transformation. Fortunately, most HPV infections and lesions are cleared by the host 
immune system eventually, with HPV-specific CD4 and CD8 T cells as the crucial driving force to 
fight the infection. For this reason, therapeutic vaccines that trigger T cell responses are under 
intensive investigation and further insights of the molecular mechanisms of HPV immune escape can 
contribute to render these vaccines more successful.  
 
 
1.3 Immunotherapy approaches against HPV 
HPV is the most frequent viral infectious agent of the reproductive tract and HPV-induced diseases are 
regarded as a significant global health burden. Although most infections do not cause symptoms and 
are cleared by the host immune system, there is a risk that an infection becomes persistent and causes a 
pre-cancer lesion which can progress to cancer (see 1.2.2). In developing countries, cervical cancer is 
the second most common cancer in women. The impact of HPV is even higher because the virus also 
causes other ano-genital and also oropharyngeal cancers (93-97). Hence, vaccination against HPV is 
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one of the major breakthroughs in medical research.      
 There are two different vaccination concepts, prophylactic and therapeutic vaccination, which 
are used against HPV-induced malignancies. Prophylactic vaccines are administered to individuals 
that have not yet been exposed to the virus in order to prevent infection. On the contrary, therapeutic 
vaccination concepts intend to cure patients that already suffer from an HPV infection by mounting 
specific cellular immune responses against HPV antigens.  
 
1.3.1 Prophylactic vaccines 
In the 1980s, zur Hausen and colleagues were able to prove that HPV causes cervical cancer (90-92) 
and this was honored with the Nobel Prize for Physiology and Medicine in 2008. After this discovery, 
it was shown that HPV-specific immunoglobulins protect animals against a subsequent challenge with 
the virus (141). Several years later, it was reported that HPV virus-like particles (VLPs) consisting of 
the capsid protein L1 are highly immunogenic and stimulate the induction of neutralizing antibodies, 
which confer protection against infection with the HPV type of which the L1 protein was used (142, 
143). L1 is produced recombinantly and the proteins self-assemble spontaneously into VLPs, resulting 
in conformationally correct capsids containing no viral DNA. Thus, VLPs harbor major epitopes of the 
HPV virion and have a good safety profile, which render this technology a clear candidate for a 
prophylactic vaccine. Indeed, the first two HPV VLP-based prophylactic vaccines were approved in 
2006.            
 Today, two prophylactic vaccines are approved by the FDA in the US and the European 
Medicines Agency (EMA) of the European Union (144). One of the first two vaccines, Cervarix™ 
(GlaxoSmithKline), is bivalent and effective against the most common HPV high-risk types, HPV16 
and HPV18. The included VLPs are produced recombinantly in Trichoplusia ni Hi-5 insect cells by 
baculovirus expression vectors and as an adjuvant, a mixture of aluminum hydroxide and 
monophosphoryl lipid A (MPLA), known as AS04, is included (145). The other vaccine, Gardasil™ 
(Merck) is quadrivalent and protects against infections with HPV16/18 and the low-risk types HPV6 
and 11 that cause genital warts and respiratory papillomatosis. In contrast to Ceravix™, the VLPs are 
produced in Saccharomyces cerevisiae and the adjuvant is aluminum hydroxyphosphate sulphate 
(146). In 2014, the FDA approved Gardasil™9, which is a nonavalent vaccine containing VLPs from 
HPV6, 11, 16, 18, 31, 33, 45, 52 and 58. Currently, the EMA is evaluating the new vaccine for 
approval in Europe. Joura and colleagues have performed a clinical study on 14,215 women and 
showed that Gardasil™9 has the potential to protect against more HPV types, thereby increasing the 
overall prevention of cervical cancer from 70% to 90% (147). However, the exact impact of the 
prophylactic vaccines cannot be determined yet, because the time span from initial infection to 
development of cancer is 10-20 years. A long-term follow up study (9.4 years), which assessed the 
efficacy of Cervarix™, showed that antibody titers were much higher compared to natural infection 
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and remained high during the whole study period. Furthermore, vaccinated individuals were 100% 
protected from incident infection, persistent infection and cancer precursor lesions (CIN I and CIN II) 
(148). The final report of the PATRICIA (Papilloma Trial against Cancer In Young Adults) trial 
strengthened that vaccination of teenagers was effective against high-grade cervical lesions (149). 
FUTURE and FUTURE II (Females United to Unilaterally Reduce Endo/Ectocervical Disease), the 
follow-up studies of Gardasil™, evaluated the efficacy of the vaccine against infection, malignant 
disease and condylomata acuminate and found similar positive results (150).  
 
1.3.2 Therapeutic vaccines 
Although the prophylactic vaccines against HPV are highly effective, vaccination coverage is not 
optimal everywhere (151-153). Australia is a good example of effective vaccination introduction 
because a national HPV immunization program was introduced in 2007, which already resulted in 
coverage of over 70% of eligible persons. In developing countries, vaccination coverage is poor 
caused by financial and social issues. But even in the US and Europe, HPV vaccination coverage is 
lower when compared to other vaccines. Additionally, prophylactic vaccines are HPV type specific 
(see above) resulting only in protection against the strains included in the vaccine. Thus, there are still 
many people prone to HPV infection. Moreover, prophylactic vaccination has no therapeutic effect 
and cannot cure individuals that already have an infection (154). The current treatments for HPV 
lesions are surgical, but these treatments entail disfigurations, functional impairment and also high 
recurrence rates. For all these reasons, the development of a non-invasive therapeutic vaccine 
represents an attractive option to fight HPV-mediated cancer.     
 HPV-associated malignancies represent a perfect target for immunotherapeutic anti-cancer 
approaches, because in this case the malignant cells permanently express the viral proteins E6 and E7, 
which are non-self antigens. Various therapeutic anti-HPV vaccination approaches are being 
investigated, including DNA-based, viral/bacterial vector-based, cell-based, protein-based and 
peptide-based approaches (155, 156).         
 DNA vaccines offer many advantages in regard to safety, production and stable antigen 
production. Furthermore, the DNA itself may have adjuvant functions since DNA plasmids contain 
unmethylated CpG motifs that are detected by TLR9. Clinical trials have been performed for a DNA 
plasmid called ZYC101. ZYC101 encodes E783-95 derived from HPV16, which contains several HLA-
A2-restricted CTL epitopes, and achieved immune responses in 11 out of 15 CIN2/3 patients, with 5 
patients even showing complete histological regression (157). The enhanced vaccine ZYC101a 
contains E6 and E7 fragments derived from HPV16 and HPV18, but the phase 2 clinical trials did not 
result in an overall significant difference between treatment and placebo groups (158). Nevertheless, in 
women younger than 25 the resolution of CIN2/3 was promoted and reached statistical significance. 
Recently, another DNA vaccine named VGX-3100 (Inovio Pharmaceuticals), consisting of plasmids 
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encoding mutated HPV16 and HPV18 E6 and E7 proteins that are delivered by electroporation, was 
proved to be effective against CIN2/3 in a phase 2b trial (159). This vaccine was selected as the “Best 
Therapeutic Vaccine” by the World Vaccine Congress (March, 2016 in Washington, D.C.) and 
honored with a Vaccine Industry Excellence Award.       
 Viral vectors have also been used as a basis for therapeutic HPV vaccines. The viral vector 
itself represents a strong immunogenic stimulant resulting in a wide range of immune responses. 
However, one has to keep in mind that individuals may already have existing immunity against the 
viral vector or that they produce neutralizing antibodies upon vaccination, which renders a subsequent 
treatment non effective. This problem is primarily addressed by the use of viruses that normally infect 
other species. For therapeutic vaccination, Vaccinia virus, modified vaccinia virus ankara (MVA), 
recombinant adenoviral vectors, alphaviruses and lentiviruses are currently exploited for vaccine 
design. However, not all viral vectors have been introduced into a clinical trial due to different 
reasons. Viral vectors based on recombinant adenovirus have the major disadvantage that there is a 
high prevalence of already existing humoral responses in humans and so far no therapeutic effect of 
these vectors was reported (155). The main limitations of lentiviruses are safety concerns, since they 
harbor the risk of malignant transformation due to insertion of the viral vector to the host’s genome. 
Alphaviruses are under extensive study because as RNA viruses they do not integrate into the host’s 
genome and the recombinant gene is expressed transiently at a high level within the cytoplasm. 
Vaccinia virus based vaccines (TA-HPV) encoding a HPV16 and HPV18 E6/E7 fusion protein have 
been used in several clinical trials (160-163). E7 is mutated and the fusion construct has no 
transforming capacity. It was reported that this vaccine elicited HPV-specific CTL responses, antibody 
responses and partial regression of vulvar intraepithelial neoplasia (VIN). Clinical trials using a MVA 
vector were more successful and even achieved complete regressions in some patients (164). 
 Only one bacterial-based vaccine was employed for several clinical studies. The vaccine is 
based on Listeria monocytogenes (ADXC11-001), which is live attenuated and produces a fusion 
protein consisting of HPV16 E7 and a truncated form of listeriolysin O (LLO) serving as an adjuvant 
(155). The fusion protein has no transforming activity. During the phase 1 trial, 4 high-grade cervical 
cancer patients showed tumor regression (165). One phase 2 trial has been terminated in April 2016 
due to lack of enrollment (NCT01116245). The second phase 2 trial has suspended patient recruitment 
because of a pending safety amendment (NCT01266460) and is estimated to be completed in 2018. 
For both phase 2 trials no preliminary results are available yet.     
 Clinical trials based on cell-based vaccines using autologous DCs also have been conducted. 
To this end, DCs from a patient were loaded with HPV specific peptides or proteins or they were 
transduced with HPV-protein-encoding DNA or viral vectors and reinjected into the patient. Although 
T cell responses against HPV antigens were observed, there were no clinical responses (155). 
 The use of complete E6 and E7 proteins in vaccine design was not promising for a long 
time. Recently, van Damme and colleagues reported the outcome from a phase I clinical trial with 
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their vaccine called GTL001, used to treat women infected with HPV16 or HPV18 and normal 
cytology (166). GTL001 contains recombinant versions from HPV16 and HPV18 E7. To prevent 
binding of E7 to pRB, parts of E7 were separately fused to inactive Bordetella pertussis CyaA. 
Immunogenicity and safety of this vaccine could be confirmed in this first clinical study.   
 The disadvantage of whole protein vaccines is that E6 and E7 need to be mutated for their use 
in a vaccine to ensure loss of their oncogenic properties, but possibly leading to destruction of 
immunodominant epitopes. This issue is circumvented by peptide vaccines, which only present part 
of the oncoproteins to the immune system. The most important advantage of peptide vaccines is that 
antigen presentation is facilitated by using peptides because they are quickly translocated from 
endolysosomes to the cytoplasm after DC uptake. Thus, antigens can be efficiently cross-presented 
leading to both CD4 and CD8 T cell responses (167). Peptides can be categorized into short minimal 
peptides and synthetic long peptides (SLP). Whereas short peptides consist of a specific CTL epitope 
of 8-11 amino acids in length, SLPs are between 15 to 35 amino acids long and therefore contain 
potential CD4 and CD8 T cell epitopes. At the Leiden University Medical Center, SLP-based vaccines 
have reached the clinical trial phase, representing a milestone in cancer vaccination research. The 
vaccine, HPV16-SLP, consists of 9 E6 and 4 E7 SLPs derived from HPV16 and was injected 
subcutaneously together with the adjuvant Montanide ISA 51 in patients suffering from VIN lesions, 
resulting in complete regression in 47% of VIN3 patients (168). Follow-up studies in CIN, however, 
showed CTL responses but they were not accompanied by clinical responses (155, 169). The authors 
suggest that subsequent trials should be based on combination therapies including for instance 
checkpoint inhibitors and immunmodulators to improve the efficacy of the vaccine. The VIN study 
was recently repeated with the addition of the immunmodulator imiquimod at the injection site. 
However, the success of the vaccination was not enhanced by imiquimod (170). The latest study from 
the group in Leiden combined standard chemotherapy, carboplatin and paclitaxel, with HPV16-SLP 
vaccination (171). Chemotherapy promoted tumor-specific T cell responses when the patients were 
vaccinated after carboplatin/paclitaxel therapy. The time point after chemotherapy was optimal when 
abnormal elevated frequencies of circulating myeloid cells, observed during tumor progression and 
induced by chemotherapy, had reached normal levels.       
 Vaccines based on SLPs contain several potential epitopes for CD4 and CD8 T cells, which 
entails the problem that it is not exactly known in which direction the immune response is triggered 
and the risk of unwanted immune responses cannot be excluded. Therefore, vaccines based on short 
peptides, which contain defined CTL epitopes, is an approach to circumvent these problems. With 
short peptides, however, it is indispensable to design the vaccine for the different HLA types present 
within the population, since CTL epitopes are HLA-restricted (see 1.1.3). This issue is addressed using 
epitope prediction servers and employing HLA supertypes, which share peptide-binding specificities, 
allowing narrowing down the number of potential epitopes. In HLA binding assays, the binding 
specificity of a given peptide can be analyzed experimentally. In addition, mass spectrometry is an 
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important tool to investigate whether an epitope is truly presented on the target cell (172). For HPV16, 
the HLA-A2-restricted epitope E711-19 has been found on the long-standing HPV16-positive tumor cell 
line CaSki and two other cell lines transfected with the whole HPV16 genome (C66-3 and C66-7). 
Importantly, E711-19 elicited CTL immune responses in vitro (173). Nevertheless, the immunogenicity 
of a peptide has to be tested in vitro and in vivo. It also becomes clear that T helper cell epitopes 
should be included in a successful vaccine because they support the optimal activation and prolong the 
period of robust CTL responses (174, 175). In clinical trials, the HPV16 epitopes E711-20, E712-20 and 
E786-93 have been employed. One of the major challenges in short peptide vaccination is the right 
choice of adjuvants. The best clinical responses (complete regression in 3 of 18 patients) of a vaccine 
formulation with these peptides linked to a lipid tail (lipopeptides) included the CD4 T cell epitope 
PADRE and incomplete Freud’s adjuvant (176). Recently, a phase 1 clinical trial with 24 enrolled 
patients suffering from CIN2/3 finished successfully (177). The vaccine called PepCan was composed 
of 4 HPV16 E6 epitopes and Candida albicans extract as a new adjuvant. The vaccine reached an 
overall regression rate of 52%. In order to improve clinical success of vaccines there are other novel 
adjuvant and delivery systems in preclinical studies such as liposomes (VacciMax®) and nanoparticles 
(155). Nanoparticles are polymers that gain increasing interest because the antigen can be delivered 
along with the adjuvant to the same APC (see 1.1.1).      
 In summary, there are various approaches for therapeutic HPV vaccination. Unfortunately, 
overall clinical success is so far limited. However, preclinical and clinical data are promising and 
demonstrate that the development of a therapeutic HPV vaccine is feasible. Besides vaccine 
formulation including antigens and adjuvants, it is absolutely necessary to further unravel mechanisms 
of immune evasion in HPV-induced malignancies in order to make vaccines more powerful.  
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1.4 Aims of this study 
Nowadays, prophylactic HPV vaccines can prevent initial infection with up to nine HPV types, 
whereas experimental therapeutic vaccines can cure patients with already established infections. 
However, the overall clinical success of anti-HPV therapeutic approaches is limited so far. To increase 
the success of vaccines, it is important to thoroughly study molecular mechanisms that may hinder the 
optimal efficacy of a vaccine.        
 Manipulation of APM component expression is observed in various tumor entities. For some 
clinically relevant and dominant tumor-associated antigens it has been demonstrated that altered APM 
component expression decreases the presentation of these antigens. Inhibition of antigen presentation 
has been shown to be directly associated with reduced anti-tumor CTL responses. In HPV-induced 
malignancies, multiple strategies of immune evasion were described, including changes of APM 
component expression. However, potent T cell responses are necessary to clear HPV infections and 
lesions. Until now, a systematic analysis of the whole APM has not been performed in a large array of 
HPV-positive tumor samples. Moreover, experimental evidence describing the immunological 
consequences of APM changes is limited.        
 The first aim of this thesis was a systematic analysis of the APM on the mRNA level in a 
comprehensive collection of HPV16-positive tumor cell lines compared to HPV-negative cell lines. 
According to this screen, selected APM components were analyzed on the protein level in selected cell 
lines. This analysis revealed that the only APM component that was consistently overexpressed in 
HPV16-positive cell lines was ERAP1. This could be confirmed in immunohistochemistry of cervical 
tissue including all three grades of CIN and established cervical cancer. The second aim of this thesis 
was to analyze whether the elevated ERAP1 expression impacts on the HPV16 E6 and E7 epitope 
presentation. This question was addressed first by analyzing HLA-A2-restricted peptides using a 
highly sensitive mass spectrometry approach and second by peptide-specific CTLs in cytotoxicity 
assays.  
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2 Materials and Methods 
2.1 Materials 
2.1.1 Laboratory equipment  
Equipment Name Company 
Analytical balance  Ohaus, Nänikon, Switzerland 
Cell counter 
Countess® Automated Cell 
Counter 
Invitrogen, Carlsbad, CA, USA 
Cell freezing device Cryo-Safe cryogenic vial cooler 
Bel-Art Products, Wayne, NJ, 
USA 
Centrifuge 
Biofuge Pico, Fresco 
Centrifuge 5417R, 5418 
Labofuge 400R 
Minicentrifuge SU1550 
Multifuge® 16R 
Refrigerated Ultracentrifuge 
Sorvall RC5C 
Heraeus, Hanau 
Eppendorf, Hamburg 
Heraeus, Hanau 
Sunlab, Aschaffenburg 
Heraeus, Hanau 
DuPont Instruments 
Centrifuge rotor 
75008179 
A-8-11 
FA-45-18-11 
FA-45-30-11 
TX-400 
M-20 
Heraeus, Hanau  
Eppendorf, Hamburg 
Eppendorf, Hamburg 
Eppendorf, Hamburg 
Heraeus, Hanau 
Heraeus, Hanau 
Cytology processor Cytyc ThinPrep® 2000 system Hologic, Wiesbaden 
Documentation agarose gels 
Gel Jet Imager 2006 
Printer P39D 
Intas, Göttingen 
Mitsubishi, Electric, Tokio 
 Gel Doc ™ EZ Imager Biorad, Hercules, CA, USA 
Documentation polyacrylamide 
gels 
Fusion-SL chemiluminescence 
camera 
Vilber Lourmat, Eberhardzell 
Electrophoresis chamber for 
agarose gels 
Owl Easycast B2 
Owl Seperation Systems, 
Portsmouth, NH, USA 
Electrophoresis chamber for 
SDS-PAGE  
Mini-PROTEAN® Tetra Cell Biorad, Hercules, CA, USA 
ELISpot plate reader 
CTL-Immunospot® S6 Ultra-
UV 
CTL, Bonn 
Flow cytometer FACS Canto II™ 
BD Biosciences, Franklin Lakes, 
NJ, USA 
Freezer (-20°C) Mediline  Liebherr, Biberach an der Riss 
Bosch, Stuttgart 
Freezer (-80°C) U725 Innova New Brunswick, Nürtingen 
Glasware 
Duran 
Fisherbrand 
Schott, Mainz 
Thermo Fisher Scientific, 
Waltham, MA, USA  
Ice machine Hoshizaki Cube Star Hoshizaki, Tokio, Japan 
Incubator (37°C, 5% CO2, cell 
culture) 
Heracell 150i 
 
C200 
Thermo Fisher Scientific, 
Waltham, MA, USA 
Labotec Göttingen 
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Incubator (37°C)  WTB Binder, Tüttlingen 
Irradiator Gammacell 1000 
Atomic Energy of Canada 
Limited, Ottawa, Canada 
Laminar flow hood SterilGard® Class II TypA B3  
The Baker Company, Sanford, 
ME, USA 
Light microscope 
Wilovert Standard 30 
microscope 
Olympus BX43, Olympus 
Colorview Camera 
Hund Wetzlar, Wetzlar  
 
Olympus, Hamburg 
Liquid nitrogen tank Locator 8 plus 
Barnstead/Thermolyne, 
Dubuque, IA, USA 
Magnet for MACS Quadro MACS 
Miltenyi Biotec, Bergisch 
Gladbach 
Magnetic stirrer Combimag RCO  
IKA-Werke GmbH, Staufen 
Heidolph Instruments, 
Schwabach 
Mass spectrometer Qtrap6500 Ab Sciex, Foster City, CA, USA 
Microwave  Sharp, Osaka, Japan 
Multilable plate reader 
Multiskan™ FC microplate 
photometer 
Thermo Scientific, Rockford, IL, 
USA 
 Victor3 
Perkin Elmer, Waltham, MA, 
USA 
Nano Drop ND-1000 
PeqLab Biotechnologies, 
Erlangen 
Neubauer cell counting 
chamber 
Profondeur Brand, Wertheim  
PCR cycler 
C1000 Touch™ Thermal 
Cycler  
PTC-200 
Biorad, Hercules, CA, USA 
 
MJ Research, Canada 
pH Meter 
766 
MP220 InLab Microelectrode 
Knick, Berlin 
Mettler Toledo, Glostrup, 
Denmark 
Pipette-Boy Pipetboy acu Integra Biosciences, Biebertal 
Pipettes (single-channel) 
Pipetman® Gilson  
FinnPipette F2 
 
ErgoOne 
Eppendorf Reference® 
Gilson, Bad Camberg 
Thermo Scientific, Rockford, IL, 
USA 
Starlab, Hamburg 
Eppendorf, Hamburg 
Pipette (multi-channel) 
Transferpette® S-12, 20-200µl, 
yellow 
Brand, Wertheim 
Pipettes glass  
Hirschmann Labortechnik, 
Eberstadt 
Platform shaker 
STR6 
 
Rotamax120 
 
3013 
Stuart Bibby Scientific, 
Staffordshire, UK 
Heidolph Instruments, 
Schwabach 
GFL, Burgwedel 
Power supply 
EPS500-400, EPS3500 
MP 250V 
 
PowerPac300 
Pharmacia, Uppsala, Sweden 
MS Major Science, Saratoga, 
CA, USA 
BioRad, Hercules, CA, USA 
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Pump N86KT.18 KNF Neuberger, Freiburg 
Quantitative PCR MX300P qPCR System 
Agilent Technologies, 
Waldbronn 
Refrigerator (4°C) 
Mediline  
 
Liebherr, Biberach an der Riss 
Bosch, Stuttgart 
Rolling shaker CAT RM5 Zipperer, Staufen 
Rotator  NeoLab, Heidelberg 
Scale Kern EG 4200-2NM Kern & Sohn, Balingen 
Surgical tweezer and scissors  Dimeda, Tuttlingen 
Thermomixer Thermomixer compact Eppendorf, Hamburg 
Trans-blot Semidry Transfer 
Cell 
 Biorad, Hercules, CA, USA 
Ultrasonic water bath 
VWR Ultrasonic cleaner 
USC300TH 
VWR International, Leuven, 
Belgium 
UPLC nanoAcquity UPLC system Waters, Milford, MA, USA 
Vacuum centrifuge Speedvac concentrator 
Bachofer, Laboratoriumsgeräte, 
Reutlingen 
Vortexer Vortex-Genie 2 
Scientific Industries, Bohemia, 
NY, USA 
Water bath  GFL, Burgwedel 
Water purification system TKA™ X-CAD Thermo Scientific, Braunschweig 
WB transfer chamber (tank 
blot) 
Mini Trans-Blot® Cell Biorad, Hercules, CA, USA 
WB transfer chamber (semidry)  Cti, Idstein/Taunus 
 
2.1.2 Consumables 
Name Company 
96-well qPCR plate semi-skirted, transparent 
Applied Biosystems at Thermo Fisher Scientific, 
Waltham, MA, USA 
Aluminium foil CeDo GmbH, Mönchengladbach 
Blood collection tubes (Sodium Heparin, 170 
I.U.) 
BD, Plymouth, UK 
Blood collection set (Safety-lok™) BD, Franklin Lakes, NJ, USA 
Cell culture dish (60mm D x 16mm H; 6cm ø) TPP, Trasadingen, Switzerland 
Cell culture dish (100mm D x 20mm H; 10cm ø) TPP, Trasadingen, Switzerland 
Cell culture flask (25cm2) TPP, Trasadingen, Switzerland 
Cell culture flask (75cm2) TPP, Trasadingen, Switzerland 
Cell culture flask (150cm2) TPP, Trasadingen, Switzerland 
Cell culture plate “CytoOne” (6-well) Starlab, Hamburg 
Cell culture plate (12-well) Corning, Corning, NY, USA 
Cell culture plate (24-well) Corning, Corning, NY, USA 
Cell culture plate (48-well) Corning, Corning, NY, USA 
Cell culture plate (96-well) 
- Flat bottom 
- U bottom 
 
BD, Franklin Lakes, NJ, USA 
TPP, Trasadingen, Switzerland 
Cell scraper Sarstedt, Newton, NC, USA 
Cell strainer (40µM, 70µM) BD, Corning, NY, USA 
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Cling film  CeDo GmbH, Mönchengladbach 
Countess® cell counting chamber slides Invitrogen, Carlsbad, CA, USA 
Cryogenic vials (Nalgene) Thermo Fisher Scientific, Rochester, NY, USA 
ESI emitters  New objective, Woburn, USA 
FACS tubes (5ml Polystrene round-bottom tube) BD, Franklin Lakes, NJ, USA 
Falcon tubes (15ml and 50ml) Nerbe Plus, Winsen 
Leucosep™ Greiner Bio-One, Frieckenhausen 
Filter (Millex®-GS, pore size 0.22µm) Merck Milipore, Cork, Ireland 
GammaBind™ Plus Sepharose™ GE Healthcare, München 
Gel-loading tips Starlab, Hamburg 
Gloves  Microflex, Reno, NV, USA 
Immobilon®-P PVDF Transfer Membrane Millipore, Bedford, MA, USA 
Kimwipes delicate task wipers Kimberly-Clark, Irving, TX, USA 
Kimtech precision wipes tissue wipers Kimberly-Clark, Irving, TX, USA 
MACS Seperation Column LS Miltenyi Biotec, Bergisch Gladbach 
MultiScreen®-HA, 96-well filtration plate Merck Milipore, Cork, Ireland 
Mini-PROTEAN®TGX™ gels, Any kD™, 
various combs 
Biorad, Hercules, CA, USA 
nanoAcquity UPLC column, 75µm ID, length 
25cm, 1.7µm CSH130 C18 material 
Waters, Milford, MA, USA 
NuPAGE Novex 4–12% Bis-Tris Mini Gels Life Technologies, Brown Deer, WI, USA 
Optical adhesive covers Applied Biosystems 
Pap Pen Dako Agilent Pathology Solutions, Hamburg 
Parafilm Bemis, Neeah, WI, USA 
PVDF Transfer Membrane Thermo Scientific, Rockford, IL, USA 
Pipette tips, with and without filter Starlab, Hamburg 
Reaction tubes (0.2ml, 0.5ml, 1.5ml and 2ml)  Starlab, Hamburg 
Reaction tubes, black, flip cap (1.5ml) NeoLab, Heidelberg 
Reaction tubes, protein low binding (1.5ml) Eppendorf, Hamburg 
Scalpel  Feather, Osaka, Japan 
Syringe (2ml Injekt®)  Braun, Melsungen  
Syringe (10ml BD Plastipak Luer-Lok™) BD, Drogheda, Ireland 
Syringe (20ml BD Plastipak Luer-Lok™) BD, Drogheda, Ireland 
Syringe (50ml BD Plastipak Luer-Lok™) BD, Drogheda, Ireland 
Syringe for MS injection (500µl and 1ml) Hamilton, Reno, USA 
UPLC vials MZ-Analysentechnik, Mainz, Germany 
Vacuum filter (bottle top, 500ml, pore size 
0.22µM) 
TPP, Trasadingen, Switzerland 
Western Blotting Filter Paper Thermo Scientific, Rockford, IL, USA 
 
2.1.3 Chemicals and biological reagents 
Product Company 
6x Orange DNA Loading Dye  Thermo Fisher Scientific Ldt., Loughborogh, UK 
Acetic acid (100%) Merck Millipore, Billerica, MA, USA 
Acetone Sigma-Aldrich, Taufkirchen 
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Acteonitrile (I), HPLC/MS grade Biosolve BV, CE Valkenswaard, The Netherlands 
Agarose NEEO Ultra-Qualität Roti®garose Roth, Karlsruhe 
Albumin, from bovine serum albumin (BSA) Sigma-Aldrich, Taufkirchen 
Ammonium chloride (NH4Cl) Roth, Karlsruhe 
Ammonium hydroxide (NH4OH) Sigma-Aldrich, Steinheim 
Aquatex® aqueous mounting agent Merck Millipore, Darmstadt 
β-mercaptoethanol Roth, Karlsruhe 
BCIP/NBT-Plus substrate for ELISpot Mabtech, Nacka Strand, Sweden 
Bromophenol blue sodium salt Roth, Karlsruhe 
BSA standard Biorad, Hercules, CA, USA 
Calcium chloride (CaCl2) Sigma-Aldrich, Taufkirchen 
Carboxyfluorescein (CFSE) Invitrogen, Carlsbad, CA, USA 
CEF Control Peptide Pool HLA Class I PANATecs, Heilbronn 
CE Peptide Pool HLA-A24 PANATecs, Heilbronn 
Citric acid AppliChem, Darmstadt 
Complete mini protease inhibitor cocktail Roche, Basel, Switzerland 
Concanavalin A (ConA) from Canavalia 
ensiformis 
Sigma-Aldrich, Steinheim 
Deoxynucleoside Triphosphate Roche, Mannheim 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Taufkirchen 
Disodium hydrogen phosphate (Na2HPO4 2 H2O) Sigma-Aldrich, Taufkirchen 
Distilled DNase/RNase free water MP Biomedicals, Illkirch, France 
ECL Prime Western Blotting Detection Reagent GE Healthcare, Buckinghamshire, UK 
Empore Octyl C8 extraction material 3M company, St. Paul, MN, USA 
Ethanol (absolute) Sigma-Aldrich, Taufkirchen 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich, Taufkirchen 
FarRed (dimethyldodecylamine oxide-
succinimidyl ester) 
Invitrogen, Carlsbad, CA, USA 
Formic acid (FA), LC/MS grade 
ProteoChem, Inc., Denver, USA 
Biosolve BV, CE Valkenswaard, The Netherlands 
GelRed™ 10,000x in water Biotium, CA, USA 
Glow Writer Phosphorescent Marking Pen Diversified Biotech, MA, USA 
Glycerole Sigma-Aldrich, Taufkirchen 
Glycine Sigma-Aldrich, Taufkirchen 
Hydrogen chloride (HCl) VWR International, Fontenay-sous-Bois, France  
Hydrogen peroxide (H2O2) Sigma-Aldrich, Taufkirchen 
IGE-PAL-630 Sigma-Aldrich, Taufkirchen 
Isopropanol  Sigma-Aldrich, Taufkirchen 
Magnesium chloride (MgCl2) Roche, Branchburg, NJ, USA 
Mayer’s Hematoxylin Dako Agilent Pathology Solutions, Hamburg 
Methanol Sigma-Aldrich, Taufkirchen 
Milk powder, low-fat Roth, Karlsruhe 
Nonyl phenoxypolyethoxylethanol (NP-40) Sigma-Aldrich, Taufkirchen 
OneComp eBeads eBioscience, San Diego, CA, USA 
Pefabloc Merck, Whitehouse Station, NJ, USA 
Phenylmethylsulfonylfluorid (PMSF) Roth, Karlsruhe 
Pierce ECL Western Blotting Substrate Thermo Fisher Scientific, Waltham, MA, USA 
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Ponceau red solution Serva, Heidelberg 
Potassium bicarbonate (KHCO3) Roth, Karlsruhe 
Potassium chloride (KCl) Roth, Karlsruhe 
Potassium dihydrogen phosphate (KH2PO4) Roth, Karlsruhe 
PreservCyt solution Hologic, Wiesbaden 
Protease Inhibitor Cocktail Sigma-Aldrich, Steinheim 
Proteinase K Qiagen, Hilden 
Seppak extraction cartridge C18 Waters, Milford, MA, USA 
Sodium acetate (C2H3NaO2) Roth, Karlsruhe 
Sodium azide (NaN3) AppliChem, Darmstadt 
Sodium bicarbonate (NaHCO3) Sigma-Aldrich, Taufkirchen  
Sodium chloride (NaCl) Sigma-Aldrich, Taufkirchen 
Sodium dihydrogen phosphate (NaH2PO4 2 H2O) Sigma-Aldrich, Taufkirchen 
Sodium dodecyl sulfate (SDS), ultrapure Roth, Karlsruhe 
Sodium deoxycholate (Na-DOC) AppliChem, Darmstadt 
Sodium hydroxide (NaOH) Sigma-Aldrich, Taufkirchen 
Streptavidin-Alkaline Phosphatase Mabtech, Nacka Strand, Sweden 
ThinPrep®, cytology slides Hologic, Wiesbaden 
Trifluoroacetic acid (TFA), > 99% pure, protein 
sequencing grade 
Sigma-Aldrich, Steinheim 
Trizmabase Sigma-Aldrich, Taufkirchen 
Trypan blue stain (0.4%) Invitrogen, Carlsbad, CA, USA 
Tween20 (= Polysorbat 20) MP Biomedicals, Illkirch, France 
LC/MS grade water  Biosolve BV, CE Valkenswaard, The Netherlands 
Xylol VWR Chemicals, Darmstadt 
Zorbax C18 chromatographic material, 5µm Agilent Technologies, Santa Clara, CA, USA 
 
2.1.4 Cell culture basal media and supplements 
Basal media 
Product Company 
DermaLife K serum free keratinocyte culture 
medium 
Cell Systems, Troisdorf 
Dulbecco’s Modified Eagle Medium (DMEM) Sigma-Aldrich, Taufkirchen 
DMEM with GlutaMAX™ Invitrogen, Carlsbad, CA, USA 
Eagle’s minimum essential medium (EMEM) Sigma-Aldrich, Taufkirchen 
Iscove’s Modified Dulbecco’s Medium (IMDM) Life Technologies, Brown Deer, WI, USA 
Ham’s F12 Nutrient Mix Invitrogen, Carlsbad, CA, USA 
Keratinocyte serum-free medium (K-SFM) Invitrogen, Carlsbad, CA, USA 
Opti-MEM® Invitrogen, Darmstadt 
RPMI 1640 with L-glutamine  Sigma-Aldrich, Taufkirchen 
  
Supplements 
Product Company 
Adenine PAA Laboratories, Cölbe 
β-mercaptoethanol, 50mM, sterile Life Technologies, Grand Island, NY, USA 
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Bovine pituitary extract (BPE) Invitrogen, Carlsbad, CA, USA 
Calcium chloride (CaCl2) Sigma-Aldrich, Steinheim 
Cholera toxin Sigma-Aldrich, Taufkirchen 
Cyclosporin A Sigma, St. Louis, MO, USA 
Epidermal growth factor (EGF)  Invitrogen, Carlsbad, CA, USA 
Fetal Calf Serum (FCS) 
Biowest, Nuaillé, France 
Sigma-Aldrich, Taufkirchen 
Ficoll-Paque™ Plus GE Healthcare Bio-Sciences, Uppsala, Sweden  
G-418 Sulfate  Cayman Chemical, Ann Arbor, MI, USA 
Gentamycin BioConcept, Allschwil, Switzerland 
GM-CSF, recombinant human R & D Systems, Minneapolis, MN, USA 
HEPES Life Technologies, Grand Island, NY, USA 
Human serum, type AB Sigma-Aldrich, Taufkirchen 
Hydrocortizone Sigma-Aldrich, Taufkirchen 
IL-1β, recombinant, human R & D Systems, Minneapolis, MN, USA 
IL-2, recombinant, human PeproTech, Rocky Hill, NJ, USA 
IL-4, recombinant, human R & D Systems, Minneapolis, MN, USA 
IL-6, recombinant, human R & D Systems, Minneapolis, MN, USA 
IL-7, recombinant, human R & D Systems, Minneapolis, MN, USA 
IFNγ, recombinant, human BASF, Ludwigshafen 
Insulin, recombinant, human Sigma-Aldrich, Taufkirchen 
L-glutamine Sigma-Aldrich, Taufkirchen 
Lipopolysaccharide (LPS) Invivogen, Toulouse, France 
MEM non-essential amino acid solution (MEM 
NEAA) 
Invitrogen, Carlsbad, CA, USA 
Paraformaldehyde (PFA) Sigma-Aldrich, Taufkirchen 
Penicillin/Streptomycin-Solution (P/S) Sigma-Aldrich, Taufkirchen 
Prostaglandin E2 (PGE2) Cayman Chemical, Ann Arbor, MI, USA 
Sodium bicarbonate (NaHCO3) Sigma-Aldrich, Taufkirchen 
Sodium pyruvate (C3H3NaO3) PAA Laboratories, Cölbe 
TNFα, recombinant human R & D Systems, Minneapolis, MN, USA 
Transferrin, recombinant human Sigma-Aldrich, Taufkirchen 
Tri-iodo-thyronine Sigma-Aldrich, Taufkirchen 
Trypsin-EDTA solution Sigma-Aldrich, Taufkirchen 
 
2.1.5 Kits 
Name Company 
AccuScript High Fidelity 1st Strand cDNA 
Synthesis Kit 
Agilent Technologies, Waldbronn 
CD8 T Cell untouched Isolation Kit, human Miltenyi Biotec, Bergisch Gladbach 
CD14 microbeads, human Miltenyi Biotec, Bergisch Gladbach 
DC™ Protein Assay Biorad, Hercules, CA, USA 
DharmaFECT I Thermo Fisher Scientific, Carlsbad, CA, USA 
Lipofectamine® RNAiMAX Invitrogen, Carlsbad, CA, USA 
peqGOLD Gel Extraction Kit PEQLAB Biotechnologie, Erlangen 
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QIAamp DNA Mini Kit Qiagen, Hilden 
QIAquick PCR Purification Kit Qiagen, Hilden 
QuantiTect Reverse Transcription Kit Qiagen, Hilden 
QIAshredder Homogenization Kit Qiagen, Hilden 
RNeasy Mini Kit Qiagen, Hilden 
TaqMan® Gene Expression Assay Kits 
Applied Biosystems at Thermo Fisher Scientific, 
Waltham, MA, USA 
TaqMan® Gene Expression Master Mix 
Applied Biosystems at Thermo Fisher Scientific, 
Waltham, MA, USA 
VECTASTAIN Elite ABC Kit Vector Laboratories, Burlingame, CA, USA 
 
2.1.6 Enzymes 
Enzyme Company 
AmpliTaq Gold® Roche, Branchburg, NJ, USA 
KOD Hot Start Master Mix Merck Millipore, Billerica, MA, USA 
 
2.1.7 Antibodies 
Name Clone Species Company 
Western blot 
anti-HPV16 E7 NM2 mouse 
Kindly provided by Martin Müller, 
Tumorvirus-specific Vaccination 
Strategies, DKFZ, Heidelberg 
anti-human α-tubulin B-5-1-2 mouse Sigma-Aldrich, Steinheim 
anti-human β-actin AC-74 mouse Sigma-Aldrich, Steinheim 
anti-human calreticulin EPR3924 rabbit Merck Millipore, Billerica, MA, USA 
anti-human ERAP1 EPR6069 rabbit OriGene, Rockville, MD, USA 
anti-human ERAP2 3F5 rabbit R&D Systems, MN, USA 
anti-human MHC class I EP1395Y rabbit Abgent, San Diego, CA, USA 
anti-human PSMB8 polyclonal rabbit Enzo Life Sciences, Lörrach 
anti-human PSMB9 polyclonal rabbit Enzo Life Sciences, Lörrach 
anti-human PSMB10 polyclonal rabbit Enzo Life Sciences, Lörrach 
anti-human PSME1 polyclonal rabbit Enzo Life Sciences, Lörrach 
anti-human PSME1 polyclonal rabbit Enzo Life Sciences, Lörrach 
anti-human tapasin polyclonal rabbit LifeSpan BioSciences, WA, USA 
    
Immunohistochemistry 
anti-human ERAP1 EPR6069 rabbit OriGene, Rockville, MD, USA 
anti-human p16INK4a (CINtec® 
Histology) 
E6H4 mouse Roche mtm Laboratories, Mannheim 
    
ELISpot 
anti-human IFNγ 1-D1K mouse Mabtech, Nacka Strand, Sweden 
anti-human IFNγ biotin 7-B6-1 mouse Mabtech, Nacka Strand, Sweden 
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Immunoprecipitation 
anti-human HLA-A2 BB7.2 mouse 
BD Biosciences, San Diego, CA, USA 
and a kind gift from Hans-Georg 
Rammensee (University of Tübingen, 
Germany)  
    
Flow cytometry 
anti-human CD3-Pacific Blue™ UCHT1 mouse BioLegend, San Diego, CA, USA 
anti-human CD4-PE  RPA-T4 mouse BD Biosciences, San Diego, CA, USA 
anti-human CD8-APC SK1 mouse BioLegend, San Diego, CA, USA 
anti-human CD8-FITC RPA-T8 mouse BD Biosciences, San Diego, CA, USA 
anti-human CD14-FITC M5E2 mouse BD Biosciences, San Diego, CA, USA 
anti-human CD19-Pacific 
Blue™ 
HIB19 mouse BioLegend, San Diego, CA, USA 
anti-human CD40-APC HB14 mouse BioLegend, San Diego, CA, USA 
anti-human CD80-PE/Cy7 2D10 mouse BioLegend, San Diego, CA, USA 
anti-human CD83-PE/Cy7 HB15e mouse BD Biosciences, San Diego, CA, USA 
anti-human CD86-APC 2331 mouse BD Biosciences, San Diego, CA, USA 
anti-human CD154-PE 24-31 mouse BioLegend, San Diego, CA, USA 
anti-human HLA-A2-FITC BB7.2 mouse BioLegend, San Diego, CA, USA 
anti-human HLA-A24 17A10 mouse MBL, Nagano, Japan 
anti-human HLA-A,-B,-C-FITC W6/32 mouse BioLegend, San Diego, CA, USA 
Mouse IgG1 κ isotype control-
Pacific Blue™ 
MOPC-21 mouse BioLegend, San Diego, CA, USA 
    
Conjugated secondary antibodies 
anti-mouse IgG (H&L) 
horseradish peroxidase (HRP) 
anti-mouse 
IgG (H&L) 
horseradish 
peroxidase 
(HRP) 
goat Dianova, Hamburg 
anti-mouse IgG (H&L) HRP 
anti-mouse 
IgG (H&L) 
HRP 
goat Promega, Madison, WI, USA 
anti-rabbit IgG (H&L) HRP 
anti-rabbit 
IgG (H&L) 
HRP 
goat 
Rockland Immunochemicals, Limerick, 
PA, USA 
anti-mouse FITC 
anti-mouse 
FITC 
goat BD Biosciences, San Diego, CA, USA 
 
2.1.8 Cell lines 
Cell line Description HPV status Source Medium Reference 
866 
human, 
cervical, 
adherent  
HPV16 
positive 
kindly provided by 
Peter L. Stern, 
University of 
Manchester, 
Manchester, UK 
F-medium (178) 
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915 
human, 
cervical, 
adherent 
HPV16 
positive 
kindly provided by 
Peter L. Stern, 
University of 
Manchester, 
Manchester, UK 
F-medium (178) 
C66-3 
human, 
cervical, HPV-
transfected, 
adherent 
HPV16 
positive 
kindly provided by 
John H. Lee, Sanford 
Health Center, Sioux 
Falls, SD, USA 
E-medium (179) 
C66-7  
human, 
cervical, HPV-
transfected, 
adherent 
HPV16 
positive 
kindly provided by 
John H. Lee, Sanford 
Health Center, Sioux 
Falls, SD, USA 
E-medium (179) 
CaSki 
human, 
cervical, 
adherent 
HPV16 
positive 
kindly provided by 
Felix Hoppe-Seyler, 
Molecular Therapy of 
Virus-Associated 
Cancers, DKFZ, 
Heidelberg; 
purchased from 
ATCC 
complete 
DMEM 
 
 
 
 
CaSki 
medium 
(180) 
FK16A 
human, 
foreskin 
keratinocytes, 
HPV-
transfected, 
adherent 
HPV16 
positive 
kindly provided by 
Renske Steenbergen, 
University Medical 
Center Amsterdam, 
Netherlands 
complete 
K-SFM 
(181) 
Goe 
human, 
cervical, 
adherent 
HPV16 
positive 
kindly provided by 
Andreas Kaufmann, 
Charité, Berlin 
M10 
medium 
 
HPK1A 
human, 
foreskin 
keratinocytes, 
HPV-
transfected, 
adherent 
HPV16 
positive 
Kindly provided by 
Elisabeth Schwarz, 
Molecular 
Diagnostics of 
Oncogenic Infections, 
DKFZ, Heidelberg 
complete 
DMEM 
(182) 
Mar 
human, 
keratinocytes, 
adherent 
HPV16 
positive 
kindly provided by 
Andreas Kaufmann, 
Charité, Berlin 
complete 
DMEM 
 
MRIH196 
human, 
cervical, 
adherent 
HPV16 
positive 
kindly provided by 
Elisabeth Schwarz, 
DKFZ, Heidelberg 
complete 
DMEM 
(183) 
SiHa 
human, 
cervical,  
adherent 
HPV16 
positive 
kindly provided by 
Felix Hoppe-Seyler, 
Molecular Therapy of 
Virus-Associated 
Cancers, DKFZ, 
Heidelberg 
complete 
DMEM 
(184) 
SNU1000 
human, 
cervical,  
adherent 
HPV16 
positive 
Korean Cell Line 
Bank, Seoul, South 
Korea 
complete 
RPMI-H 
(185) 
SNU1005 
human, 
cervical,  
adherent 
HPV16 
positive 
Korean Cell Line 
Bank, Seoul, South 
Korea 
complete 
RPMI-H 
(185) 
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SNU1299 
human, 
cervical,  
adherent 
HPV16 
positive 
Korean Cell Line 
Bank, Seoul, South 
Korea 
complete 
RPMI-H 
(185) 
SNU17 
human, 
cervical,  
adherent 
HPV16 
positive 
Korean Cell Line 
Bank, Seoul, South 
Korea 
complete 
RPMI-H 
(185) 
SNU703 
human, 
cervical, 
adherent 
HPV16 
positive 
Korean Cell Line 
Bank, Seoul, South 
Korea 
complete 
RPMI-H 
(185) 
2A3 
human, 
HNSCC, HPV-
transfected, 
adherent 
HPV16 
positive 
kindly provided by 
Ekaterina Dadachova, 
Albert Einstein 
College of Medicine, 
Bonx, NY, USA 
2A3 
medium 
(186) 
93VU147T 
human, 
HNSCC, 
adherent 
HPV16 
positive 
kindly provided by 
Renske Steenbergen, 
University Medical 
Center Amsterdam, 
Netherlands 
complete 
DMEM 
(187) 
SCC090 
human, 
HNSCC, 
adherent 
HPV16 
positive 
kindly provided by 
Susanne Gollins, 
University of 
Pittsburgh, Pittsburgh, 
PA, USA  
M10 
medium 
(188) 
SCC152 
human, 
HNSCC, 
metastasis of 
SCC90, 
adherent 
HPV16 
positive 
kindly provided by 
Susanne Gollins, 
University of 
Pittsburgh, Pittsburgh, 
PA, USA 
M10 
medium 
(188) 
SCC154 
human, 
HNSCC,  
HPV16 
positive 
kindly provided by 
Susanne Gollins, 
University of 
Pittsburgh, Pittsburgh, 
PA, USA 
M10 
medium 
(189) 
UDSCC2 
human, 
HNSCC, 
adherent 
HPV16 
positive 
kindly provided by 
Thomas Hoffmann, 
Uniklinikum Essen, 
Essen 
complete 
RPMI-P + 
1% (v/v) 
P/S 
(190) 
UMSCC47 
human, 
HNSCC, 
adherent 
HPV16 
positive 
kindly provided by 
Tom Carey, 
University of 
Michigan, Ann Arbor, 
MI, USA 
complete 
DMEM 
(191) 
SNU1160 
human, 
cervical,  
adherent 
HPV18 
positive 
Korean Cell Line 
Bank, Seoul, South 
Korea 
complete 
RPMI-H 
(185) 
C33A 
human, 
cervical, 
adherent 
HPV  
negative 
kindly provided by 
Felix Hoppe-Seyler, 
Molecular Therapy of 
Virus-Associated 
Cancers, DKFZ, 
Heidelberg 
complete 
DMEM 
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HaCat 
human, 
keratinocytes, 
adherent 
HPV 
negative 
kindly provided by 
Petra Boukamp, 
Genetics of Skin 
Carcinogenesis, 
DKFZ, Heidelberg 
complete 
DMEM 
(192) 
NOK 
human, oral 
keratinocytes 
(hTERT 
immortalized) 
HPV 
negative 
kindly provided by 
Karl Münger, 
Brigham and 
Women’s Hospital, 
Boston, MA, USA 
complete 
K-SFM 
(193) 
RiSh 
human, B-
LCL, EBV-
immortalized, 
suspension 
HPV 
negative 
generated from a 
healthy blood donor 
by Stephanie Hoppe, 
Immunotherapy and   
-prevention, DKFZ, 
Heidelberg  
B-LCL 
medium 
(194) 
tCD40L 
NIH3T3 
mouse, 
fibroblasts, 
transduced 
with human 
tCD40L 
HPV 
negative 
kindly provided by 
Derin Keskin, 
Harvard Medical 
School, Boston, MA, 
USA 
NIH 3T3 
tCD40L, 
NIH 3T3 
WT 
(195) 
 
2.1.9 Primary cells 
Cell line Description Source Medium 
primary human 
keratinocytes (pHK) 
human, keratinocytes, 
adherent 
kindly provided by 
Petra Boukamp, 
Genetics of Skin 
Carcinogenesis, DKFZ, 
Heidelberg 
Complete DermaLife K 
primary human 
foreskin keratinocytes 
(pHFK)  
human, keratinocytes, 
adherent 
purchased from Life 
Technologies, CA, 
USA  
Complete DermaLife K 
 
2.1.10 Primers 
All primers used in this study were synthesized by Sigma-Aldrich (Taufkirchen). The primers in the 
Table below are listed in the direction 5’3’.  
Primers for ERAP1 amplification and sequencing 
ERAP1 F ATGGTGTTTCTGCCCCTCAAATGG 
ERAP1 F 955 CAGCATACCGTATCCCCTACCC 
ERAP1 F 1773 CACCAGCAAATCCGACATGGTCC 
ERAP1 F seq6 AAGTGGAAGGAATCCAATGG 
ERAP1 F seq7 AATACGACTTCCTGAGTACG 
ERAP1 R TTACATACGTTCAAGCTTTTCACTTT 
ERAP1 R 1031 CAGTCCCCAGTTTTCCATAGCACC 
ERAP1 R 1881 GTAATAGCCATTCATGCCCACATTA 
ERAP1 seq1 GATTTTGAGTCTGTCAGCAAGAT 
ERAP1 seq2 GGGGAGGAATGTACACATGA 
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ERAP1 seq3 CCCTAGATATCTGCAGGTGG 
Other primers 
HPRT1.FOR TATGGACAGGACTGAACGTCTT 
HPRT1.REV TCCCCTGTTGACTGGTCATT 
Myco1.F GGGAGCAAACAGGATTAGATACCCT 
Myco2.R TGCACCATCTGTCACTCTGTTAACCTC 
 
2.1.11 TaqMan® Gene Expression Assays 
Gene  Assay ID NCBI ID Amplicon length 
β2m Hs00984230 m1 NM 004048.2 81 
calreticulin Hs00189032 m1 NM 004343.3 95 
calnexin Hs01558409 m1 NM 001024649.1, NM 001746.3 129 
ERAP1 Hs00429970 m1 
NM 001040458.1, NM 001198541.1, 
NM 016442.3 
66 
ERAP2 Hs01073631 m1 NM 001130140.1, NM 022350.3 116 
GAPDH Hs02758991 g1 NM 001256799.1, NM 002046.4 93 
HLA-A Hs01058806 g1 NM 001242758.1, NM 002116.7 70 
HLA-B Hs00818803 g1 NM 005514.6 189 
HLA-E Hs03045171 m1 NM 005516.5 130 
IPO8 Hs00183533 m1 NM 001190995.1, NM 006390.3 71 
PDIA3 Hs00607126 m1 NM 005313.4 129 
PGK1 Hs00943178 g1 NM 000291.3 73 
PPIA Hs04194521 s1 NM 021130.3 97 
PSMB10 Hs00988194 g1 NM 002801.3 60 
PSMB5 Hs00605652 m1 NM 001144932.1, NM 002797.3 149 
PSMB6 Hs00382586 m1 NM 002798.1 93 
PSMB7 Hs00160607 m1 NM 002799.2 120 
PSMB8 Hs00544757 g1 NM 148919.3, NM 004159.4 72 
PSMB9 Hs00160610 m1 NM 002800.4 80 
PSME1 Hs00389210 g1 NM 176783.1, NM 006263.2 115 
PSME2 Hs01923165 u1 NM 002818.2 95 
TAP1 Hs00388675 m1 NM 000593.5 74 
TAP2 Hs00241060 m1 NM 000544.3, NM 018833.2 66 
tapasin Hs00917451 g1 
NM 172208.2, NM 172209.2, 
NM 003190.4 
73 
 
2.1.12 Small interference RNAs (siRNAs) 
The siRNA sequences in the Table below are listed in the direction 5’3’. 
Name Target/Sequence Features Company 
siERAP1 ERAP1 (NCBI ID: 51752) 
pool of 30 specific 
siRNAs 
siTOOLs Biotech, 
Martinsried 
sicontrol  
pool of 30 non-specific 
siRNAs 
siTOOLs Biotech, 
Martinsried 
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siHPV16E6/E7 
CCGGACAGAGCCCAUUACA 
 
CACCUACAUUGCAUGAAUA 
 
CAACUGAUCUCUACUGUUA 
pool targets all 3 
HPV16 E6/E7 
transcript classes 
Ambion, Life 
Technologies, 
Carlsbad, CA, USA 
control siRNA CAGUCGCGUUUGCGACUGG 
contains at least 4 
mismatches to all 
known human genes 
Ambion, Life 
Technologies, 
Carlsbad, CA, USA 
 
2.1.13 Protein Marker 
Name Company 
Precision Plus Protein™ Standards 
Kaleidoscope™, 10-250kDa 
Biorad, Hercules, CA, USA 
 
2.1.14 DNA Ladder 
Name Company 
GeneRuler™ Ladder Mix, 100-10,000bp Thermo Fisher Scientific Ldt., Loughborogh, UK  
 
2.1.15 Buffers, solutions and media 
Molecular Biology 
50x TAE 
484g Tris  
41g C2H3NaO2 
37g EDTA 
pH 7.8 adjusted with acetic acid 
ad. 2l ddH2O 
dNTP mix 10mM each dATP, dCTP, dGTP, dTTP 
Proteinase K buffer 
50mM Tris 
20mM NaCl 
1mM EDTA 
1% (w/v) SDS 
pH 8.0 
  
Protein analysis 
0.5% IGE-PAL-630 buffer 
1xPBS 
0.5% (v/v) IGE-PAL-630 
10x SDS-PAGE running buffer 
30.3g Tris  
144g Glycine 
10g SDS 
ad. 1l ddH2O 
Complete mini protease inhibitor cocktail stock 
(14x) 
2 tablets dissolved in 1.5ml ddH2O 
GammaBind™ Plus Sepharose™ beads washing 
buffer 
ddH2O 
10% (v/v) acetic acid 
pH 3.0 
GammaBind™ Plus Sepharose™ beads storage 
buffer 
1x PBS 
0.02% (v/v) sodium azide 
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IP lysis buffer 
1xPBS 
1% (v/v) IGE-PAL-630 
2x complete mini protease inhibitor cocktail 
1mM PMSF 
PMSF stock (100mM) PMSF dissolved in 100% ethanol 
Protein sample buffer (4x) 
222.24mM Tris (pH 6.8) 
3.52% (w/v) SDS 
35.2% (v/v) glycerol 
0.016% (w/v) bromophenol blue 
10% (v/v) β-mercaptoethanol 
RIPA buffer 
1% (w/v) Na-DOC (Sodium Deoxycholate) 
0.1% (w/v) SDS 
0.15M NaCl 
0.01M Na-phosphate, pH 7 
2mM EDTA 
1% (v/v) NP-40 
1mM PMSF 
2x complete mini protease inhibitor cocktail  
RIPA buffer II 
0.5% (w/v) Na-DOC (sodium deoxycholate) 
0.1% (w/v) SDS  
150mM NaCl 
10mM Tris, pH 7.5 
1mM EDTA 
1% (v/v) NP-40 
25µl/ml Pefabloc 
10µl/ml Protease Inhibitor Cocktail 
Western blot blocking buffer 
1xPBS 
5% (w/v) milk powder  
Western blot semidry transfer buffer 
48mM Tris  
39mM glycine 
1.3mM SDS  
20% (v/v) methanol  
pH 9-9.4 
Western blot tank transfer buffer 
9g Tris 
43.2g glycine 
20% (v/v) methanol 
ad. 3l ddH2O 
Western blot washing buffer 
1xPBS  
0.1% (v/v) Tween20  
  
LC mobile phases and MS solutions prepared with LC/MS grade water 
Mobile phase A 
0.1% (v/v) FA 
0.01% (v/v) TFA 
in LC/MS grade water 
Mobile phase B 
0.1% (v/v) FA 
0.01% (v/v) TFA 
in ACN  
Solvent for manual injection of peptides 
50% (v/v) ACN 
0.1% (v/v) FA 
in LC/MS grade water 
Other solutions used for detergent removal from IP samples and LC-MS are indicated within the 
method section 2.2.2.7. 
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Other buffers 
10x Phosphate buffered saline (1xPBS)  
1.37M NaCl 
27mM KCl 
100mM Na2HPO4 
20mM KH2PO4
 
pH 7.2 adjusted with NaOH or HCl 
Ammonium-chloride-potassium (ACK) lysis 
buffer 
0.829g NH4Cl 
0.1g KHCO3 
0.38mg EDTA  
pH 7.2-7.4 adjusted with NaOH or HCl 
ad. 100ml ddH2O  
Antigen retrieval buffer 
ddH2O 
10mM citric acid 
pH 6.0 
Blocking buffer (FACS) 
1xPBS 
10% (v/v) FCS  
Blocking buffer (immunohistochemistry) 
1xPBS 
10% (v/v) horse serum 
FACS buffer 
1x PBS 
1% (v/v) FCS  
0.1% (v/v) NaN3
  
Fixation buffer 
1x PBS 
1% (w/v) PFA 
MACS buffer 
1xPBS 
0.5% (w/v) BSA  
2mM EDTA  
ELISpot washing buffer 
1xPBS 
0.05% (v/v) Tween20 
Permeabilization and washing buffer 
(immunohistochemistry) 
1x PBS 
0.1% (v/v) Tween20 
  
Cell culture media 
2A3 medium 
DMEM  
10% (v/v) FBS, 1% P/S, 0.2mg/ml G418 
B cell medium  
IMDM 
10% (v/v) human serum, AB, 2mM L-glutamine, 
50µg/ml human transferrin, 5µg/ml human 
insulin, 15µg/ml gentamycin 
B-LCL medium 
RPMI-1640 
10%-20% (v/v) FCS 
CaSki medium 
RPMI-1640 
1% (v/v) P/S, 10% (v/v) FCS, 2mM L-glutamine 
Cell freezing medium 
Heat-inactivated FCS or human serum with 20% 
DMSO  
Complete DermaLife K 
DermaLife K 
1% (v/v) P/S, 10% (v/v) FCS 
Complete DMEM 
DMEM 
1% (v/v) P/S, 10% (v/v) FCS, 2mM L-glutamine 
Complete K-SFM  
K-SFM 
1% (v/v) P/S, 10% (v/v) FCS, 5ng/ml EGF, 
50µg/ml bovine pituitary extract (BPE) 
Complete RPMI-P  
RPMI-1640 
15% (v/v) FCS, 1% 100mM sodium pyruvate 
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Complete RPMI-H 
RPMI-1640 
1% (v/v) P/S, 10% (v/v) FCS, 25mM HEPES, 
25mM NaHCO3 
DC medium 
DMEM with GlutaMAX™ 
1% (v/v) P/S, 10% (v/v) human serum, AB, 
10mM HEPES 
E-medium 
DMEM  
22.5% (v/v) Ham’s F12. 10% (v/v) FCS 1% (v/v) 
P/S, 0.5µg/ml hydrocortisone, 8.4ng/ml cholera 
toxin, 5µg/ml transferrin, 5µg/µL insulin, 
1.36ng/ml tri-iodo-thyronine, 5µg/ml EGF 
F-medium 
Ham’s F12  
DMEM 25% (v/v), 5% (v/v) FCS, 1% (v/v) P/S, 
0.4mg/ml hydrocortisone, 0.5µg/ml cholera toxin, 
5µg/ml insulin, 24.2µg/ml adenine, 0.1µg/ml EGF 
M10 medium 
EMEM 
10% (v/v) FCS, 1% (v/v) P/S, 2mM L-glutamine, 
1% (v/v) MEM NEAA 
T cell medium  
RPMI 
1% (v/v) P/S, 10% (v/v) human serum, AB, 2mM 
L-glutamine, 12.5mM HEPES, 0.05mM β-
mercaptoethanol 
T cell ELISpot medium 
RPMI 
1% (v/v) P/S, 5% (v/v) FCS, 2mM L-glutamine, 
12.5mM HEPES, 0.05mM β-mercaptoethanol 
NIH3T3 tCD40L  
Ham’s F12/DMEM 
10% (v/v) FCS, 2mM L-glutamine, 10mM 
HEPES, 15µg/ml gentamycin, 500µg/ml G418 
NIH3T3 WT 
Ham’s F12/DMEM 
10% (v/v) FCS, 2mM L-glutamine, 10mM 
HEPES, 15µg/ml gentamycin 
 
2.1.16 Peptides 
Peptides were synthesized with a purity of > 95% from the in-house Peptide Production Unit (Prof. 
Stefan Eichmüller, GMP & T Cell Therapy Unit, DKFZ, Heidelberg). For the solid phase synthesis, 
the Fmoc-strategy (196, 197) in a fully automated multiple synthesizer Syro II (MultiSyn Tech, 
Germany) was employed. The synthesis was carried out on preloaded Wang-Resins. 2-(1H-
benzotriazole-1-yl)-1, 1, 3, 3-tetramethyluronium hexafluorophosphate (HBTU) was used as a 
coupling agent. The material was purified by preparative HPLC on a Kromasil 100-10C 10µm 120A 
reverse phase column (20 x 150mm) using an eluent of 0.1% TFA in water (A) and 80% I in water 
(B). The peptide was eluted within 30min with a successive linear gradient of 25% B up to 80% B at a 
flow rate of 10ml/min. The fractions corresponding to the purified protein were lyophilized. The 
purified material was characterized with analytical HPLC and MS (Thermo Finnigan LCQ). 
Lyophilized peptides were dissolved in DMSO at a concentration of 10mg/ml and stocked in small 
aliquots at -80°C. 
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2.1.16.1 Control peptides 
Corresponding HLA alleles for peptide binding are indicated. 
Name Source Region Amino acid sequence HLA allele Reference 
Negative control peptides for ELISpot 
HIV-A2 HIV-1 Nef 137-145 LTFGWCFKL HLA-A2 (198) 
HIV-A24 HIV-1 Env gp41 583-591 RYLKDQQLL HLA-A24 (199) 
      
Positive control peptides for MS 
PC1 p68 RNA helicase 96-104 YLLPAIVHI HLA-A2  
PC2 coatomer subunit 
gamma-1 
147-155 AIVDKVPSV HLA-A2 
 
2.1.16.2 HP16 E6 and E7 peptides 
Corresponding HLA alleles for peptide binding are indicated. Bold letters are highlighting amino acid 
changes in peptides from HPV variants. 
E6 
Name Origin Region Amino acid sequence HLA allele 
E618-26variant HPV16 E6 18-26 KLPDLCTEL HLA-A2 
E618-28 HPV16 E6 18-28 KLPQLCTELQT HLA-A2 
E618-28variant HPV16 E6 18-28 KLPDLCTELQT HLA-A2 
E625-33 HPV16 E6 25-33 ELQTTIHDI HLA-A2 
E625-33variant HPV16 E6 25-33 ELQTTIHEI HLA-A2 
E628-38 HPV16 E6 28-38 TTIHDIILECV HLA-A2 
E628-38variant1 HPV16 E6 28-38 TTIHEIILECV HLA-A2 
E628-38variant2 HPV16 E6 28-38 TTIHEIRLECV HLA-A2 
E629-38 HPV16 E6 29-38 TIHDIILECV HLA-A2 
E629-38variant HPV16 E6 29-38 TIHEIILECV HLA-A2 
E634-44 HPV16 E6 34-44 ILECVYCKQQL HLA-A2 
E652-60 HPV16 E6 52-60 FAFRDLCIV HLA-A2 
E626-34 HPV16 E6 26-34 LQTTIHDII HLA-A24 
E626-34variant HPV16 E6 26-34 LQTTIHEII HLA-A24 
E638-45 HPV16 E6 38-45 VYCKQQLL HLA-A24 
E638-46 HPV16 E6 38-46 VYCKQQLLR HLA-A24 
E638-47 HPV16 E6 38-47 VYCKQQLLRR HLA-A24 
E644-54 HPV16 E6 44-54 LLRREVYDFAF HLA-A24 
E647-54 HPV16 E6 47-45 REVYDFAF HLA-A24 
E649-57 HPV16 E6 49-57 RAHYNIVTF HLA-A24 
E649-58 HPV16 E6 49-58 VYDFAFRDLC HLA-A24 
E649-59 HPV16 E6 49-59 VYDFAFRDLCI HLA-A24 
E651-59 HPV16 E6 51-59 DFAFRDLCI HLA-A24 
E660-69 HPV16 E6 60-69 VYRDGNPYAV HLA-A24 
E666-74 HPV16 E6 66-74 PYAVCDKCL HLA-A24 
E666-75 HPV16 E6 66-75 PYAVCDKCLK HLA-A24 
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E666-76 HPV16 E6 66-76 PYAVCDKCLKF HLA-A24 
E672-80 HPV16 E6 72-80 KCLKFYSKI HLA-A24 
E675-83 HPV16 E6 75-83 KFYSKISEY HLA-A24 
E676-83 HPV16 E6 76-83 FYSKISEY HLA-A24 
E676-85 HPV16 E6 76-85 FYSKISEYRH HLA-A24 
E676-86 HPV16 E6 76-86 FYSKISEYRHY HLA-A24 
E681-90 HPV16 E6 81-90 SEYRHYCYSL HLA-A24 
E681-90variant HPV16 E6 81-90 SEYRHYCYSV HLA-A24 
E682-90 HPV16 E6 82-90 EYRHYCYSL HLA-A24 
E682-91 HPV16 E6 82-91 EYRHYCYSLY HLA-A24 
E682-91variant HPV16 E6 82-91 EYRHYCYSVY HLA-A24 
E685-95 HPV16 E6 85-95 HYCYSLYGTTL HLA-A24 
E687-96 HPV16 E6 87-96 CYSLYGTTLE HLA-A24 
E688-95 HPV16 E6 88-95 YSLYGTTL HLA-A24 
E688-95variant HPV16 E6 88-95 YSVYGTTL HLA-A24 
E690-99 HPV16 E6 90-99 LYGTTLEQQY HLA-A24 
E690-99variant HPV16 E6 90-99 VYGTTLEQQY HLA-A24 
E698-106 HPV16 E6 98-106 QYNKPLCDL HLA-A24 
E698-108 HPV16 E6 98-108 QYNKPLCDLLI HLA-A24 
E6128-135 HPV16 E6 128-135 KKQRFHNI HLA-A24 
E6131-139 HPV16 E6 131-139 RFHNIRGRW HLA-A24 
     
E7 
Name Origin Region Amino acid sequence HLA allele 
E77-15 HPV16 E7 7-15 TLHEYMLDL HLA-A2 
E77-17 HPV16 E7 7-17 TLHEYMLDLQP HLA-A2 
E710-19 HPV16 E7 10-19 EYMLDLQPET HLA-A2 
E711-18 HPV16 E7 11-18 YMLDLQPE HLA-A2 
E711-19 HPV16 E7 11-19 YMLDLQPET HLA-A2 
E711-20 HPV16 E7 11-20 YMLDLQPETT HLA-A2 
E711-21 HPV16 E7 11-21 YMLDLQPETTD HLA-A2 
E712-19 HPV16 E7 12-19 MLDLQPET HLA-A2 
E712-20 HPV16 E7 12-20 MLDLQPETT HLA-A2 
E766-74 HPV16 E7 66-74 RLCVQSTHV HLA-A2 
E776-86 HPV16 E7 76-86 IRTLEDLLMGT HLA-A2 
E777-86 HPV16 E7 77-86 RTLEDLLMGT HLA-A2 
E777-87 HPV16 E7 77-87 RTLEDLLMGTL HLA-A2 
E778-86 HPV16 E7 78-86 TLEDLLMGT HLA-A2 
E780-90 HPV16 E7 80-90 EDLLMGTLGIV HLA-A2 
E781-90 HPV16 E7 81-90 DLLMGTLGIV HLA-A2 
E781-91 HPV16 E7 81-91 DLLMGTLGIVC HLA-A2 
E782-90 HPV16 E7 82-90 LLMGTLGIV HLA-A2 
E782-91 HPV16 E7 82-91 LLMGTLGIVC HLA-A2 
E782-92 HPV16 E7 82-92 LLMGTLGIVCP HLA-A2 
E783-93 HPV16 E7 83-93 LMGTLGIVCPI HLA-A2 
E784-93 HPV16 E7 84-93 MGTLGIVCPI HLA-A2 
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E785-93 HPV16 E7 85-93 GTLGIVCPI HLA-A2 
E786-93 HPV16 E7 86-93 TLGIVCPI HLA-A2 
E748-57 HPV16 E7 48-57 DRAHYNIVTF HLA-A24 
E750-57 HPV16 E7 50-57 AHYNIVTF HLA-A24 
E751-58 HPV16 E7 51-58 HYNIVTFC HLA-A24 
E751-59 HPV16 E7 51-59 HYNIVTFCC HLA-A24 
E756-65 HPV16 E7 56-65 TFCCKCDSTL HLA-A24 
E767-76 HPV16 E7 67-76 LCVQSTHVDI HLA-A24 
E769-76 HPV16 E7 69-76 VQSTHVDI HLA-A24 
 
2.1.17 Blood samples  
In this study, blood samples were taken from healthy donors after written informed consent (ethical 
approval S-393/2011). HLA typing of volunteers was performed by a diagnostic lab (Bernhard Thiele, 
Institut für Immunologie und Genetik, Kaiserslautern). 
 
2.1.18 Software 
Name Company 
Adobe Illustrator CS4 Adobe, San José, CA, USA 
Analyst 1.6.2 Ab Sciex, Foster City, CA, USA  
BD FACS Diva Software BD Biosciences, San José, CA, USA 
CellD Imaging Software 5 Olympus Soft Imaging Solutions, Hamburg 
Chromas 2.1.1 Technelysium Pty Ltd 
CTL ImmunoSpot 5.1.36 Professional DC CTL, Bonn 
EndNote X7.5 Thomas Reuters, Philadelphia, PA, USA 
FlowJo 6.5 
FlowJo 10.1 
TreeStar, Ashland, OR, USA 
Fusion Vilber Lourmat, Eberhardzell 
GENtle Magnus Manske, University of Cologne, Cologne 
GIMP 2.8.14 
Spencer Kimball, Peter Mattis and the GIMP 
development team, www.gimp.org 
ImageJ 1.45b 
Rasband, W.S., ImageJ, U. S. National Institutes of 
Health, Bethesda, Maryland, USA, 
http://imagej.nih.gov/ij/, 1997-2015 
Inkscape 0.48 The Inkscape Team, www.inkscape.org 
LinRegPCR 2012.3 Heart Failure Research Center, Amsterdam 
MS Office 2010 Microsoft Corporation, Redmond, WA, USA 
MxPRO 4.10 build 389 Agilent Technologies, Santa Clara, CA, USA 
PRISM® 5 GraphPad, La Jolla, CA, USA 
Notepad 6.1 build 7601 Microsoft Corporation, Redmond, WA, USA 
Notepad ++ 6.6.9 Notepad++ Team, www.notepad-plus-plus.org 
qBase Plus 2.4 Biogazelle, Zwijnaarde, Belgium 
R 2.15.2 R Project, www.r-project.org 
SnapGene® 3.1 GSL Biotech LLC, Chicago, IL, USA 
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2.2 Methods 
2.2.1 Molecular biological methods 
2.2.1.1 Isolation of genomic DNA 
DNA extraction using proteinase K 
Cells were harvested (approximately 1x106 cells) and washed once with 1xPBS and transferred to a 
1.5ml reaction tube. The cell pellet was digested in 49µl proteinase K buffer supplemented with 1µl of 
proteinase K and incubated at 56°C overnight or for 3-4h. After the digest, samples were spun down, 
300µl of distilled DNase/RNase free water were added and the enzyme was inactivated at 95°C for 
1min. The samples were stored at 4°C or at -20°C until analysis.  
DNA isolation using the QiaAmp DNA Kit 
This kit is based on DNA-binding columns. Genomic DNA was purified using 1x106 cells in 200µl 
1xPBS per column. 20µl of Proteinase K was pipetted to a 1.5ml tube and the cells were added. 200µl 
of AL buffer was added and the sample was quickly vortexed and incubated for 10min at 56°C. Then, 
200µl of 100% ethanol was added, mixed and the sample was transferred to a spin column and spun 
(1min, 6,000xg). The filtrate was removed and 500µl AW1 buffer was added and centrifuged (1min, 
6,000xg). Afterwards, the sample was washed by centrifugation (1min, full speed) using 500µl of 
AW2 buffer. To remove residual washing buffer the column was centrifuged (1min, full speed). For 
eluting the DNA, the column was placed in a new 1.5ml reaction tube, 200µl of distilled 
DNase/RNase free water was added to the column, incubated for 1min and eluted by centrifugation 
(1min, 6,000xg,). DNA samples were stored at 4°C or at -20°C for further analysis. 
2.2.1.2 RNA isolation 
RNA isolation was done using the RNeasy Kit. RNA purification is based on RNA-binding columns. 
First, cells were harvested (see 2.2.3). A maximum of 8x106 cells was taken for a single RNA isolation 
preparation. Cells were washed twice with sterile 1xPBS and the supernatant was removed carefully. 
Cells from a T75 cell culture bottle (2-8x106 cells) were resuspended in 600µl of RLT buffer, and 
350µl of this buffer was taken for the cells from one well of a 12-well plate (1x105-5x105). The mix 
was vortexed and kept for 2min on ice to disrupt the cell membrane. 700µl of the whole cell lysate was 
transferred to the QIAshredder spin column and centrifuged (1min, full speed) for homogenization of 
cell lysates. Then, the flow through was mixed 1:1 with 70% ethanol and slowly pipetted up and down 
to precipitate the DNA. 700µl of this mixture was transferred to the spin column and centrifuged 
(1min, > 8,000xg). If the sample volume exceeded 700µl the step was repeated within the same spin 
column. The flow through was discarded after each centrifugation. 700µl of RW1 buffer was added to 
the spin column and centrifuged (1min, > 8,000xg). Then, the spin column was washed with 500µl of 
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RPE buffer by centrifugation (1min, > 8,000xg). This step was repeated, but centrifugation was done 
for 2min at 8,000xg. A dry spin was performed by centrifugation (1min, > 8,000xg) to remove residual 
buffer from the column. The column was inserted into a new collection tube and 35µl (cell amount 
from a T75 cell culture bottle) or 15-25µl (cell amount from one well of a 12-well plate) of distilled 
DNase/RNase free water was added to the column and incubated for 1min. Only then, the cap of the 
tube was closed gently and the RNA was eluted (1min, > 8,000xg). The flow through containing the 
RNA was kept at -20°C and for long-time storage samples were stored at -80°C. The concentration 
was measured via Nano Drop (see 2.2.1.3). 
2.2.1.3 Determination of DNA and RNA concentration 
1µl of DNA or RNA sample was applied to the Nano Drop spectrophotometer. This device can 
measure the concentration and the purity of a sample. Nucleic acids absorb light at different 
wavelengths. The absorbance can be related to the concentration of a sample by using the Lambert-
Beer law.  
A = ε x c x d 
(A: absorbance, ε: extinction coefficient; c: concentration; d: distance) 
At a wavelength of 260nm, the extinction coefficient for dsDNA is 0.02(µg/ml)-1cm-1 and for 
RNA 0.025(µg/ml)-1cm-1. In contrast, proteins show a maximum light absorption at 280nm. Thus, the 
purity of nucleic acids can be determined by measuring the ratio of 260nm to 280nm with an optimal 
value between 1.8 and 1.95. 
2.2.1.4 Agarose gel electrophoresis 
Nucleic acids are negatively charged because of their covalently bound phosphate groups. Therefore, 
they can easily be separated by agarose gel electrophoresis using an electric field (200). 1-2% agarose 
gels were prepared by boiling agarose powder in TAE buffer. The agarose was chilled to 
approximately 50°C and supplemented with GelRed™ (1:10,000). The agarose gel tray was placed in 
the electrophoresis chamber and the comb was inserted. Then, the agarose was poured on the agarose 
gel tray for solidification. Later, the comb was removed and the electrophoresis chamber was filled 
with TAE buffer. Before loading, the DNA was mixed with 6x Orange loading buffer. Additionally, 
4µl of the DNA marker GeneRuler™ 100-10,000bp was used as a reference for DNA fragment size. 
The gel was run at 80-120V depending on the gel volume until the DNA fragments were sufficiently 
separated. For visualization of the separated DNA, UV light excitation was used employing the Gel 
Doc™ EZ Imager.  
2.2.1.5 Agarose gel extraction 
After agarose gel electrophoresis, specific bands were cut out and the DNA was extracted with the 
peqGOLD™ Gel Extraction Kit. In this thesis, bands of ERAP1 amplified by the KOD enzyme (see 
2.2.1.6) were cut out, purified and send for sequencing to GATC Biotech, Konstanz.   
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 The DNA band was cut out from the agarose gel with a scalpel on the UV table of the Gel 
Doc™ EZ Imager. The agarose gel slice was cut as small as possible and the duration while cutting on 
the UV table was kept short in order to reduce UV-induced DNA damage. The agarose slice 
containing the DNA of interest was transferred into a 1.5ml reaction tube and was weighed. Binding 
buffer was added 1:1 to the agarose gel slice (e.g. 0.2g of agarose + 0.2ml binding buffer). The 
agarose gel slice was dissolved on a thermoblock at 60°C for approximately 7min. In between, the mix 
was shortly vortexed or shaken once in a while. After an agarose gel slice is dissolved, the color of the 
solution should be bright yellow. In the case of a color shift towards orange or red 5µl of 3M sodium 
acetate (pH 5.2) was added. 750µl of the solution was added to the spin column, centrifuged (1min, 
10,000xg) and the flow through was discarded. This step was repeated if the volume was more than 
750µl. Later, 300µl of binding buffer was added, centrifuged (1min, 10,000xg) and the flow through 
was discarded. Then, 750µl of CE washing buffer was added to the column and centrifuged (1min 
10,000xg). This washing step was repeated and the flow through discarded. The column was 
centrifuged once again to get rid of all residual buffer (1min, 10,000xg). For DNA elution, the column 
was put into a new 1.5ml reaction tube, 30-50µl of distilled DNase/RNase free water was added on the 
silica membrane of the column and centrifuged (1min, 10,000xg). The flow through containing the 
DNA was kept for further analysis and stored at -20°C. DNA concentration was measured via Nano 
Drop (see 2.2.1.3). 
2.2.1.6 Polymerase chain reaction (PCR) 
The polymerase chain reaction is a molecular biological method used to amplify a particular DNA 
fragment (201, 202). Short synthetic oligonucleotides, called primers, are used as starter molecules 
that specifically flank the DNA fragment which is going to be amplified. A heat stable polymerase is 
used for the synthesis of the strand occurring in 5’ to 3’ direction.     
 An initial heating step is conducted before the first denaturation step to activate the 
polymerase (hot start polymerase). Then, the PCR reaction starts by heating up the DNA template to 
95°C, which denatures the double strands into single strands. The sample is cooled to a specific 
temperature which is primer specific and allows the primers to anneal to the ssDNA templates. 
Primers were designed to have an annealing temperature of 60°C and the GC content was 40-60%. 
 The sample is subsequently heated up again to the polymerase-specific extension temperature. 
Then, the polymerase utilizes the primers as starting points to synthesize a complementary DNA 
strand to the DNA template. This cycle is repeated multiple times as indicated in the temperature 
profile of the PCR. After the last cycle, a terminal elongation step ensures extension of all remaining 
ssDNA strands.  
Amplification of ERAP1 
The AccuScript High Fidelity 1st Strand cDNA Synthesis Kit was used for samples that were later sent 
for sequencing. In this thesis, cDNA from cell lines was synthetized in order to amplify ERAP1 by a 
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subsequent PCR using the KOD enzyme (Thermococcus kodakaraenis). For this purpose, a high 
fidelity enzyme was absolutely necessary to ensure that the sequence was correct after reverse 
transcription.           
 The reaction was set up as indicated in Table 2.1. First, the RNA and the primers had to be 
denatured at 65°C. The reaction was chilled to room temperature, DTT and the AccuScript enzyme 
were added to the reaction. Subsequently, cDNA synthesis was performed at 42°C. A final heat 
inactivation of the enzyme was done because the AccuScript enzyme could inhibit subsequent PCR 
reactions. For a shorter time period cDNA was stored at -20°C or at -80°C for long-term storage. 
Table 2.1: Reverse transcription reaction using the AccuScript High Fidelity 1st Strand cDNA Synthesis Kit. 
 
RNA 0.5µg, max. 12µl 
RNA and primer 
denaturation 
Oligo dT Primer 1µl 
AccuScript RT buffer 2µl 
dNTP mix 0.8µl 
Distilled DNase/RNase free water ad 17µl 
Total volume 17µl 
5min, 65°C 
DTT 2µl 
cDNA synthesis 
AccuScript RT 1µl 
Total volume 20µl 
90min, 42°C 
15min, 70°C Enzyme inactivation 
The human ERAP1 gene from cell lines was then amplified by PCR to determine single 
nucleotide polymorphisms (SNPs). As a positive control for cDNA quality, primers targeting 
hypoxanthine-guanine phosphoribosyltransferase (HPRT1) were used (data not shown). Table 2.2 
displays the pipetting scheme of the PCR reaction and Table 2.3 summarizes the temperature profile 
used for this PCR. 
Table 2.2: PCR reaction using the KOD polymerase. 
 Stock concentration Volume Final concentration 
Template DNA  2µl  
5’ Primer 10µM 1.5µl 0.3µM 
3’ Primer 10µM 1.5µl 0.3µM 
KOD Hot Start Master Mix 0.04U/µl 25µl 0.02U/µl 
Distilled DNase/RNase free water  20µl  
Total volume 50µl 
 
 
Table 2.3: Temperature profile of the PCR reaction using the KOD polymerase. 
Number of cycles Temperature Time Step 
1 95°C 2min Polymerase activation 
35 
95°C 20sec Denaturation 
60°C 10sec Annealing 
70°C 2min (20sec/kb) Extension 
1 70°C 10min Terminal elongation 
 4°C ∞  
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PCR using AmpliTaq Gold® DNA polymerase 
For any analytic PCR, the AmpliTaq Gold® DNA polymerase was used. The PCR reaction was set up 
as described in Table 2.4 and the reaction was run in a thermocycler as described in Table 2.5.  
Table 2.4: PCR reaction using the AmpliTaq Gold® polymerase. 
 Stock concentration Volume Final concentration 
Template DNA  1-2ng, max. 16µl 1-2ng 
Primer F  10µM 0.75µl 0.3µM 
Primer R  10µM 0.75µl 0.3µM 
10x buffer 10x 2.5µl 1x 
dNTPs 10mM 2µl 0.2mM 
MgCl2 25mM 2µl 2.5mM 
AmpliTaq Gold® 5U/µl 0.125µl 0.625U 
Distilled DNase/RNase free water  ad 25µl  
Total volume 25µl 
 
 
Table 2.5: Temperature profile of the PCR reaction using the AmpliTaq Gold® polymerase. 
Number of cycles Temperature Time Step 
1 95°C 5min Polymerase activation 
34  
95°C 40sec Denaturation 
60°C 30sec Annealing 
72°C 1min Elongation 
1 72°C 10min Terminal elongation 
 4°C ∞  
 
2.2.1.7 PCR product purification 
The PCR-amplified product was purified directly after the PCR reaction using the QIAquick PCR 
Purification Kit to remove enzymes chemicals included in the buffer used for the PCR. Enzyme 
contamination of DNA samples could interfere with subsequent applications. First, 5 volumes of PBI 
buffer were added to 1 volume of the PCR reaction mix (250µl PBI buffer + 50µl PCR reaction mix). 
Then, the color of the mix had to be checked and, if deviating from the yellow color of the PBI buffer, 
10µl of 3M sodium acetate (pH 5) had to be added. The sample was transferred onto the membrane of 
the spin column and DNA bound to the column by centrifugation (1min, full speed). The flow through 
was discarded. 750µl of PE washing buffer was added and the column was again centrifuged (1min, 
full speed). Then, the flow through was discarded and the column spun dry (1min, full speed). 30µl of 
distilled DNase/RNase free water was added to the column and incubated for 1min. For the elution 
step, the column was put into a new reaction tube and centrifuged (1min, full speed). Purified PCR 
products were stored at -20°C or at -80°C for long-term storage.  
2.2.1.8 Sequencing of human ERAP1  
DNA was diluted in distilled DNase/RNase free water to a final concentration of 50ng/µl and a total 
volume of 20µl and then sent for sequencing. Sanger sequencing was conducted by GATC Biotech, 
Konstanz. Primers had a concentration of 10µM in a total volume of 20µl. DNA and primers were 
prepared in 1.5ml reaction tubes.  
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2.2.1.9 Analysis of the human ERAP1 sequences 
In order to analyze ERAP1 variants present in our cell lines the most common haplotype of ERAP1 
(203) was used as a reference sequence (NM 001198541.1). Sequence alignments were conducted 
using SnapGene® 3.1 and GENtle. Human genes have two alleles within the genome of cells. 
Therefore, the sequences were checked in parallel with the Chromas 2.1.1 software in order to detect 
SNPs as ambiguities in the sequence traces. By this means, sequence differences within ERAP1 were 
identified. If nucleotide exchanges were detected, the respective codon was checked for silent or 
missense mutations using SnapGene® 3.1.  
2.2.1.10 Quantitative Real-Time PCR (qRT-PCR) 
QuantiTect Reverse Transcription Kit 
This kit was used for samples that were subsequently analyzed by qRT-PCR. All steps were performed 
on ice unless otherwise indicated. For each reverse transcription reaction 0.5-1µg of RNA was used. 
The reaction was pipetted following the pipetting scheme in Table 2.6. First, the RNA was diluted in 
distilled DNase/RNase free water in a maximal volume of 12µl. Next, gDNA wipeout buffer was 
added to remove genomic DNA contaminants. The total volume of this first reaction was 14µl and was 
incubated for 2min at 42°C. Afterwards, the sample was directly put back on ice and a mixture of RT 
buffer, RT primer and reverse transcriptase was added so that the total volume of the reaction was 
20µl. The reverse transcription reaction was incubated for 15min at 42°C and the enzyme was 
inactivated for 3min at 95°C. The cDNA was stored at -20°C or at -80°C for long-term storage.  
Table 2.6: Reverse transcription reaction using the QuantiTect Reverse Transcription Kit. 
 
RNA 0.5-1µg, max. 12µl 
DNase treatment 
gDNA wipeout buffer 2µl 
Distilled DNase/RNase free water ad 14µl 
Total volume 14µl 
2min, 42°C 
RT primer 1µl 
cDNA synthesis 
RT buffer 4µl 
RT enzyme  1µl 
Total volume 20µl 
15min, 42°C 
3min, 95°C Enzyme inactivation 
Quantitative Real-Time PCR (qRT-PCR) is a quantitative technique which monitors the 
relative amplification of a specific cDNA sequence during a PCR reaction, in real-time. In this study, 
the TaqMan® system was used. Applied TaqMan® Gene Expression Assays consist of a pair of 
unlabeled PCR primers and a TaqMan® probe with a FAM™ (fluorescein amidite) dye label. The 
TaqMan® Gene Expression Master Mix reagent contains general PCR reagents: AmpliTaq Gold® 
DNA polymerase, desoxiribonucleotide triphosphates, ROX™ (6-carboxyl-X-rhodamine) dye and 
buffer. A maximum of four reference genes was used (GAPDH, PGK1, PPIA, IPO8) that have been 
validated previously (204). The qPCR was performed in semi-skirted 96-well qPCR plates based on 
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the sample maximization approach (205) in a reaction volume of 20µl. The cDNA was diluted 1:90 in 
distilled DNase/RNase free water and the reaction was set up as described in the pipetting scheme in 
Table 2.7. Each sample was run in triplicates. In addition, each run included a no template control 
(NTC) for the respective target gene. 
Table 2.7: Pipetting scheme of the qRT-PCR reaction. 
 
1:90 diluted cDNA (cDNA input 0.1µl) 9µl 
Gene-specific TaqMan® Gene Expression Assay 
TaqMan® Gene Expression Master Mix  
1µl 
10µl 
Total volume 20µl 
The thermal profile of the qPCR is shown in Table 2.8 and was composed of two plateau 
phases and two segments. The relative quantification of gene expression was conducted by the relative 
quantification strategy (206) and was corrected for differences in PCR efficiency by LinRegPCR. 
Table 2.8: qRT-PCR temperature profile. 
Number of cycles Temperature Time Step 
1 50°C 2min Preincubation 
1 95°C 10min AmpliTaq enzyme activation 
45 
95°C 15sec Denaturation 
60°C 1min Annealing/Elongation 
 
2.2.1.11 qRT-PCR data analysis and quantification  
Analysis of quantitative real-time PCR data was done using Notepad++, MxPro Software, LinRegPCR 
and qBase Plus. After passive normalization, raw data was exported from MxPro software and 
imported to LinRegPCR. Within LinRegPCR, the baseline was estimated, both PCR efficiencies and 
the Cq value were calculated and the qPCR quality of each single well was checked. Data was stored 
as an RDML file (207) and finally analyzed using the qBase Plus software. 
 
2.2.2 Biochemical Methods  
2.2.2.1 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is widely used to separate 
proteins in an electric field according to their molecular weight. In this work, the most commonly used 
Laemmli system with Tris-glycine buffers was employed (208). Mini-PROTEAN®TGX™ gels, any 
kD™, were used to separate protein samples. β-mercaptoethanol was added to the 4x loading buffer 
and then the buffer was stored at 4°C and was used within 4 weeks. Prior to sample loading, samples 
were mixed with 4x protein loading buffer and boiled for 5min at 95°C. If not indicated otherwise, 
50µg of whole protein extract was pipetted into the gel slots. As a marker for molecular weight, 4µl of 
the Precision Plus Protein™ Standards Kaleidoscope™ 10-250kDa was loaded for Western blot. The 
gel was run at 90V until the samples had completely entered the gel. Then, the gel was run at 150V. 
Afterwards, the gel was used for Western blot analysis (see 2.2.2.4).     
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 SDS-PAGE from CaSki cells treated with siRNAs knocking down HPV16 E6 and E7 (see 
2.2.3.5) was performed using NuPAGE Novex 4-12% Bis-Tris Mini Gels as described in (209) and 
used for semidry Western blot (see 2.2.2.4). 
2.2.2.2 Protein extraction 
In order to analyze the expression of a particular protein from cell lines by Western blot, protein 
extraction was performed. All steps of this isolation were strictly performed on ice. PMSF and 
complete mini protease inhibitor cocktail were always added freshly to the RIPA buffer prior to use. 
Cells were washed twice with ice-cold 1xPBS and all residual liquid was removed. For 10cm ø cell 
culture dishes (2-6x106 cells), 0.5ml of RIPA buffer was added, cells were scraped from the dishes and 
transferred to a reaction tube. For protein extracts that were isolated from cells grown in one well of a 
12-well plate (1-5x105 cells per well), cells were harvested by trypsinization (see 2.2.3.2), washed 
twice with ice-cold 1xPBS and resuspended in 50µl of RIPA buffer. Then, cells were incubated for 
10min on ice with vortexing every 30 seconds. Samples were centrifuged (15min, 12,000xg, 4°C) and 
supernatants were transferred to a new reaction tube. A second centrifugation step was performed 
(5min, 12,000xg, 4°C), the supernatants were again transferred to a new reaction tube and protein 
concentration was determined (see 2.2.2.3). Protein samples were stored at -80°C.  
 Protein extraction from CaSki cells treated with siRNAs for knocking down HPV16 E6 and 
E7 (see 2.2.3.5) was performed by lysing cells in RIPA buffer II as described in (209). 
2.2.2.3 DC™ Protein Assay 
The DC™ Protein Assay is a detergent compatible colorimetric assay to determine protein 
concentration. First, 1ml of solution A was mixed with 20µl of solution S. A bovine serum albumin 
(BSA) standard curve was prepared every time the assay was performed in concentrations ranging 
from 1.5mg/ml to 0.02mg/ml. 2µl of protein sample or BSA standard was pipetted into a 96-well plate 
to be tested in triplicates. Then, 20µl of the A/S mix was added to each well. Finally, 200µl solution B 
was added to each well and incubated for 15min at room temperature. Absorbance was measured with 
the Multiskan™ FC microplate photometer at 750nm within 1h. The concentration was calculated 
according to the BSA standard curve using MS Excel.  
2.2.2.4 Western blot 
Proteins that were first separated by SDS-PAGE (see 2.2.2.1), were transferred to a PVDF membrane 
and were detected by using specific antibodies. The gel and the membrane were put in direct contact to 
each other in a transfer chamber (tank blot chamber or semidry blot chamber) and an electric field was 
applied. Due to SDS, all proteins are negatively charged and migrate from the gel towards the anode 
and are fixed onto the PVDF membrane via hydrophobic interactions. By this means, the 
electrophoretic patterns are conserved on the membrane. 
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Tank blot 
The PVDF Transfer Membrane was activated in 100% methanol for 1min. Afterwards, the membrane, 
the gel, 2 filter papers and a sponge on each side were incubated shortly in tank transfer buffer and 
assembled in the WB transfer chamber (tank blot) to a Western blot “sandwich” with removal of 
occurring bubbles. Proteins were transferred for 90min, at 30V and 4°C. A magnetic stir was placed 
into the transfer chamber to ensure a constant temperature within the entire chamber.  
Semidry blot 
First, the PVDF Transfer Membrane was activated in 100% methanol for 1min. Afterwards, the 
membrane, 2 filter papers on each side and the gel were incubated shortly in semidry transfer buffer 
and assembled in the WB transfer chamber (semidry) to a Western blot “sandwich” with removal of 
occurring bubbles. Proteins were transferred at 150mA for 1h.      
 This methodology was used for HPV16 E6 and E7 knockdown CaSki samples with the Trans-
blot Semidry Transfer Cell and the Immobilon®-P PVDF Transfer Membrane as described in (209).  
2.2.2.5 Immunodetection of proteins 
All incubation steps were performed on a platform shaker. After Western blot transfer (see 2.2.2.4), 
the membrane was blocked for 45min in 5% of low-fat milk powder diluted in 1xPBS at room 
temperature. Then, the blot was incubated for 1h with the desired primary antibody diluted in 1.5% 
low-fat milk powder in 1xPBS at room temperature for 1h or at 4°C overnight. The antibody solution 
was poured off and the membrane washed three times for 5min with Western blot washing buffer. 
After washing, the blot was incubated with goat-anti-mouse (Dianova) or goat-anti-rabbit (Rockland) 
secondary antibody coupled to horseradish peroxidase (HRP) diluted 1:5,000 in 1.5% milk powder in 
1xPBS for 1h at room temperature. Subsequently, the blot was washed three times for 5min with 
Western blot washing buffer. Residual buffer was removed and 500µl of ECL Western Blotting 
Substrate was applied to each blot and incubated for 3min at room temperature. Chemiluminescent 
signals were detected using the Fusion-SL chemiluminescence camera.    
 Immunodetection of HPV16 E7 from CaSki cells treated with siRNAs in order to knockdown 
HPV16 E6 and E7 (see 2.2.3.5) was performed using the secondary anti-mouse HRP coupled antibody 
from Promega and the ECL Prime Western Blotting Detection Reagent as described in (209). 
2.2.2.6 Immunoprecipitation  
In this thesis, immunoprecipitation (IP) of HLA-A2 molecules was performed in order to analyze via 
mass spectrometry (MS) which HPV16 epitopes were bound to this MHC molecule. Prior to IP, cells 
were treated with an ERAP1-targeting siRNA pool or a control siRNA pool (see 2.2.3.5) and cultured 
in 10cm ø dishes (see 2.2.3.2) for 72h. 1ml of GammaBind™ Plus Sepharose™ beads were washed in 
one volume of 10% acetic acid (pH 3.0), vortexed and centrifuged in a swinging-bucket rotor (3min, 
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2,500xg). The supernatant was removed and beads were washed five times with 1xPBS until they were 
finally resuspended in 1ml 1xPBS supplemented with 0.02% sodium azide for storage at 4°C.  
 50µl of the bead suspension was washed three times using 1.5ml 0.5% IGE-PAL-630 buffer 
and coupled with 20µg of HLA-A2 antibody and filled up with 0.5% IGE-PAL-630 buffer to 1ml. 
Antibody coupling was done in 15ml falcons on a rotator for 2-3h at room temperature. Meanwhile, 
the cells plated in 10cm ø dishes were put on ice, washed two times with 1xPBS and covered with 1ml 
of ice cold IP lysis buffer. Subsequently, cells were scraped from the dish and the lysate was 
transferred to the next dish. This procedure was repeated for a total of four dishes (4 dishes = 1 IP 
sample) and approximately 1.2-2.4x107 cells in 1ml of lysis buffer. The lysates were incubated for 
10min on ice, vortexed every 3min and then centrifuged (30min, 20,000xg, 4°C). Supernatants were 
pooled in 15ml falcons (4-5 IP samples in one falcon) to achieve homogeneity and to be equally 
distributed to the coupled beads. After coupling of antibodies to beads, the beads were centrifuged 
(3min, 4,700xg) and washed twice with 5ml of 0.5% IGE-PAL-630 buffer. The cleared lysate of 4-5 
IP samples was incubated with 20µg/ml coupled antibody-beads for 3-4h at 4°C on a rotator platform. 
 After incubation, samples were centrifuged (3min, 4,700xg, 4°C), the supernatant was 
removed and beads containing the immunoprecipitated HLA-A2 molecules were washed nine times 
with ice cold 1xPBS. The beads were transferred to protein low binding tubes and the supernatant was 
removed completely by using thin gel-loading tips. Finally, the IP samples were stored at -80°C until 
liquid chromatography-mass spectrometry (LC-MS) analysis or quality analysis by Western blot (see 
2.2.2.4).  
2.2.2.7 Liquid chromatography-mass spectrometry (LC-MS) analysis of cell surface 
epitopes  
The preparation of samples and LC-MS analysis were performed by Dr. Renata Blatnik in the group. 
Synthetic versions of the peptides to be detected were analyzed by MS first. Three of the four most 
intense fragments were assigned per peptide during injection of synthetic peptides. Mass spectrometer 
parameters were manually optimized to yield the highest signal for selected fragments. Epitopes 
dissociate from HLA class I molecules at a low pH (< 2.9), therefore IP samples were subjected to 
acetic elution with 0.3% TFA in LC/MS grade water. This results in a complex eluate out of which 
peptides were extracted with a Seppak reverse phase C18 material cartridge for LC-MS analysis.  
 For Seppak reverse phase C18 material cartridge sample processing, IP eluates were 
resuspended in 800µl of 0.1% TFA in LC/MS grade water. The cartridge was prewetted with 1ml 
100% ACN twice, then once with 1ml 70% ACN/0.1% TFA in LC/MS grade water and finally three 
times with 1ml 40% ACN/0.1% in LC/MS grade water. The cartridge was equilibrated by washing 
three times with 1ml 0.1% TFA in LC/MS grade water before sample loading. After the sample was 
loaded, the cartridge was washed three times with 1ml 0.1% TFA in LC/MS grade water. Elution of 
the sample from the cartridge was conducted with 1ml 35% ACN/0.1% TFA in LC/MS grade water. 
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The eluate was subjected to drying in a vacuum centrifuge.     
 Samples were resuspended in 3% ACN/0.1% TFA in LC/MS grade water and sonicated in an 
ultrasonic water bath before nano ultra-performance liquid chromatography mass spectrometry (nano-
UPLC-MS) analysis. The analysis was performed using a NanoAcquity UPLC system coupled to a 
Qtrap6500 mass spectrometer, which was equipped with a nano-ESI (electron spray ionization) 
source. Chromatographic separation was performed using a nanoAquity CSH130 C18 material column 
and the solutions for mobile phase A and B indicated in section 2.1.15. Solvent A of the mobile phase 
was composed of 0.1% FA and 0.01% TFA in ACN. The linear gradient started with 37% eluent B to 
10% eluent B by 1min and then to 40% eluent B by 50min with a linear gradient at a flow rate of 
300nl/min. The content of the eluate from the LC column was on-line analyzed with the Qtrap6500 
mass spectrometer during separation. The instrument was operated in the targeted MS3 measuring 
mode. Targeted MS3 analysis measures only pre-defined and optimized peptides achieving optimal 
sensitivity for low abundant (HLA-A2 HPV16 E6 and E7-derived) peptides. The MS3 data analysis 
was evaluated by manual comparison of MS3 reference spectra of synthetic peptides with MS3 spectra 
of IP samples using the Analyst 1.6.2 software. Identity of the targeted peptides was confirmed by 
their retention times, chromatographic profiles and MS3 spectra of each fragment. 
 
2.2.3 General cell culture methods 
Working with cells was always performed in a laminar flow hood under sterile conditions. Equipment, 
material and solutions were sterilized and equipment and material was additionally disinfected by 
wiping with 80% ethanol prior to usage under the laminar flow hood. Mycoplasma testing and cell 
authentication was conducted for every newly acquired cell line. Additionally, mycoplasma and cell 
authenticity testing were conducted regularly. For this purpose, either an analytical PCR to detect 
Mycoplasma specific genes was performed using the AmpliTaq Gold® DNA polymerase (see 2.2.1.6) 
or a cell pellet was sent to Multiplexion (Multiplexion, Immenstaad) for a comprehensive cell 
contamination test or cell authentication test. 
2.2.3.1 Freezing and thawing of cells 
DMSO was used as a cryoprotective agent hindering crystallization of the cells. For the freezing 
procedure, cells were grown to a confluency of 90% in a T75 cell culture flask. First, cells were 
trypsinized for approximately 2min, harvested by centrifugation (3min, 400xg) and the supernatant 
was discarded. Cells were counted and 1x106-1x107 cells were resuspended in 1ml of the 
corresponding culture medium. Then, 1ml of freezing medium was added to reach a final DMSO 
concentration of 10%, mixed gently and the suspension was transferred to a 2ml cryogenic vial. This 
step had to be performed quickly, because of the cytotoxicity of DMSO. The tubes were immediately 
placed into a pre-cooled (4°C) Cryo-Safe cryogenic vial cooler allowing a gradual temperature drop of 
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1°C/min, and kept in a -80°C freezer. On the next day, the tubes could be placed into the liquid 
nitrogen tank for permanent storage.        
 Also the thawing procedure had to be performed quickly, because of the cytotoxicity of 
DMSO. 20ml of pre-warmed culture medium was filled into 50ml falcons. Cells were rapidly thawed 
in a 37°C water bath and then transferred to the prepared falcon and distributed properly. 
Subsequently, they were centrifuged (3min, 400xg) and the supernatant was decanted. Cells were 
washed once in their respective cell culture media and then they were put into in a suitable cell culture 
flask or cell culture plate depending on the cell number and the particular cell type. The following day, 
the culture medium was exchanged to remove any residual DMSO. 
2.2.3.2 Culturing and passaging of cells 
In this study, all cell lines were cultured in an incubator at 37°C, 95% relative humidity and 5% CO2 in 
either cell culture flasks or cell culture plates. While adherent cells were grown in horizontally lying 
flasks, suspension cells were grown in flasks standing upright. The flasks or well plates were always 
replaced after each second cell passage. Cells were split when they reached a confluency of 80-100%.
 Adherent cells were passaged by removing the medium and gentle washing with 1xPBS to 
remove residual medium which could interfere with the subsequent trypsinization. Then, cells were 
detached by incubation with a suitable volume of trypsin-EDTA solution completely covering the cell 
layer at 37°C (e.g. 2ml for a T75 cell culture flask). Cell detachment was checked by microscopy. 
When cells were detached, the reaction was stopped by the addition of serum-containing medium (at 
least five times the volume of the trypsin solution) and pipetting up and down. Cells were transferred 
to a 50ml falcon and centrifuged (3min, 400xg). After removal of the supernatant, cells were 
resuspended in an appropriate amount of fresh culture medium (e.g. 10ml medium in a T75 cell 
culture flask) and either split at ratios depending on the particular cell type or used for experiments.
 Suspension cells were harvested from the flask or plate, centrifuged (3min, 400xg) and the 
supernatant was discarded. Then, they were resuspended in fresh culture medium and for splitting a 
desired amount of cells was added to a fresh culture plate or flask. Approximately, 0.5-1x106cells/ml 
were seeded depending on the growth characteristics of the particular cell type.  
2.2.3.3 Counting of cells 
Cells were harvested via trypsinization (see 2.2.3.2), diluted in 1xPBS and then mixed 1:1 with Trypan 
blue stain for life-dead discrimination. Cells were either counted employing a Neubauer counting 
chamber or automatically using the Countess® Automated Cell Counter. For counting with the 
Countess® Automated Cell Counter, the cell suspension has to be of a concentration ranging from 
1x104 up to 1x107cells/ml, because the cell counter only counts accurately in this range. For manual 
counting with the Neubauer counting chamber the cell number was calculated according to this 
formula: 
MATERIALS & METHODS 
59 
cell	number/ml = counted	cells	in	large	squares	number	of	counted	large	squares 	x	dilution	factor	x	chamber	factor	(10000) 
2.2.3.4 Treatment of cells with IFNγ 
In this study, cells were treated with recombinant human IFNγ to analyze the expression of APM 
components under these conditions either by qRT-PCR, Western blot or flow cytometry. Cells were 
grown until they reached a confluency of 70-80%. Then, medium was removed and exchanged for 
fresh medium. IFNγ was diluted in 1xPBS and added with a final concentration of 50ng/ml. Cells were 
cultured for another 48h.         
 The IFNγ used within this study had a specific activity of 5x107IU/mg protein and reached an 
antiviral bioassay titer of 5.5x107IU determined in the lab of Prof. Rainer Zawatzky (Prof. Frank Rösl, 
Viral Transformation Mechanisms, DKFZ, Heidelberg).  
2.2.3.5 Transfection of eukaryotic cells with siRNA 
Knockdown of ERAP1 
ERAP1 (NCBI ID: 51752) was knocked down with a siPOOL from siTOOLs BIOTECH. As a 
negative control a non-targeting siPOOL was used. The experiments were either conducted in 12-well 
plates or in 10cm ø dishes for subsequent IPs (see 2.2.2.6). First, cells were trypsinized (see 2.2.3.2), 
counted (see 2.2.3.3) and diluted in 900µl (for one well of a 12-well plate) of the respective culture 
medium. Depending on the cell size and growth properties different amounts of cells were needed for 
the knockdown experiments: 
Table 2.9: Cell numbers and siRNA concentration needed to efficiently knockdown ERAP1. 
Cell line Cell number per well siRNA concentration 
CaSki 1x105 10nM 
866 5x104 5nM 
SNU17 4x105 5nM 
SNU703 3x105 8nM 
SiHa 1x105 10nM 
FK16A 1x105 10nM 
 
The siRNA dilution was prepared in RNase-free water provided by the company. The siRNA 
pool was in a volume of 10µl and 40µl of Opti-MEM® was added. For one reaction 2µl of the 
transfection reagent RNAiMAX was diluted in 48µl of Opti-MEM®. The siRNA mix and the 
transfection reagent mix were combined (1:1) and incubated for 5min at room temperature. 
Afterwards, 100µl of the mix was transferred per well of a 12-well plate and the cell suspension was 
added. For 10cm ø dishes, cell number, medium and siRNA/RNAiMAX were scaled up 
proportionally. Cells were incubated for 72h if not indicated otherwise.  
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Knockdown of HPV16 E6 and E7  
Knockdown of the HPV16 oncogenes E6 and E7 was performed in cooperation with Prof. Karin 
Hoppe-Seyler (Prof. Felix Hoppe-Seyler, Molecular Therapy of Virus-Associated Cancers, DKFZ, 
Heidelberg). HPV16 E6 and E7 were knocked down using three specific siRNAs (see 2.1.12) that 
target all three HPV16 E6 and E7 transcript classes. As a negative control a non-targeting siRNA was 
used that had at least 4 mismatches to all known human genes. CaSki cells were transfected using 
DharmaFECT I based on the manufacturer’s instructions. All three siRNAs were pooled at equimolar 
concentrations to reach a final siRNA concentration of 10nM. Cells were incubated with siRNAs for 
72h. Afterwards, cells were lysed (see 2.2.2.2) and used for semidry Western blot analysis (see 
2.2.2.4). 
 
2.2.4 In vitro assessment of T cell function 
2.2.4.1 Peripheral blood mononuclear cell (PBMC) isolation 
Peripheral blood mononuclear cells (PBMCs) were isolated from fresh blood donations of healthy 
donors by density gradient centrifugation. Ficoll-Paque™ Plus and ACK lysis buffer were used at 
room temperature.           
 First, 15ml of Ficoll-Paque™ Plus was pipetted into Leucosep™ tubes and centrifuged, 
passaging the porous layer (1min, 300xg). After blood donation, 10ml of heparinized blood was 
poured carefully into Leucosep™ tubes onto the porous barrier. In order to dilute the blood, 15ml of 
1xPBS was added carefully and the blood was centrifuged (10min, 300xg, centrifuge break turned 
off). Tubes were removed cautiously from the centrifuge in order to preserve the layering. The Ficoll-
Paque™ Plus and most of the erythrocytes and granulocytes were located on the bottom of the tube. 
Above the porous barrier, the desired PBMC layer was found. The blood plasma located above the 
PBMCs was taken off down to 1cm above the PBMC layer and discarded. Then, the PBMC layer was 
carefully taken up with a 10ml pipette and transferred into a fresh 50ml tube which was then filled up 
with 1xPBS in order to wash the cells. Cells were centrifuged (10min, 300xg) and erythrocyte lysis 
was performed to get rid of residual erythrocytes. In general, 3-5ml of ACK lysis buffer was used for 
cell pellet resuspension. The tubes were shaken gently for 3-5min depending on the amount of residual 
erythrocytes. Lysis was stopped by filling up the tubes with 1xPBS. Cells were washed twice with 
1xPBS, counted (see 2.2.3.3) and stored on ice for subsequent experiments.  
2.2.4.2 Magnetic-activated cell sorting (MACS) 
Magnetic-activated cell sorting (MACS) was used for separating different cell types according to their 
surface molecules. Separation was achieved by incubation with magnetic microbeads coated with 
antibodies specific for a particular surface molecule. The antibody binds to the cell surface marker of 
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the corresponding cell type and this complex can be subjected to a magnetic field, thereby separating 
the desired cell population from a mixed cell population. In this study, MACS was used to isolate 
CD14 monocytes from PBMCs (see 2.2.4.1) using CD14 microbeads and to isolate CD8 T cells via 
the “untouched CD8 T Cell Isolation Kit” from T cell cultures (see 2.2.4.3). The whole procedure was 
conducted with ice-cold buffers and under sterile conditions. Prior to isolation, the cell number was 
determined (see 2.2.3.3), cells were resuspended in ice-cold MACS buffer and a maximum of 1x108 
cells per column were used. MACS isolations were performed strictly following the manual of the 
company. Afterwards, cells were counted and used for the experiments described in the following 
paragraphs. 
2.2.4.3 Generation of peptide-specific T cell lines 
In this study, HPV16-specific T cells were expanded in order to investigate immunogenicity of certain 
peptides in the donors and as a read-out tool to observe changes in the presented HPV16 epitopes on 
tumor cell lines. HPV16-specific T cell memory was analyzed using short-term T cell lines whereas 
long-term T cell lines were used as a read-out tool. For long-term T cell lines, autologuous DCs and B 
cells were matured and activated, and used as antigen-presenting cells (APCs) for T cell stimulations. 
Generation of monocyte-derived dendritic cells (Mo-DCs) 
CD14-positive monocytes were either purified by MACS (see 2.2.4.2) or using the monocyte 
adherence strategy described in detail below. MACS purified cells were resuspended at a 
concentration of 1x106cells/ml in DC medium, supplemented with 500U/ml IL-4 and 1000U/ml GM-
CSF and 2ml of this cell suspension was added to one well of a 6-well plate. For the monocyte 
adherence strategy, 1x107 PBMCs were cultured in one well of a 6-well plate with DC medium for 2-
3h at 37°C. During this time, monocytes adhered to the plastic surface. Floating cells containing other 
lymphocytes were harvested, transferred to tubes and further used to generate T cell lines or CD40-
activated B cells. Adherent monocytes were washed twice using DC medium. Then, 2ml DC medium 
containing 500U/ml IL-4 and 1000U/ml GM-CSF was added to each well. On day 3, DC medium 
supplemented with IL-4 and GM-CSF reaching a final concentration of 500U/ml and 1000U/ml, 
respectively, was added in a volume of 500µl to each well. On day 6 or 7, the maturation cocktail 
containing 1000U/ml TNFα, 10ng/ml IL-1β, 10ng/ml IL-6, 1µM PGE2 (1mg/ml) and 1µl/ml LPS 
(5mg/ml, 5x104 EU/ml) was added to the cells and incubated for at least 36h up to 48h before cells 
were used as APCs. After maturation, mature dendritic cells could be verified using microscopy by a 
unique morphology with long thread-like dendrites and were harvested by pipetting up and down 
thoroughly. Cells were stored on ice and were then used as APCs for T cell stimulation. Purity and 
expression of surface molecules (CD83, CD86 and CD80) was checked by flow cytometry analysis 
(see 2.2.5, data not shown).  
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Generation of CD40-activated B cells 
The day before the B cell culture was started, the feeder cell line tCD40L NIH3T3 was harvested (see 
2.2.3.2), washed with 1xPBS and irradiated at 98Gy. Then, cells were washed again with 1xPBS and 
were diluted in tCD40L WT medium of a concentration of 2x105cells/ml. 2ml of this cell suspension 
was plated into one well of a 6-well plate and incubated overnight at 37°C with 5% CO2.   
 The next day, the CD14-negative cell population or floating cells that did not adhere to the 6-
well plate (see 2.2.4.2) were counted and diluted at a concentration of 2x106cells/ml in B cell medium 
supplemented with 0.63µg/ml cyclosporin A, 10ng/ml or 100U/ml IL-4 and 2ng/ml IL-6 (210). 
Cyclosporin A was added to the cytokines in order to kill T cells contained in the mixed cell 
population. The medium was removed from the feeder cell line and cells were washed gently with B 
cell medium and 4ml of the CD14-negative cell suspension or non-adherent PBMCs was added and 
incubated for at least 96h.          
 At day 5, clustered CD40-activated B cells were harvested from 6-well plates and centrifuged 
(3min, 300xg). Cells were resuspended at a concentration of 2x106cells/ml in B cell medium 
supplemented with 0.63µg/ml cyclosporin A, 10ng/ml or 100U/ml IL-4 and 2ng/ml IL-6. 4ml of the 
cell suspension was added to pre-plated feeder cells as described above. B cell lines were always re-
cultivated every 3-4 days on feeder cells prepared one day before. After one week of culture, 4x106 B 
cells per well of a 6-well plate were plated. At day 14, the culture consisted of more than 95% of B 
cells (assessed by CD19-positive expression analyzed by flow cytometry on a regular basis) and those 
cells were further used as APCs for T cell stimulation. 
Peptide-specific short-term T cell lines 
Short-term T cell lines were generated to assess the HPV16-specific T cell memory of each healthy 
donor. On day 0, PBMCs were prepared (see 2.2.4.1), 1-2x106 cells were resuspended in 2ml of T cell 
medium supplemented with 10ng/ml IL-7 and in one well of a 24-well plate. Peptides were added to 
each well at a concentration of 10µg/ml and dispensed by pipetting. Cells were cultured at 37°C with 
5% CO2. On day 3 and 7, 1ml of the medium was carefully removed and 1ml of fresh T cell medium, 
supplemented with 40U/ml IL-2 with a final concentration of 20U/ml IL-2, was added. On day 12, 
cells were used for ELISpot analysis (see 2.2.4.4).  
Peptide-specific long-term T cell lines 
Long-term T cell lines were generated by expanding HPV16-reactive T cells. First, autologous mature 
DCs were pulsed with selected HPV16-derived peptides. To this end, mature Mo-DCs (see above) 
were harvested and washed with serum-free DC medium, resuspended at a concentration of 
1x106cells/ml in serum-free DC medium in 50ml tubes and selected peptides were added (10µg/ml 
final concentration). Cells were incubated for 3-4h at 37°C with 5% CO2 with gently tapping of the 
tube each hour. Afterwards, cells were washed with serum-free DC medium, counted and resuspended 
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in 1ml of T cell medium. In between, PBMCs from the same healthy donor were prepared (2.2.4.1) 
and 1x107 were diluted in 1ml T cell medium supplemented with 20ng/ml IL-7 to reach a final 
concentration of 10ng/ml. The DCs were added to the PBMCs in a volume of 1ml. Peptide pulsed DCs 
and PBMCs were plated at a ratio of 1:10-1:200 in 24-well plates. On day 5 after stimulation, 1ml of 
the supernatant was carefully removed and 1ml of fresh T cell medium containing 40U/ml IL-2 was 
added to each well with a final concentration of 20U/ml IL-2. One week after the first stimulation, 
PBMCs were restimulated with matured peptide-pulsed DCs and IL-7 supplemented T cell medium. 5 
days after this stimulation, IL-2 was added as described before. The third stimulation was performed 
one week after the second one using peptide-pulsed CD40-activated B cells. For the HLA-A24 
positive donor the autologous EBV-immortalized B cell line, RiSh, could be used. B cells were pulsed 
with peptides as described above, but afterwards they were irradiated at 32Gy (RiSh cells were 
irradiated at 70Gy), washed twice with T cell medium and were added to the T cell lines at a ratio of 
1:5 (B to T cells). 5 days after stimulation, IL-2 was added as described before. One week after the 
third stimulation, T cell lines were harvested and used for subsequent experiments.  
2.2.4.4 Interferon (IFN)γ enzyme-linked immunospot (IFNγ ELISpot) 
The ELISpot assay was used to quantify peptide-specific T cell responses. Short-term T cell lines (see 
2.2.4.3) were tested for peptide-specificity in an ELISpot assay via restimulation with the 
corresponding peptide within the ELISpot plate.       
 On day 1, 96-well MultiScreen®-HA plates were coated using 100µL/well of anti-human 
IFNγ capture antibody diluted 1:500 in 1xPBS. Plates were incubated at 4°C overnight. On the 
following day, the capture antibody was removed by inverting the plate shortly. Then, plates were 
washed three times with 1xPBS. For blocking, 200µl of ELISpot medium was added to each well and 
plates were incubated for 1-2h at 37°C with 5% CO2. Meanwhile, T cells were harvested and diluted to 
the desired concentration. Blocking medium was removed and 100µl of ELISpot medium containing a 
control peptide or a HPV16-derived peptide diluted to a final concentration of 10µg/ml was added to 
each well. As positive controls, 2µg/ml ConA or 1µg/ml of a CEF or a CE peptide pool was used; 
whereas a HIV-derived peptide for the respective HLA type of the donor and the peptide diluent 
DMSO served as negative controls. 1 or 2x105cells resuspended in 100µl ELISpot medium were 
added per well. The total volume of each well was 200µl and if possible at least triplicates were 
prepared for each sample if not indicated otherwise. The ELISpot was incubated for 18-24h at 37°C 
with 5% CO2 without any movement of the plate. After incubation, the plates were quickly inverted 
and washed twice with 1xPBS and twice with ELISpot washing buffer. 100µl of biotinylated anti-
human IFNγ antibody, diluted 1:1,000 in 1xPBS, was added per well and incubated for 2h at room 
temperature. Plates were washed four times with ELISpot washing buffer. Then, 100µl of 
Streptavidin-alkaline phosphatase, diluted 1:2,000 in 1xPBS, was added per well and incubated for 
90min at room temperature. Then, plates were washed four times with ELISpot washing buffer and 
100µl of BCIP/NBT-Plus substrate was added to each well and incubated for 20-25min. The reaction 
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was stopped by rinsing the plates on both sides of the membrane with tap water. The plates were air 
dried in a flow hood. ELISpot plates were scanned and spot forming units (SFU) were counted with 
the CTL ImmunoSpot 5.1.36 Professional DC software using the Smart Count™-ImmunoSpot 
“wizard” counting mode with automated parameter set up. Finally, SFU were calculated to 1x106 input 
cells. 
2.2.4.5 VITAL-FR cytotoxicity assay  
The VITAL-FR cytotoxicity assay is a flow cytometry based assay to assess small frequencies of 
CTLs by their cytolytic function. This assay was established in the group of Dr. Andreas Kaufmann 
(211, 212). On the first day, 1x106/ml target cells were incubated with 5µM CFSE 
(carboxyfluorescein) or 0.25µM FarRed (dimethyldodecylamine oxide-succinimidyl ester) in a 50ml 
falcon for 10min, at 37°C, in a waterbath. The reaction was stopped by adjusting the volume to 50ml 
with pre-warmed RPMI supplemented with 10% FCS. Labeled cells were centrifuged (5min, 300xg) 
and either directly plated into 12-well plates or first used for siRNA-mediated knockdown (see 
2.2.3.5), then plated and incubated at 37°C with 5% CO2. Cells treated with control siRNA were 
labeled with FarRed, whereas those treated with the ERAP1-specific siRNA pool were stained with 
CFSE.            
 On the second day, purified CD8 T cells from long-term T cell lines (see 2.2.4.2 and 2.2.4.3) 
and target cells were harvested and counted. Triplicates or duplicates of effector T cells were titrated 
in 48-well plates (effector:target ratios ranging from 1.25:1 to 20:1) and 3x103 CFSE-labeled as well 
as 3x103 FarRed-labeled target cells were added to each well. Wells containing only target cells were 
plated, serving as negative control. Cells were plated in T cell medium supplemented with 10U/ml   
IL-2, reaching a final volume of 200µl. The mixes were incubated for 48h at 37°C and carefully 
resuspended after 24h. After 48h, cells were collected and either directly used for flow cytometry 
analysis (see 2.2.5) or fixed in fixation buffer for 10min, washed in FACS buffer and stored for max. 3 
days at 4°C until analysis. For analysis of specific killing, the entire target cell population was defined 
in a life gate with the forward/sideward scatter. CFSE- and FarRed-labeled target cells were detected 
and calculated as the percentage from the life gate. Specific lysis was calculated using this formula: 
 
specific	lysis	(%) = 100 − frequency	of	target	cells	with	T	cellsfrequency	of	target	cells	only x	100" 
 
2.2.5 Flow cytometry 
The FACS Canto II™ flow cytometer provided by the DKFZ FACS Core Facility was used. All 
reagents were ice-cold throughout the experiments and incubation was either performed on ice or at 
4°C. Stainings were either performed in 96-well plates or in reaction tubes depending on the amount 
of samples. In general, 1x106 cells were used for flow cytometry staining and out of these 1x104-1x105 
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cells were recorded. After harvesting, cells were washed with FACS buffer, centrifuged (3min, 400xg, 
4°C) and blocked for 15min in 1xPBS supplemented with 10% FCS on ice. Then, the cells were 
resuspended in 100µl FACS buffer containing the appropriate dilution of antibody. After 30min of 
incubation, covered from light, at 4°C, cells were washed twice with FACS buffer. When the primary 
antibody was unlabeled and a secondary antibody staining was necessary, the secondary antibody was 
diluted in FACS buffer, applied to the cells and incubated for 30min, covered from light and at 4°C. 
Then, cells were washed twice with FACS buffer, resuspended in an appropriate volume of FACS 
buffer and analyzed on the FACS Canto II™. For later analysis, cells were fixed in fixation buffer for 
10min in the dark. Cells were washed once with FACS buffer, resuspended in an appropriate volume 
of FACS buffer, stored at 4°C and flow cytometry analysis was performed within 3 days.  
 Throughout flow cytometry analysis, cells were kept on ice and protected from light. 
Acquisition of unstained cells was used to determine background autofluorescence. If staining with a 
labeled secondary antibody was necessary, cells stained with the secondary antibody only served as 
background control. Voltages and compensation were adjusted using single color stainings. For this, 
cells and compensation beads were stained with only one antibody. OneComp eBeads were stained 
with the corresponding antibodies used for cell stainings. The single-color stained cells and beads were 
then acquired with the FACS Canto II™ to perform manual compensation. Data processing was 
performed with the FlowJo 6.5 software.  
 
2.2.6 Immunohistochemistry 
In this study, immunohistochemistry (IHC) for ERAP1 in human tissue sections was performed in 
cooperation with Dr. Miriam Reuschenbach (Prof. Magnus von Knebel Döberitz, Department of 
Applied Tumor Biology, Institute of Pathology, University of Heidelberg). Human tissue sections 
were anonymized in accordance with the regional ethical regulations and exclusion of personal data of 
the subjects.           
 For validating the ERAP1 antibody, CaSki cells were plated and either transfected with a 
siPOOL specific for ERAP1, a non-targeting siRNA pool (see 2.2.3.5) or left untreated. Cells were 
trypsinized 72h after transfection, washed twice with 1xPBS and pelleted (3min, 400xg). Cell pellets 
were resuspended in 10ml of the methanol-based preservation solution, PreservCyt, and stored at 4°C. 
Cells were prepared on thin-layer ThinPrep® cytology slides using a cytology processor.   
 For immunohistochemistry stainings, human tissue sections of formalin-fixed, paraffin-
embedded cervical cancer biopsy specimens were deparaffinized and rehydrated using xylol and a 
series of graded alcohols as shown in Table 2.10. 
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Table 2.10: Deparaffinization and rehydration of tissue sections. 
Alcohol type Incubation time 
100% xylol I 5min 
100% xylol II 5min 
100% xylol III 5min 
100% ethanol I 5min 
100% ethanol II 5min 
96% ethanol 5min 
70% ethanol 5min 
deionized H2O 5min 
 
 
Afterwards, sections were placed into a black cuvette and filled with deionized H2O (dH2O). 
dH2O was replaced with fresh dH2O four times. Sections were placed in antigen retrieval buffer and 
microwaved three times for 5min at 550W. Sections were chilled for 20min. Sections were washed 
two to three times with dH2O and incubated for 15min in 3.5M HCl solution at room temperature. 
Subsequently, sections were washed for 5min in dH2O and then incubated in dH2O containing 3% 
H2O2. Sections were washed several times with dH2O. Then, they were placed in permeabilization 
buffer for 2-3min. Blocking (horse serum) and development (secondary biotinylated antibody and 
avidin/biotin complex) of the sections was done using the VECTASTAIN Elite ABC Kit. 
Immunostainings were encircled with a Pap Pen and put into a humidity chamber. Sections were 
blocked with blocking buffer for 20-30min. The blocking solution was removed by tapping. Sections 
were incubated with antibodies for ERAP1 and p16 diluted 1:2,000 in 1xPBS supplemented with 1% 
horse serum overnight at 4°C. The following day, sections were washed twice for 5min with 
immunohistochemistry washing buffer. Then, the secondary biotinylated antibody was diluted 1:50 in 
1% horse serum diluted in 1xPBS and incubated for 1h at room temperature. The sections were 
washed twice for 5min with immunohistochemistry washing buffer. Afterwards, sections were 
incubated with component A and B of the avidin/biotin complex mixed 1:50 in 1xPBS for 30min at 
4°C. Sections were washed three times for 5min with immunohistochemistry washing buffer. For 
color development, one drop of the DAB chromogen was added to 1ml of substrate, applied to the 
section and incubated for several minutes. Sections were washed with dH2O and placed in Mayer’s 
Hematoxylin solution for 1-3min. Subsequently, sections were washed by rinsing them with tap water 
for 5min. Finally, sections were embedded in Aquatex® aqueous mounting agent and stored in 
darkness until microscopical analysis.  
2.2.6.1 Analysis of IHC data 
To evaluate ERAP1 expression an immunohistochemical score was calculated as the product of the 
staining frequency and maximal intensity based on the following system: the staining frequency 
ranged from 0 (no ERAP1 expressing cells) to 5 (< 10%), 30 (10-50%), 70 (50-90%) or 95 (> 90%) 
reflecting the percentage of ERAP1 expressing cells and the maximal intensity was set to 0 = no, 1 = 
low, 2 = intermediate and 3 = high expression. The staining frequency (0, 5, 30, 70 or 95) and the 
maximal intensity (0, 1, 2 or 3) were multiplied to determine the immunohistological score. The 
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immunohistochemical score of ERAP1 expression was determined for the cytoplasmic and perinuclear 
regions of the cells within a section. Finally, the average of the immunohistochemical score for the 
cytoplasmic and perinuclear region was calculated. All sections were analyzed independently, 
randomly and by two different researchers (Dr. Miriam Reuschenbach and Alina Steinbach). An 
average score was determined for the rare occasion of differing histological scores.  
 
2.2.7 Statistics  
For statistical analyses the PRISM® 5 software was used. The employed statistical test is indicated in 
the figure legend of the respective experiment. 
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3 Results 
Diseases caused by human papillomavirus (HPV) are a global health burden. Despite the success of 
prophylactic anti-HPV vaccines there is a need for a therapeutic vaccine that can cure already 
established infections. In order to develop a clinically successful vaccine it is crucial to elucidate 
molecular evasion strategies that HPV-mediated cancers use to evade the immune system. The present 
study aimed at the systematic identification of components of the antigen processing machinery 
(APM) that are altered in HPV-mediated cancers and to investigate whether these changes have an 
impact on the HLA class I epitope presentation of HPV16, the most common HPV high-risk type. 
 The first part of the results section describes the assessment of the APM on the mRNA and 
protein level in HPV16-positive compared to HPV-negative cell lines. Furthermore, the impact of the 
cytokine interferon (IFN)γ on APM component expression was analyzed. These experiments revealed 
that the endoplasmic reticulum aminopeptidase 1 (ERAP1) was consistently overexpressed in HPV16-
positive tumor cell lines. Thus, ERAP1 was further analyzed by immunohistochemistry in cervical 
tissue. Immunohistochemical analysis showed that ERAP1 levels increased with disease state and 
were significantly higher than in histologically normal cervical epithelium. Further, possible 
mechanisms were studied that could account for ERAP1 overexpression and imply functional 
consequences. Single nucleotide polymorphisms (SNPs) of ERAP1 were analyzed in several HPV16-
positive cell lines and one HPV-negative cell line. Additionally, the influence of the HPV16 
oncogenes E6 and E7 on ERAP1 expression was investigated.      
 In the final part of this thesis, a small interference RNA (siRNA) approach to knockdown 
ERAP1 was established. This tool was used to analyze whether overexpression of ERAP1 affects the 
presentation of HLA class I of HPV16 E6 and E7-derived peptides. For the direct detection of 
naturally processed and presented epitopes on HPV16-transformed cells a highly sensitive mass 
spectrometry approach was used. HPV16 E6 and E7-specific CD8 T cells were used in cytotoxicity 
assays to study the impact of ERAP1 expression on defined epitopes.  
 
 
3.1 Analysis of the antigen processing machinery (APM) 
HPV is able to perturb antigen processing (see 1.2.2) which is the intracellular pathway for the 
generation of T cell epitopes. Thereby, anti-tumor responses mediated by CD8 T cells could be 
hampered. However, so far no comprehensive screen of the APM is available in HPV-induced cancers. 
Thus, the expression of the whole APM was analyzed in a comprehensive collection of cell lines in the 
first part of this study. This collection included HPV-negative cell lines, HPV16-positive cervical 
cancer cell lines, HPV16-positive head and neck squamous carcinoma (HNSCC) cell lines, and cell 
lines that have been transfected with the HPV16 genome. The collection included long-standing as 
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well as newly-established cell lines. First, APM component expression on the mRNA level was 
investigated in all cell lines using quantitative Real-Time PCR (qRT-PCR). Constitutive expression as 
well as expression upon IFNγ stimulation was investigated. Secondly, the protein expression of 
selected APM components in selected cell lines was analyzed to confirm the observations of the qRT-
PCR approach. Thirdly, immunohistochemistry of cervical tissue sections was performed to compare 
ERAP1 expression in histologically normal and HPV-transformed tissue.  
 
3.1.1 Expression of APM components on the mRNA level 
In the initial part of the APM component expression analysis, a qRT-PCR screen was used to assess 
the expression of 20 APM components in 29 cell lines. The qRT-PCR approach used in this study was 
thoroughly established in our laboratory by Jan Winter (213). Quality control parameters applied by 
the data processing software LinRegPCR and qBase plus for qRT-PCR are summarized in Table 7.1 in 
the appendix. For data analysis, passive normalization was done by the MxPro software of the qPCR 
machine. The LinRegPCR software (214, 215) was used for baseline subtraction, Cq and PCR 
efficiency determination. LinRegPCR has many advantages over simple qPCR analysis using only the 
supplied software of the qPCR machine. LinRegPCR finds the linear log-phase for each qPCR 
reaction, the background is subtracted individually and only then the Cq values are calculated. In 
addition, LinRegPCR includes single well kinetics for baseline subtraction and PCR efficiency 
calculation, thereby further minimizing variations. Mean PCR efficiencies calculated by LinRegPCR 
of all used genes are illustrated in Figure 7.1 A and B in the appendix. A second software, qBase plus, 
was employed for reference gene normalization, calibration and data management. Since reference 
genes can be regulated (216), multiple experimentally validated reference genes (GAPDH, PGK1, 
PPIA, IPO8) for keratinocyte-derived cell lines were used in our approach (204).   
 The HPV-negative control group included human primary keratinocytes from three different 
donors (pHKI-III) and primary human foreskin keratinocytes (pHFK) pooled from multiple neonatal 
foreskins. In addition, the HPV-negative normal oral keratinocytes (NOK), which were immortalized 
by human telomerase reverse transcriptase (hTERT), were used (193). The spontaneously 
immortalized keratinocyte cell line HaCat also served as a HPV-negative control (192). HPV16-
positive cell lines consisted of 12 cell lines derived from cervical cancer, 6 from HNSCC and 5 
keratinocyte cell lines that have been HPV16-immortalized by transfection with the whole HPV16 
genome (for names and origin of the cell lines see Figure 3.1).  
3.1.1.1 Constitutive expression of APM components 
The first qRT-PCR screen was done to analyze constitutive expression of APM components in 
HPV16-positive cell lines compared to HPV-negative cell lines. Total RNA was isolated, genomic 
DNA was removed, and RNA reverse transcribed into cDNA. FAM (fluorescein amidite)-labeled 
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TaqMan® hydrolysis probes were used for qRT-PCR (see 2.1.11). In order to minimize variation of 
the results, the sample maximization approach introduced by Hellemans et al. (205) was followed. To 
this end, all cell lines were analyzed for one particular gene on one qPCR plate. The determined 
expression levels were calibrated to the HPV-negative cell line NOK.    
 Figure 3.1 shows the obtained data of constitutive APM component expression as a heatmap 
generated by R. Genes that are overexpressed compared to NOK are shown in green, while 
downregulated genes are shown in red. A similar expression level to the NOK cell line is shown in 
black. The first observation was that the HPV-negative cell lines had a strikingly uniform behavior. 
Cell lines transfected with the whole HPV16 genome (except for HPK1A and 2A3) behaved similarly 
to the HPV-negative group. However, gene expression levels of tumor-derived cell lines either from 
cervical cancer or from HNSCC were different for many APM components. Gene expression of HLA-
A and -B was elevated in the majority of tumor cell lines, as were β2m (β2-microglobulin) levels. 
Many peptide loading complex associated genes, tapasin, calnexin, calreticulin, ERAP1 and ERAP2, 
also showed a trend to upregulation when compared to the HPV-negative group. Furthermore, all 
tested components of the immunoproteasome, PSMB8, PSMB9, PSMB10, PSME1 and PSME2, had 
higher expression levels in the cervical cancer and HNSCC group. Detailed bar diagrams of each 
tested gene for all cell lines of this screen are given in Figure 7.2 to 7.5 in the appendix. 
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Figure 3.1: Constitutive expression of the APM on the mRNA level. Total RNA was purified from cells, reverse 
transcribed to cDNA and analyzed for APM component expression by qRT-PCR using TaqMan® probes. PCR reactions 
were run in triplicates. At least three of the following genes were used as internal reference genes: GAPDH, PGK1, PPIA and 
IPO8. Gene expression was calibrated to the NOK cell line. All quantitative qRT-PCR data were processed by LinRegPCR 
and data management was done by qbasePLUS 2. Log10 data were plotted as a heatmap using R. Expression of 20 APM 
components is shown. Each column represents a single gene and each row represents one cell line. Increased expression is 
shown in green and decreased expression is shown in red (see scale bar in the bottom right corner). HNSCC = head and neck 
squamous cell carcinoma 
Since in the heatmap representation a trend was observed that many APM associated genes 
were upregulated in tumor-derived cell lines, the next step was to statistically validate these 
observations. To this end, the different cell lines were grouped into HPV-negative cell lines and 
HPV16-positive tumor cell lines, including cervical and HNSCC. Statistical significance for gene 
expression was tested between the two groups. Of note, the HPV16-transfected group was omitted 
from this analysis because this group behaved similarly to HPV-negative cells as described above. 
Figure 3.2 A shows all genes that were found to be significantly upregulated in tumor-derived cell 
lines. These genes were the chaperone calreticulin, the aminopeptidase ERAP1 and all tested 
components of the immunoproteasome (PSMB8, PSMB9, PSMB10, PSME1 and PSME2). All other 
genes did not show a significantly different expression from the HPV-negative group (Figure 3.2 B). 
These results complement observations made by the heatmap representation. This provides a first 
indication that APM components are indeed constitutively altered in HPV16-positive cell lines.  
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Figure 3.2: Constitutive expression of the APM on the mRNA level. Total RNA was purified from cells, reverse 
transcribed to cDNA and analyzed for APM component expression by qRT-PCR using TaqMan® probes. PCR reactions 
were run in triplicates. At least three of the following genes were used as internal reference genes: GAPDH, PGK1, PPIA 
and IPO8. Gene expression was calibrated to the NOK cell line. All quantitative qRT-PCR data were processed by 
LinRegPCR and data management was done by qbasePLUS 2. Log10 expression data were plotted for each cell line, 
additionally mean ± SD of each group are shown. A. APM components that showed a significantly elevated expression in 
cervical cancer and head and neck squamous cell carcinoma (HNSCC) compared to HPV-negative cells. * p ≤ 0.05, ** p ≤ 
0.01 (unpaired t-test) B. APM components that showed no significantly different expression in HPV16-positive tumor cell 
lines compared to HPV-negative cells. 
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3.1.1.2 The influence of interferon (IFN)γ on APM component expression 
The second qRT-PCR screen was performed to analyze expression of APM components in HPV16-
positive cell lines compared to HPV-negative cell lines after IFNγ stimulation. There are many genes 
of the APM known to be inducible by IFNγ, namely HLA-A, HLA-B, HLA-E, β2m, TAP1, TAP2, 
tapasin, ERAP1, ERAP2, PSMB8, PSMB9, PSMB10, PSME1 and PSME2 (67, 217, 218), which is 
crucial during anti-viral immune responses. These genes are written in red below the heatmap in 
Figure 3.3. Total RNA was isolated, genomic DNA was removed, and RNA reverse transcribed into 
cDNA. FAM-labeled TaqMan® hydrolysis probes were used for qRT-PCR (see 2.1.11). In order to 
minimize variation of the results, untreated and treated samples of the same cell line were analyzed for 
gene expression on one qPCR plate. The IFNγ-induced determined expression levels were calibrated 
to the respective untreated expression levels.       
 Figure 3.3 shows the obtained data of IFNγ stimulated APM component expression as a 
heatmap like in Figure 3.1. In general, the results revealed that all APM components that should be 
IFNγ-inducible were upregulated upon stimulation, but to a variable extent. HPV-negative as well as 
HPV16-positive cell lines all reacted to the cytokine, suggesting that IFNγ signaling is intact in the cell 
lines. 
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Figure 3.3: Relative expression level change per cell line of indicated APM components after IFNγ treatment. Cells 
were either treated with IFNγ for 48h or left untreated. Total RNA was purified from cells, reverse transcribed to cDNA and 
analyzed for APM component expression by qRT-PCR using TaqMan® probes. PCR reactions were run in triplicates. At 
least two of the following genes were used as internal reference genes: GAPDH, PGK1, PPIA and IPO8. Gene expression 
was calibrated to the respective untreated expression levels. All quantitative qRT-PCR data were processed by LinRegPCR 
and data management was done by qbasePLUS 2. Log10 data were plotted as a heatmap using R. Expression of 20 APM 
components is shown. Known IFNγ-inducible genes are labeled in red. Each column represents a single gene and each row 
represents one cell line. Increased expression is shown in green and decreased expression is shown in red (see scale bar in the 
bottom right corner). HNSCC = head and neck squamous cell carcinoma  
 
Figure 3.4 shows the data obtained from the IFNγ stimulated APM screening in a dot plot 
diagram. Data was calibrated to the respective untreated level of each cell line. Thus, values below 
zero indicate a downregulation of a particular gene in a cell line upon IFNγ exposure. Conversely, 
values above zero indicate an IFNγ-mediated upregulation of a particular gene. Blue dots represent 
data from HPV-negative cell lines. The mean value of all IFNγ inducible genes, HLA-A, HLA-B, HLA-
E, β2m, TAP1, TAP2, tapasin, ERAP1, ERAP2, PSMB8, PSMB9, PSMB10, PSME1 and PSME2, was 
highly elevated (marked by asterisks in Figure 3.4). This indicated that IFNγ signaling was intact in all 
our cell lines, supporting observations from the heatmap representation. All cell lines upregulated 
HLA-A, HLA-B, TAP1, TAP2, PSME8, PSME9 and PSME1 and almost all cell lines upregulated   
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HLA-E, β2m, tapasin, ERAP1, ERAP2, PSMB10 and PSME2. As expected, the mean expression 
values for the genes calnexin, calreticulin, PDIA3, PSMB5, PSMB6 and PSMB7 were close to zero.  
 
Figure 3.4: Relative expression level change per cell line of indicated APM components after IFNγ treatment. Cells 
were either treated with IFNγ for 48h or left untreated. Total RNA was purified from cells, reverse transcribed to cDNA and 
analyzed for APM component expression by qRT-PCR using TaqMan® probes. PCR reactions were run in triplicates. At 
least two of the following genes were used as internal reference genes: GAPDH, PGK1, PPIA and IPO8. Gene expression 
was calibrated to the respective untreated expression levels. All quantitative qRT-PCR data were processed by LinRegPCR 
and data management was done by qbasePLUS 2. Log10 expression data were plotted for each cell line, additionally mean ± 
SD of each group are shown. Blue symbols stand for HPV-negative cell lines. Genes marked with an asterisk (*) are known 
to be inducible by IFNγ. 
 
It seemed that most HPV-negative cell lines reacted with a higher expression of IFNγ-
inducible APM components than the mean expression level (Figure 3.3 and blue dots in Figure 3.4). 
However, these findings can be explained by a lower constitutive expression of these APM 
components observed in the first qRT-PCR screen (see 3.1.1.1). Constitutive expression levels from 
the first screen were multiplied with the fold change of IFNγ-induced levels from the second screen 
resulting in the calculated final levels of APM component expression after IFNγ treatment (Figure 
3.5). This mathematical approach demonstrated that final expression levels upon IFNγ treatment were 
similar between HPV-negative and HPV16-positive cells. Only for calreticulin the final expression 
after IFNγ treatment was significantly elevated in HPV16-positive tumor cells compared to HPV-
negative cells (Figure 3.5 A). Taken together, these results revealed that overall expression is not 
significantly different in response to IFNγ in HPV16-positive tumor cell lines and HPV-negative cell 
lines.  
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Figure 3.5: Mathematically calculated final expression levels of APM components after IFNγ treatment. Cells were 
either treated with IFNγ for 48h or left untreated. Total RNA was purified from cells, reverse transcribed to cDNA and 
analyzed for APM component expression by qRT-PCR using TaqMan® probes. PCR reactions were run in triplicates. At 
least two of the following genes were used as internal reference genes: GAPDH, PGK1, PPIA and IPO8. All quantitative 
qRT-PCR data were processed by LinRegPCR and data management was done by qbasePLUS 2. Constitutive APM 
expression levels were calibrated to NOK. IFNγ-induced fold change of APM expression was calculated by calibration to the 
respective untreated cells. Final gene expression after IFNγ treatment was calculated by multiplying constitutive APM 
expression with the fold change of IFNγ-induced levels of the respective APM component. Log10 expression data were 
plotted for each cell line, additionally mean ± SD of each group are shown. A. APM components that showed a significantly 
elevated expression in HPV-16 positive tumor cell lines compared to HPV-negative cells. * p ≤ 0.05 (unpaired t-test) B. 
APM components that showed no significantly different expression in HPV16-positive tumor cell lines compared to HPV-
negative cells. 
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3.1.2 Expression of selected APM components and surface HLA class I on the 
protein level 
The qRT-PCR screen of the APM was conducted in all available cell lines of our collection under 
normal conditions and upon IFNγ exposure. Based on this broad analysis, cell lines and APM 
components were selected for protein expression analysis as mRNA data always needs to be 
confirmed on the protein level. Protein expression was either analyzed by flow cytometry or by 
Western blot. First, surface HLA class I levels were investigated, followed by components of the 
immunoproteasome, the peptide loading complex and ER-resident aminopeptidases.  
3.1.2.1 Surface HLA class I expression 
The qRT-PCR approach had shown that the classical HLA types, HLA-A and HLA-B, tended to have a 
higher expression in many HPV16-positive cell lines (see 3.1.1.1). The difference, however, was not 
statistically significant when HPV-negative cells were compared to cell lines derived from HPV16-
positive tumor cells. Nevertheless, knowledge about HLA class I surface expression is important for 
later experiments with CD8 T cells and immunoprecipitation (IP) of HLA class I/peptide complexes. 
The qRT-PCR approach only measures mRNA levels of HLA class I, which does not reveal whether 
these molecules are actually presented on the cell surface. Therefore, the surface expression of HLA 
class I was determined in 18 HPV16-positive cell lines and compared to the HPV-negative cell lines 
NOK, HaCat and primary human keratinocytes (pHKs). To this end, cells were stained with an anti-
HLA class I antibody and analyzed by flow cytometry (Figure 3.6). 10 out of 18 HPV16-positive cell 
lines had a higher mean surface HLA class I expression than the HPV16-negative cell line with the 
highest HLA class I expression (HaCat, Figure 3.6 A and B, dashed lines). The expression was also 
analyzed after IFNγ treatment (Figure 3.6 B). All cell lines responded to IFNγ by upregulating surface 
HLA class I. The expression was similar in the analyzed cell lines consistent with observations from 
the qRT-PCR screen. Only SNU1005 and SNU1299 had much higher expression levels after IFNγ 
stimulation. The UDSCC2 cell line showed the lowest HLA class I surface expression consistent with 
the qRT-PCR analysis.  
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Figure 3.6: Surface HLA class I expression. Cells were left untreated (A) or treated with IFNγ for 48h (B). Afterwards, 
cells were harvested and stained with an anti-HLA class I antibody coupled to FITC and the mean fluorescence intensity 
(MFI) was analyzed by flow cytometry and calculated over the background of each cell line. Results are plotted as means ± 
SD of at least three independent experiments (except for data from IFNγ treated SNU1000 cells which are derived from two 
independent experiments). The dashed line marks the highest HLA class I surface expression of a HPV-negative cell line 
(HaCat). 
 
3.1.2.2 Selected components of the immunoproteasome 
The qRT-PCR approach had shown that the immunoproteasome subunits PSMB9, PSMB10, PSME1 
and PSME2 were significantly higher expressed in cell lines derived from cervical cancer and HNSCC 
when compared to HPV-negative cells when no IFNγ was present (see 3.1.1.1). Therefore, their 
expression was analyzed on the protein level in selected cell lines by Western blot. However, on the 
protein level no overexpression of these components was observed in HPV16-positive cell lines.  
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Constitutive PSMB9 protein expression is shown in Figure 3.7 A for the HPV-negative cell 
lines NOK, HaCat and for pHKs from two different donors compared to 16 HPV16-positive cell lines. 
Below each Western blot the ratio of optical density (OD) of PSMB9 and the loading control α-tubulin 
is depicted. On the protein level, no higher expression of PSMB9 could be observed in the majority of 
HPV16-positive cell lines. Only CaSki and SNU703 expressed PBMS9 at higher levels than the 
control cell lines. All other cell lines had a similar or a lower PSMB9 expression than NOK, HaCat 
and pHKs. Figure 3.7 B shows the result of PSMB9 protein expression in an IFNγ-positive milieu. On 
the protein level, only the SCC152 cell line expressed more PSMB9 than the control cell lines upon 
IFNγ stimulation, whereas all other cell lines expressed PSMB9 at similar levels as the control cell 
lines.  
 
Figure 3.7: PSMB9 protein expression with and without IFNγ treatment. Cells were either left untreated (A) or treated 
with IFNγ (B) for 48h. 50µg of each cellular lysate was analyzed for PSMB9 expression by Western blot, with α-tubulin 
detection as a loading control. Optical density (OD) was quantified using the ImageJ software and PSMB9 expression was 
normalized to α-tubulin for each cell line, as depicted below the Western blots. Results are representative of two independent 
experiments.  
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The same analysis as for PSMB9 was done for PSMB10 (Figure 3.8). Similar to PSMB9, no 
higher expression of PSMB10 could be observed in the majority of HPV16-positive cell lines. Three 
HPV16-positive cell lines (CaSki, SNU703 and 866) expressed PBMS10 at higher levels than the 
control cell lines. All other cell lines had a similar or a lower PSMB10 expression. Figure 3.8 B shows 
the result of PSMB10 protein expression upon IFNγ treatment. On the protein level, only 93VU147T 
and SCC152 expressed higher levels of PSMB10 than the control cell lines upon IFNγ stimulation, 
whereas all other cell lines expressed similar levels as the control cell lines. 
 
Figure 3.8: PSMB10 protein expression with and without IFNγ treatment. Cells were either left untreated (A) or treated 
with IFNγ (B) for 48h. 50µg of each cellular lysate was analyzed for PSMB10 expression by Western blot as in Figure 3.7. 
Optical density (OD) was quantified using the ImageJ software and PSMB10 expression was normalized to α-tubulin for 
each cell line, as depicted below the Western blots. Results are representative of two independent experiments.  
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Figure 3.9 illustrates constitutive PSME1 protein expression in HPV-negative cell lines (NOK, 
HaCat and pHKs from two different donors) compared to 16 HPV16-positive cell lines. On the protein 
level, no higher expression of PSME1 could be observed in the majority of HPV16-positive cell lines. 
Three HPV16-positive cell lines (SNU703, SNU1005 and SCC152) expressed PSME1 at slightly 
higher levels and SiHa at higher levels than control cell lines. All other cell lines had a similar or a 
lower PSME1 expression. 
 
Figure 3.9: PSME1 protein expression. 50µg of each cellular lysate was analyzed for PSME1 expression by Western blot 
as in Figure 3.7. Optical density (OD) was quantified using the ImageJ software and PSME1 expression was normalized to α-
tubulin for each cell line, as depicted below the Western blots. Results are representative of two independent experiments. 
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Constitutive PSME2 protein expression was analyzed as it was done for PSME1 (Figure 3.10). 
Again no higher expression of PSME2 could be observed in the majority of HPV16-positive cell lines. 
6 out of 16 tested HPV16-positive cell lines (SiHa, SNU703, SNU1005, 93VU147T, SCC152 and 
HPK1A) expressed PSME2 at higher levels and SCC154 expressed slightly higher levels than the 
control cell lines. All other cell lines had a similar or a lower PSME2 expression. 
 
Figure 3.10: PSME2 protein expression. 50µg of each cellular lysate was analyzed for PSME2 expression by Western blot 
as in Figure 3.7. Optical density (OD) was quantified using the ImageJ software and PSME2 expression was normalized to α-
tubulin for each cell line, as depicted below the Western blots. Results are representative of two independent experiments. 
 
3.1.2.3 Selected components of the peptide loading complex (PLC) 
A set of HPV16-positive cell lines expressed the PLC component tapasin at higher mRNA levels than 
control cell lines without IFNγ treatment, but the difference was not significant (see 3.1.1.1). 
Nevertheless, tapasin expression was investigated on the protein level because it was shown by 
Kanaseki and colleagues (219) that tapasin is directly involved in editing the peptide repertoire. Of 
note, the qRT-PCR approach had shown that the PLC component calreticulin was significantly higher 
expressed in cell lines derived from cervical cancer and HNSCC when compared to HPV-negative 
cells. For these reasons, calreticulin and tapasin were analyzed on the protein level in selected cell 
lines by Western blot. As for the immunoproteasome subunits, no higher expression of these PLC 
components was observed on the protein level (Figure 3.11 and 3.12)     
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Tapasin protein expression in the HPV-negative cell lines NOK, HaCat and pHKs from two 
different donors compared to 16 HPV16-positive cell lines is shown in Figure 3.11. Only SCC152 
expressed tapasin at higher levels than the control cell lines. All other cell lines had a similar or a 
lower tapasin expression. 
 
Figure 3.11: Tapasin protein expression. 50µg of each cellular lysate was analyzed for tapasin expression by Western blot 
as in Figure 3.7. Optical density (OD) was quantified using the ImageJ software and tapasin expression was normalized to α-
tubulin for each cell line, as depicted below the Western blots. Results are representative of two independent experiments. 
Figure 3.12 shows the result of constitutive calreticulin protein expression in the same cell 
lines as before. Below each Western blot the ratio of OD from calreticulin and the loading control α-
tubulin is depicted. One HPV16-positive cell line (SCC152) expressed calreticulin at higher levels 
than the control cell lines. All other cell lines had a similar or a lower calreticulin expression. 
 
Figure 3.12: Calreticulin protein expression. 50µg of each cellular lysate was analyzed for calreticulin expression by 
Western blot as in Figure 3.7. Optical density (OD) was quantified using the ImageJ software and calreticulin expression was 
normalized to α-tubulin for each cell line, as depicted below the Western blots. Results are representative of two independent 
experiments. 
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3.1.2.4 Endoplasmic reticulum aminopeptidase 1 (ERAP1) and 2 (ERAP2) 
The qRT-PCR approach had also shown that ERAP1 was significantly higher expressed in HPV16-
positive tumor cell lines than in HPV-negative cells (see 3.1.1.1). In humans, a second 
aminopeptidase, ERAP2, is expressed, which most probably developed from a gene duplication event 
(59). Furthermore, it was suggested that ERAP1 and ERAP2 could work in concert (60). Thus, the 
expression of both aminopeptidases was analyzed by Western blot in selected cell lines.   
 The result of constitutive ERAP1 protein expression in the same cell lines as before is 
depicted in Figure 3.13 A. The experiments revealed that ERAP1 was higher expressed in the majority 
(13/16) of HPV16-positive cell lines in comparison to the HPV-negative cell lines (Figure 3. A). In 
Figure 3.13 C, pooled data of three independent experiments is shown. Here, all tested HPV16-
positive cell lines had a higher mean ERAP1 expression than HPV16-negative cells. After IFNγ-
treatment, only 6 out of 16 HPV16-positive cell lines had a higher ERAP1 expression than the HPV-
negative cells (Figure 3.13 B). Lower ERAP1 levels were observed in 4 out of 16 HPV16-positive cell 
lines and the others had similar levels as the control cells. In pooled data of three independent 
experiments, mean ERAP1 expression upon IFNγ treatment was still elevated (Figure 3.13 D) in all 
HPV16-positive cell lines except for SCC152. 
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Figure 3.13: ERAP1 protein expression with and without IFNγ treatment. Cells were either left untreated (A) or treated 
with IFNγ (B) for 48h. 50µg of each cellular lysate was analyzed for ERAP1 expression by Western blot as in Figure 3.7. 
Optical density (OD) was quantified using the ImageJ software and ERAP1 expression was normalized to α-tubulin for each 
cell line, as depicted below the Western blots. Results are representative of three independent experiments. C. and D. 
represent pooled data from these three independent experiments. ERAP1 expression of untreated (C) and IFNγ treated cells 
(D) was calculated relative to NOK. Results are plotted as means ± SEM. pHK* = pooled data from primary human 
keratinocytes derived from three donors and pooled primary human foreskin keratinocytes from multiple donors.  
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Constitutive ERAP2 protein expression in the selected HPV-negative and HPV16-positive cell 
lines is shown in Figure 3.14 A. The experiments revealed that ERAP2 was very variable with either a 
low or a high expression, which is also shown in pooled data from three independent experiments 
(Figure 3.14 B). A higher mean ERAP2 expression than the HPV-negative cells was seen in 5 out of 
16 HPV16-positive cell lines (SNU703, SNU1005, 866, 93VU147T and HPK1A). Interestingly, these 
cell lines also overexpressed ERAP1 as described above. However, it has to be noted that also some 
pHKs expressed ERAP2 at high levels.  
 
Figure 3.14: ERAP2 protein expression. A. 50µg of each cellular lysate was analyzed for ERAP2 expression by Western 
blot as in Figure 3.7. Optical density (OD) was quantified using the ImageJ software and ERAP2 expression was normalized 
to α-tubulin for each cell line, as depicted below the Western blots. Results are representative of three independent 
experiments. B. Pooled data from these three independent experiments. ERAP2 expression was calculated relative to NOK. 
Results are plotted as means ± SEM. pHK* = pooled data from primary human keratinocytes derived from three donors and 
pooled primary human foreskin keratinocytes from multiple donors. 
In conclusion, protein expression analysis of the analyzed APM components revealed that 
only ERAP1 was expressed at higher levels in the majority of tested HPV16-positive cell lines 
compared to HPV-negative cell lines. ERAP1 has the ability to directly edit the MHC I epitope 
repertoire (86). Therefore, we decided to focus all subsequent experiments on ERAP1. 
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3.1.3 Immunohistochemistry of ERAP1 in cervical tissue 
ERAP1 was shown to be overexpressed in vitro in HPV16-positive cell lines on the mRNA as well as 
on the protein level (see 3.1.1.1 and 3.1.2.4). Thus, we next investigated whether this also holds true in 
human dysplastic cervical tissue sections. The anti-ERAP1 antibody was first validated for 
immunohistochemistry. Afterwards, immunohistochemistry of ERAP1 in all three grades of cervical 
intraepithelial neoplasia (CIN) and cervical cancer was performed. ERAP1 expression in dysplastic 
tissue was compared to its expression in histologically normal cervical epithelium.  
3.1.3.1 Validation of the anti-ERAP1 antibody 
In order to perform immunohistochemistry of ERAP1 in cervical tissue sections, the anti-ERAP1 
antibody used in this study had to be validated for this application first. CaSki cells were either left 
untreated or were transfected with a non-targeting siRNA control pool or an ERAP1-targeting siRNA 
pool. The siRNA-mediated knockdown of ERAP1 is described in detail in chapter 3.3.1. After 72h of 
transfection, CaSki cells were harvested, fixed and a thin layer of the cells was prepared on cytology 
slides. The cells were analyzed for ERAP1 expression following the immunohistochemistry staining 
protocol described in section 2.2.6. Figure 3.15 shows the validation results of the anti-ERAP1 
antibody in CaSki cells. ERAP1 was readily detectable in cells that were not transfected and cells that 
were transfected with the siRNA control pool. In contrast, ERAP1 signals in cells with siRNA-
mediated ERAP1 knockdown were clearly lower. The results confirm that the antibody is specific for 
ERAP1 and is suitable to evaluate different ERAP1 expression levels in immunohistochemistry.  
 
Figure 3.15: Validation of the anti-ERAP1 antibody for immunohistochemistry. CaSki cells were left untreated or were 
transfected with either a non-targeting RNA (sicontrol) or an ERAP1-targeting siRNA (siERAP1). After 72h, cells were 
harvested and fixed. A thin layer of cells was prepared on cytology slides and cells were stained for ERAP1. Scale bar 
corresponds to 100µm. 
3.1.3.2 Expression of ERAP1 in cervical tissue 
Immunohistochemical analysis of ERAP1 was performed in human cervical tissue sections and 
expression in dysplastic tissue was compared to histologically normal cervical epithelium. Different 
degrees of cervical intraepithelial neoplasias (CIN): CIN I (n = 9), CIN II (n = 6), CIN III (n = 9), and 
squamous cell carcinomas (SCC, n = 6) were analyzed and compared to normal cervical epithelium (n 
= 23). As a surrogate marker for HPV oncogene expression p16 was used (118). p16-negative normal 
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cervical epithelium showed very weak ERAP1 protein expression (Figure 3.16). On the contrary, 
epithelial ERAP1 expression was clearly increased in dysplastic CIN I to III lesions and in established 
cervical cancers. Notably, ERAP1 expression increased with disease progression since the expression 
in CIN I was much lower than in advanced degrees of CIN and in SCC.  
 
Figure 3.16: Immunohistochemical analysis of ERAP1 expression in cervical tissue. Human tissue sections were stained 
for ERAP1 and p16, a surrogate marker for HPV oncogene expression. The protein expression was analyzed in histologically 
normal cervical epithelium (normal cervix), in HPV16-positive dysplastic CIN (cervical intraepithelial neoplasia) I to CIN III 
lesions and in SCC (cervical squamous cell carcinoma). Scale bar corresponds to 200µm. 
A CIN III lesion directly adjacent to p16-negative normal cervical epithelium is shown in 
Figure 3.17. The drastic difference in ERAP1 expression between CIN III (highly elevated expression) 
and histologically normal tissue (weak expression) can be directly compared.  
 
Figure 3.17: Immunohistochemical analysis of ERAP1 expression in normal cervical epithelium and CIN III. Human 
tissue sections were stained for ERAP1 and p16, a surrogate marker for HPV oncogene expression. The expression was 
analyzed in histologically normal cervical epithelium adjacent to a HPV16-positive CIN (cervical intraepithelial neoplasia) 
III lesion. A. Scale bar corresponds to 200µm. B. Higher magnification of the sections shown in A. Scale bar corresponds to 
100µm.  
RESULTS 
90 
In order to quantitatively assess ERAP1 expression, a score was applied that considered both 
the percentage of ERAP1 expressing cells and the intensity of ERAP1 staining. Analysis of this 
histological score showed that epithelial ERAP1 levels were significantly increased in CIN and SCC 
when compared to normal epithelium (Figure 3.18 A and B). In addition, ERAP1 expression 
significantly increased with disease progression, being highest in SCC and lowest in CIN I. Three CIN 
I tissue sections showed similar ERAP1 expression levels as normal tissue. However, all analyzed CIN 
II, CIN III and SCC tissue sections had elevated ERAP1 expression levels. For most of the sections, 
HPV genotyping information was available. HPV16-positive tissue sections are highlighted in blue in 
Figure 3.18 A. Notably, HPV16-positive sections did not behave differently than other high-risk HPV-
positive sections regarding ERAP1 expression. In Figure 3.18 B, an alternative way of representing 
ERAP1 expression is shown. Histological scores were equally categorized into low (0-95), 
intermediate (96-190) and high expression (191-285). This analysis nicely demonstrated that ERAP1 
expression increased with disease progression, consistent with the other representation of this data set. 
Furthermore, this way of presentation revealed that histologically normal tissue expressed ERAP1 
only at low levels as well as 67% of CIN I lesions. The percentage of tissue sections that expressed 
ERAP1 at high levels was rising from CIN II to SCC. In Figure 3.18 C, the HPV type information is 
summarized. All detected HPV types (HPV16, 18, 31, 33, 52, 56, 59 and 73) are high-risk types (220). 
HPV16 was the most prevalent high-risk type in the analyzed tissue sections, which is consistent with 
the general worldwide type distribution (101). One tissue section of CIN I was typed positive for both 
HPV31 and HPV56, and one cervical cancer section was positive for both HPV16 and HPV52.  
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Figure 3.18: ERAP1 protein expression in cervical tissue. Human tissue sections were analyzed for ERAP1 expression 
by immunohistochemistry. The expression was analyzed in histologically normal cervical epithelium, in dysplastic cervical 
intraepithelial neoplasia (CIN) I to CIN III and in cervical squamous cell carcinoma (SCC). Normal tissue n = 23, CIN I n = 
9, CIN II n = 6, CIN III n = 9 and SCC n = 6. A. Immunohistochemical scores were determined by multiplying the 
frequency of ERAP1 expressing cells with the maximum intensity of ERAP1 expression. Each symbol represents one 
sample, symbols in blue represent HPV16-transformed tissue. Means ± SD are also given. *** p ≤ 0.001, **** p ≤ 0.0001 
(unpaired t test). B. Immunohistological scores were equally categorized into low (0-95), intermediate (96-190) and high 
expression (191-285). C. HPV type information of the analyzed human tissue sections. Note that one section within the CIN 
I and one section within the SCC group were transformed with two HPV types.  
In conclusion, immunohistochemical analysis of ERAP1 protein expression showed that 
ERAP1 is clearly overexpressed in HPV-positive CIN II-III and SCC compared to p16-negative 
normal cervical tissue. These results are consistent with the data from cell lines described in the 
previous chapters (see 3.1.1.1 and 3.1.2.4).  
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3.2 Exploration of possible mechanisms leading to ERAP1 upregulation 
3.2.1 Analysis of single nucleotide polymorphisms (SNPs) of ERAP1 in selected 
cell lines 
In recent years, it has become clear that ERAP1 is a polymorphic gene with many naturally occurring 
haplotypes in the human population (203). Single nucleotide polymorphisms (SNPs) are under 
extensive research because some are associated with human diseases (73, 74, 82), can affect enzymatic 
properties (73) and also the expression level of ERAP1 (221). For all these reasons, we investigated 
the haplotypes present in our cell lines. The approach was the following: isolation of total RNA, 
reverse transcription into cDNA, amplification of ERAP1 by PCR and SNP analysis by sequencing at 
GATC Biotech. As a reference sequence, the commonly accepted most frequent haplotype of ERAP1 
in the human population (NM 001198541.1) according to Reeves and colleagues (203) was used. At 
least 5 primers were used for sequencing, so that sequencing results overlapped, thus ensuring the 
reliability of the sequences. The positions of the employed primers in ERAP1 are depicted in Figure 
7.6 in the appendix. For sequence alignments and SNP identification, SnapGene®, GENtle and 
Chromas were used. SNPs were determined in the HPV-negative cell line NOK and in 6 HPV16-
positive cell lines. CaSki, 866, SNU17 and SNU703 were analyzed because they showed elevated 
ERAP1 levels compared to HPV-negative cell lines (see 3.1.2.4). SiHa and FK16A were included in 
this analysis because they were later used as target cells in cytotoxicity assays (see 3.5.2.2). Table 3.1 
shows the identified SNPs of ERAP1 in all tested cell lines compared to the reference sequence. The 
SNPs within ERAP1 that were found in the tested cell lines were already described as naturally 
occurring SNPs indicated by the respective NCBI (National Center for Biotechnology Information) 
SNP ID in the table. CaSki, SNU17 and SiHa were homozygous for the most common haplotype of 
ERAP1, whereas NOK, 866, SNU703 and FK16A harbored differing ERAP1 haplotypes. The analysis 
revealed that the SNPs detected in our cell lines did not cause ERAP1 overexpression. 
Table 3.1: Single nucleotide polymorphisms (SNPs) determined in one HPV-negative cell line (NOK) and HPV16-
positive cell lines (CaSki, 866, SNU17, SNU703, SiHa and FK16A). Total RNA was purified from cell lines and reverse 
transcribed into cDNA. ERAP1 was amplified from cDNA by PCR and analyzed by sequencing. The reference sequence 
(NM 001198541.1) is the most common haplotype of ERAP1 in the human population (203). Bases are given for the sense 
strand. Cell lines highlighted in blue are homozygous for the reference haplotype of ERAP1. Deviations from the reference 
haplotype are highlighted in red. AA = amino acid 
 NOK CaSki 866 SNU17 SNU703 SiHa FK16A 
SNP ID Polymorphism Base AA Base AA Base AA Base AA Base AA Base AA Base AA 
rs72773968 T12I C T C T C T C T C T C T T I 
rs26653 R127P G/C R/P G R G R G R G/C R/P G R G/C R/P 
rs26618 I276M A I A I A/G I/M A I A/G I/M A I A I 
rs2287987 M349V A/G M/V A M A M A M A M A M A M 
rs30187 K528R A/G K/R A K A/G K/R A K A/G K/R A K A K 
rs17482078 R725Q G/A R/Q G R G R G R G R G R G R 
rs27044 Q730E C/G Q/E C Q G E C Q C/G Q/E C Q C Q 
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3.2.2 The effect of HPV16 E6 and E7 knockdown on ERAP1 expression 
The HPV oncogenes E6 and E7 have multiple targets within the host cell and can manipulate growth 
behavior and promote immune evasion (see 1.2.2). E6 and E7 have also been reported to perturb 
expression of the APM components PSMB8, PSMB9, TAP1 and MHC I. Thus, we next addressed the 
question whether E6 and E7 also have an impact on ERAP1 expression. To answer this question, E6 
and E7 were silenced using a siRNA pool targeting all three HPV16 E6/E7 transcript classes and a 
non-targeting control siRNA (209). CaSki cells were transfected for 72h and subsequently cell lysates 
were analyzed using Western blot. Figure 3.18 A shows the Western blot that confirms the knockdown 
of HPV16 E7. Knockdown of E7 ensures that E6 is silenced too because the transcript of E7 is 
generated from the E6 transcript by alternative splicing (222). Figure 3.19 B shows the expression of 
ERAP1 after HPV16 E6 and E7 knockdown and in C the quantification these experiments. The 
experiments revealed that silencing the HPV16 oncogenes E6 and E7 had no impact on ERAP1 
expression. Thus, the observed ERAP1 overexpression is likely caused either by other viral proteins or 
by other mechanisms.  
 
Figure 3.19: ERAP1 expression after HPV16 E6/E7 knockdown. CaSki cells were treated either with a HPV16 E6/E7-
targeting (siHPV16E6/E7) or a non-targeting control siRNA for 72h. 50µg of each cellular lysate was loaded and analyzed 
for E7 or ERAP1 expression by Western blot. A. Western blot analysis of HPV16 E7 and β-actin detection as a loading 
control. The result is representative of two independent experiments. B. Western blot analysis of ERAP1 and α-tubulin 
antibody as a loading control. The result is representative of two independent experiments. C. Quantification using the 
ImageJ software. ERAP1 protein expression was normalized to α-tubulin expression and then calculated relative to CaSki 
cells treated with control siRNA. The results are plotted as means ± SD from two independent experiments. 
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3.3 Analysis of ERAP1 upregulation on HPV16 epitope presentation 
ERAP1 is of high interest in immunotherapeutic approaches since it can directly shape the epitope 
repertoire (64, 67). Interestingly, ERAP1 generates or destroys epitopes (64) depending on the cell 
type, HLA type, the particular antigen and on ERAP1 alleles. Of note, attenuation of ERAP1 
expression has been shown to improve CD8 T cell-mediated anti-tumor immunity in different models 
(83, 84). The expression of ERAP1 is elevated in many different human tumors (77, 78) and there 
have been approaches to inhibit ERAP1 function by specific synthetic inhibitors (86). This study 
revealed that ERAP1 is overexpressed in HPV-induced malignancies (see 3.1.1.1, 3.1.2.4 and 3.1.3). 
Thus, we decided to focus the subsequent experiments on the investigation whether ERAP1 expression 
levels influence HPV16 epitope presentation. We addressed this question by using direct detection of 
HPV16-derived epitopes by mass spectrometry and cytotoxicity mediated by HPV16-specific CD8 T 
cells. To elucidate ERAP1 attenuation, a siRNA-mediated approach to knockdown ERAP1 expression 
was established. First, this tool was used in context with immunoprecipitations of HLA-A2:peptide 
complexes to compare the presentation of selected HPV16-derived HLA-A2-restricted epitopes with 
and without ERAP1 knockdown. Second, the influence of ERAP1 knockdown in HPV16-positive 
target cells on cytotoxicity mediated by CD8 T cells specific for HPV16 E6 and E7 peptides was 
investigated.  
 
3.3.1 Normalization of ERAP1 expression  
A siRNA-mediated knockdown of ERAP1 was established to normalize overexpressed ERAP1 levels 
back to a level expressed in HPV-negative keratinocytes. The influence of ERAP1 attenuation on 
surface HLA class I expression was investigated as well. CaSki, 866, SNU17 and SNU703 were 
chosen for these experiments. These cell lines were selected because on the one hand they 
overexpressed ERAP1 and on the other hand they are HLA-A2-positive which is one of the most 
frequent HLA types (223). This consideration was important for later experiments with T cells and 
immunoprecipitations. In addition, the HLA-A24-positive cell lines FK16A and SiHa were used, 
because a HLA-A24-positive donor was available whose PBMCs were used for HPV16-specific long-
term T cell generation in our lab (194).  
3.3.1.1 Establishment of ERAP1 knockdown using siRNA pools 
In order to normalize ERAP1 expression, a siRNA pool from siTOOLs Biotech was used. The siRNA 
pool consisted of 30 specific siRNAs. This allowed using very low concentrations of siRNA compared 
to single siRNA approaches leading to lower off-target effects. The optimal concentration of the 
ERAP1-specific siRNA pool was established in the four HLA-A2-positive cell lines and in the two 
HLA-A24-positive cell lines mentioned above. The knockdown was set up with the intention to be 
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stable for at least 72h, providing a time window broad enough for subsequent read-out assays.  
 Figure 3.20 A illustrates the knockdown of ERAP1 after 72h in CaSki, 866, SNU17 and 
SNU703 using qRT-PCR. The residual ERAP1 transcript expression was below 15% in all cell lines 
compared to cells treated with the non-targeting siRNA control pool. Figure 3.20 B shows ERAP1 
expression after 72h of ERAP1 knockdown assessed by Western blot. Residual ERAP1 expression was 
below 20% in all cell lines when compared to the cells treated with the siRNA control pool 
(quantification data not shown).  
 
 
Figure 3.20: Knockdown of ERAP1 using siRNAs in HPV16-positive and HLA-A2-positive cells. Cells were left 
untreated or were treated either with an ERAP1-targeting (siERAP1) or a non-targeting control siRNA pool (sicontrol) for 
72h. A. Total RNA was purified from cells, reverse transcribed to cDNA and analyzed for ERAP1 expression by qRT-PCR 
using TaqMan® probes. PCR reactions were performed in triplicates. GAPDH and PGK1 were used as internal reference 
genes and ERAP1 expression was calculated relative to untreated cells. The results are plotted as means ± SD from at least 
three independent experiments. B. 50µg of each cellular lysate was loaded and ERAP1 expression analyzed by Western blot 
with α-tubulin detection as a loading control. The results are representative of at least three independent experiments.  
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Figure 3.21 A illustrates the knockdown of ERAP1 after 72h in SiHa and FK16A using qRT-
PCR. The residual ERAP1 transcript expression was in all cell lines below 21.5% compared to cells 
treated with the siRNA control pool. Figure 3.21 B shows successful attenuation of ERAP1 expression 
after 72h assessed by Western blot.  
 
Figure 3.21: Knockdown of ERAP1 using siRNAs in HPV16-positve and HLA-A24-positive cells. Cells were left 
untreated or were treated either with an ERAP1-targeting (siERAP1) or a non-targeting control siRNA pool (sicontrol) for 
72h. A. Total RNA was purified from cells, reverse transcribed to cDNA and analyzed for ERAP1 expression by qRT-PCR 
using TaqMan® probes. PCR reactions were performed in triplicates. PGK1 was used as internal reference gene and ERAP1 
expression was calculated relative to sicontrol treated cells. The results are plotted as means ± SD from at least two 
independent experiments. B. 50µg of each cellular lysate was loaded and ERAP1 expression analyzed by Western blot with 
anti-α-tubulin detection as a loading control. The results are representative of at least two independent experiments. 
 
3.3.1.2 Surface expression of HLA-A2 and HLA-A24 after ERAP1 knockdown 
The impact of ERAP1 knockdown on HLA class I expression is not clearly defined and differs with 
cell type, but most studies reported a moderate downregulation (63, 64, 84, 224). In this study, the 
expression of HLA-A2 and HLA-A24 was studied after 72h of ERAP1 knockdown using flow 
cytometry analysis.          
 In Figure 3.22 A, changes in surface expression of HLA-A2 in CaSki, 866, SNU17 and 
SNU703 cells treated with a siRNA control pool or an ERAP1-targeting siRNA pool are shown in 
representative histograms. Figure 3.22 B shows the pooled data of these experiments. CaSki cells had 
a significantly lower expression of HLA-A2 (on average reduced by 34%) after ERAP1 knockdown. In 
contrast, all other cell lines had no significant change in HLA surface expression although a slight 
trend towards a lowered expression was observed.  
RESULTS 
97 
 
Figure 3.22: HLA-A2 expression after ERAP1 knockdown. Cells were treated either with an ERAP1-targeting (siERAP1) 
or a non-targeting control siRNA pool (sicontrol) for 72h. Afterwards, cells were harvested, stained with an anti-HLA-A2 
antibody coupled to FITC and mean fluorescence intensity (MFI) was analyzed by flow cytometry and calculated over the 
background of each cell line. A. Histogram representation of HLA-A2 stainings. The histograms are representative of three 
independent experiments. B. Results are plotted as means ± SD of three independent experiments. ** p ≤ 0.01 (paired t-test) 
 
Figure 3.23 A shows the HLA-A24 surface expression of SiHa and FK16A cells treated with a 
siRNA control or an ERAP1-targeting siRNA pool. In Figure 3.23 B, representative histograms show 
whether the surface expression of HLA-A24 differed after ERAP1 knockdown. Similar to most HLA-
A2-positive cell lines the change in surface HLA-A24 was not significant, although the expression 
tended to be slightly lower in cells with attenuated ERAP1 expression.  
 
 
Figure 3.23: HLA-A24 expression after ERAP1 knockdown. Cells were treated either with an ERAP1-targeting 
(siERAP1) or a non-targeting control siRNA pool (sicontrol) for 72h. Afterwards, cells were harvested, first stained with an 
anti-HLA-A24 antibody and then with a secondary antibody coupled to FITC. Mean fluorescence intensity (MFI) was 
analyzed by flow cytometry. A. Histogram representation of HLA-A24 stainings. The histograms are representative of at 
least two independent experiments. B. Data was calculated relative to SiHa sicontrol. Results are plotted as means ± SD of at 
least two independent experiments. 
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3.3.2 Direct detection of HLA-A2 HPV16-derived epitopes by liquid 
chromatography-mass spectrometry (LC-MS) 
To assess whether ERAP1 levels have an influence on the presentation of HPV16 E6 and E7-derived 
epitopes, a targeted and highly sensitive liquid chromatography-mass spectrometry (LC-MS) approach 
was used. This method allows direct detection of low abundant epitopes bound to HLA class I on the 
surface of cells. In the present study, HLA-A2 molecules were immunoprecipitated from CaSki cells 
that were either treated with a siRNA pool specific for ERAP1 or a siRNA control pool. Peptides were 
eluted from HLA-A2-peptide complexes and purified before targeted LC-MS3 analysis. 
3.3.2.1 Immunoprecipitation of HLA-A2 molecules from HPV16-transformed cells 
Before immunoprecipitation (IP), CaSki cells were transfected for 72h with either an ERAP1-targeting 
siRNA pool or a siRNA control pool (see 3.3.1.1). HLA-A2 molecules were immunoprecipitated from 
CaSki cells using protein G coated sepharose beads coupled with an anti-HLA-A2 antibody. The 
successful enrichment of HLA-A2 molecules is shown in Figure 3.24. Detection with a pan-anti-MHC 
I antibody revealed a band at approximately 44kDa, which corresponds to the molecular weight of the 
HLA class I heavy chain. The most intense band in the IP sample indicates successful enrichment of 
HLA-A2. Weaker bands were detected in the cell lysate before and after IP. As detection was 
performed with a pan-anti-MHC class I antibody, which binds to all MHC class I types, the band of 
44kDa is still detected in the lysate after the IP. It contains the remaining heavy chains from other 
HLA class I molecules (HLA-A3, -B7, -B37 and C7; see Table 7.2 in the appendix). As expected, the 
HLA-A2 band was not detected in the negative control, only containing sepharose beads coupled to 
the HLA-A2 antibody. IPs from CaSki cells treated with the siRNA control pool (Figure 3.24 A) and 
the ERAP1-specific siRNA pool (Figure 3.24 B) show similar results. 
 
Figure 3.24: Immunoprecipitation of HLA-A2 molecules from CaSki cells. Cells were treated either with a non-targeting 
control siRNA pool (A) or an ERAP1-targeting siRNA pool (B) for 72h. Afterwards, immunoprecipitation (IP) of HLA-A2 
was performed. Western blot detection was done using a pan-anti-MHC I antibody. Arrows mark the HLA-A2 heavy chain.  
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3.3.2.2 Direct detection of HLA-A2 HPV16-derived epitopes by LC-MS3 
The HPV16 E6-derived epitope E629-38 and the E7-derived epitope E711-19 are the only HPV16-derived 
epitopes that have been directly detected on the surface of tumor cells by mass spectrometry analysis 
to date (173, 225). Recently, other epitopes from HPV16 have been detected on CaSki and other 
HPV16-positive tumor cells by Dr. Renata Blatnik in our group (unpublished data). The 
immunological importance of other HPV16 epitopes was mostly shown by in vitro T cell assays or in 
vivo vaccinations (132, 155, 226). The second aim of the present thesis was to analyze the effect of 
high and low ERAP1 expression levels on the presentation of HPV16 E6 and E7-derived peptides. To 
this end, CaSki cells were either transfected with a control siRNA pool or an ERAP1-targeting siRNA 
pool for 72h. HLA-A2 molecules were immunoprecipitated from the cells as described in the previous 
chapter. HPV16-derived peptides are presented at very low levels that were estimated to be 25 copies 
of E711-19 per cell (173). Thus, 1x10
8 to 3x108 cells were used for one IP experiment per treatment 
group to ensure the reliable detection of these peptides by LC-MS3 analysis. The same number of cells 
for each treatment group was used in one experiment. Peptides were eluted from HLA-A2:peptide 
complexes by acetic treatment and isolated for LC-MS3 analysis by Dr. Renata Blatnik. In total, 16 
peptides derived from HPV16 E7, one peptide derived from HPV16 E6 and endogenous control 
peptides were monitored by LC-MS3. To identify the target peptides in IP samples, synthetic peptides 
were manually optimized for the best MS3 reference spectra. MS spectra of three to four fragments per 
peptide were monitored. The IP MS3 spectra were manually compared to reference MS3 spectra. Only 
when the fingerprint of the reference spectra matched the fingerprint of the IP sample spectra, peptide 
presence in the IP sample was confirmed. In addition, retention times of the detected fragments in 
synthetic peptide and IP analysis had to match each time. Chromatographic profiles of peptide 
fragments showing retention times and MS3 spectra of peptide fragments are shown in Figure 7.7 in 
the appendix. Positive control peptides derived from endogenous constitutively expressed proteins 
(indicated in material section 2.1.16.1) were detected in all IP samples (data not shown). In one 
experiment, the presence of 13 of the 17 HPV16 peptides was confirmed of which 6 detected peptides 
and 4 not detected peptides are shown in Table 3.2. MS analysis of the other 7 HPV16 peptides which 
were detected showed similar results (data not shown). LC-MS3 identification of HLA-A2 HPV16 E6 
and E7-derived epitopes revealed that there were no major changes in peptide presentation between 
CaSki cells with high levels of ERAP1 expression and CaSki cells with attenuated ERAP1 expression. 
The peptide quantities seem to be similar, too, given that all peptides were detected in low amounts 
and taking sample preparation and/or LC-MS3 measurement variance into consideration. However, 
only an absolute quantification would give exact results about peptide amounts. Table 3.2 indicates 6 
out of the 13 detected peptides and 4 peptides that were not detected. This data is from one 
representative experiment of three independent experiments. In repetition experiments, fewer peptides 
were reliably detected due to lower cell number input and low presentation of these peptides on the 
cell surface in general. However, the trend observed in the repetition experiments matched the 
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observations made in the presented experiment. Taken together, direct detection of HPV16-derived 
peptides showed that ERAP1 overexpression did not result in a loss of HPV16 epitopes. In addition, 
quantities of detected peptides seem to be in the same range in both CaSki control cells and cells 
knocked down for ERAP1.  
 
Table 3.2: HLA-A2 HPV16 E7-derived peptides detected in CaSki cells. CaSki cells were treated with either a non-
targeting siRNA pool (sicontrol) or an ERAP1-targeting siRNA pool (siERAP1) for 72h. HLA-A2 molecules were 
immunoprecipitated, peptides were eluted, isolated and analyzed by LC-MS3. Results are representative of three independent 
experiments. n.d. = not detected 
Peptide CaSki sicontrol CaSki siERAP1 
E77-15 n.d. n.d. 
E77-17 n.d. n.d. 
E710-19 n.d. n.d. 
E711-19 detected detected 
E711-20 detected detected 
E712-20 n.d. n.d. 
E777-86 detected detected 
E778-86 detected detected 
E781-90 detected detected 
E782-90 detected detected 
 
 
 
3.3.3 T cell responses 
To elucidate whether high or low expression levels of ERAP1 have an impact on HPV16 HLA class I 
epitope presentation, T cell lines against peptides derived from HPV16 E6 and E7 were generated. 
First, blood donors were screened with the intention to find E6 and E7-specific memory T cell 
responses. Peptides positive in this initial screen were used to expand peptide-specific T cells in long-
term T cell lines. These long-term T cell lines were subsequently used in cytotoxicity assays. 
 In the scope of this thesis, blood from two female donors was used. One blood donor was 
HLA-A2-positive and one was HLA-A24-positive. The HLA-A24-positive donor was 39 years old 
while the HLA-A2 donor was 34 years old during the time of the experiments. No history of persistent 
infection with HPV was known for the donors. HLA typing and donor characteristics can be found in 
Table 7.3 in the appendix.  
3.3.3.1 T cell memory screening against HPV16-derived epitopes by IFNγ ELISpot assay 
using short-term T cell lines 
Prior to long-term T cell line generation, it was necessary to define T cell memory responses against 
epitopes derived from HPV16 E6 and E7 in our donors. Almost every sexually active individual has 
contact with an HPV-high risk type once in his or her life time (102). Among these, HPV16 is the 
most common high-risk type. Even though we assume that the donors have had contact with the virus, 
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immune responses are highly complex and it is not possible to predict to which peptide an individual 
reacts. Thus, HLA-A2 and HLA-A24 binding peptides derived from HPV16 E6 and E7 (194, 227), 
including binding peptides of HPV16 variants, were used in a T cell memory screening using IFNγ 
ELISpot. Peripheral blood mononuclear cells (PBMCs) were isolated and peptide-specific short-term 
T cell lines were generated ex vivo by peptide stimulation. Additionally, short-term T cell lines were 
regularly supplemented with cytokines. By these means, it is possible that existing T cell memory 
responses of the respective individual are triggered. Responses were only considered to be positive if 
the following criteria were fulfilled: a minimum of 200 SFU (spot forming units) per 1x106 cells, and a 
stimulation index (SI = fold change of SFU compared to background) of at least 2.  
 Figure 3.25 shows the results of the two T cell memory screening experiments of HLA-A2 
binding HPV16 E6 and E7 epitopes. For the ELISpot assay, every individually cultured short-term T 
cell line was seeded in medium with the peptide diluent DMSO serving as a background control, with 
ConA as a positive control and with the addition of the peptide that was initially used for stimulation. 
A negative control T cell line was generated with a HLA-A2 binding peptide derived from HIV. The 
CEF peptide pool, containing epitopes for the most frequent HLA types from CMV, EBV and 
influenza virus, was used to generate a positive control short-term T cell line. In Figure 3.25 A, SFU 
of each T cell line are plotted and in B stimulation indices are shown. Black bars represent responses 
that were positive for both criteria mentioned above. Peptide-specific T cell responses against        
E618-26variant and E781-91 were detected. In a second independent experiment, very strong peptide-
specific responses were again detected for E781-91. One plausible explanation for absence of           
E618-26variant-specific responses in the second experiment is that only low numbers of PBMCs could be 
seeded per short-term T cell line in this screening setup. Thus, it is possible to miss T cell memory 
responses especially for low abundant memory T cells. E781-91 was chosen for long-term T cell line 
generation. 
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Figure 3.25. T cell memory screening of HPV16 E6 and E7 epitopes by IFNγ ELISpot in a HLA-A2-positive donor. 
Short-term T cell lines were cultured in medium with either the peptide diluent DMSO serving as a background control, with 
ConA as a positive control and with the respective cognate peptide used for initial stimulation. A negative control short-term 
T cell line was generated using a HLA-A2-restricted HIV-derived epitope (HIV-A2) and a positive control short-term line 
with the CEF peptide pool. Data is plotted as mean ± SD from at least triplicates. Whenever there are two bars they represent 
data from two independent experiments. A. A peptide-specific T cell response was considered positive when the mean spot 
forming units (SFU) for a given peptide were ≥ 200/106 PBMCs (dashed line). B. The stimulation index (SI) was determined 
by calculating the ratio between specific SFU and background SFU. A peptide-specific T cell response was considered 
positive when the SI was at least 2 (dashed line). Positive responses by both criteria are indicated by green (positive controls) 
and black bars.  
Figure 3.26 shows the result of the T cell memory screening of HLA-A24 binding HPV16 E6 
and E7 epitopes. The ELISpot assay was set up as described above. We could detect peptide-specific T 
cell responses against 8 peptides (E626-34, E649-59, E666-75, E685-95, E690-99, E6131-139, E626-34variant and  
E769-76). Peptide-specific responses were also detected in a second independent experiment for       
E626-34variant and E769-76. As described above, due to the low number of cells seeded in the experiment it 
was possible to miss T cell memory responses especially for extremely low frequent T cells. The 
peptides E769-76 and E690-99 had highly positive responses regarding both criteria, SFU and SI. 
Therefore, these two peptides were chosen for the generation of peptide-specific long-term T cell 
lines. The strong response against E690-99 was not observed in the repetition of the screening. 
Nevertheless, we decided to generate peptide-specific long-term T cell lines against this peptide based 
on the very strong response in the first screening. For our experiments, we omitted the E626-34 variant 
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peptide, which also showed positive results, because only one HPV16-positive cell line in our 
collection carried the HPV16 variant harboring this mutation. Moreover, this cell line had poor growth 
properties, thus precluding its use in subsequent cytotoxicity assays.  
 
Figure 3.26. T cell memory screening of HPV16 E6 and E7 epitopes by IFNγ ELISpot using a HLA-A24-positive 
donor. Short-term T cell lines were cultured in medium either with the peptide diluent DMSO serving as a background 
control, with ConA as a positive control and with the respective cognate peptide used for initial stimulation. A negative 
control short-term T cell line was generated using a HLA-A2-restricted HIV-derived epitope (HIV-A24) and a positive 
control short-term line with the CE-A24 peptide pool. Data is plotted as mean ± SD from at least triplicates. Whenever there 
are two bars, they represent data from two independent experiments. A. A peptide-specific T cell response was considered 
positive when the mean spot forming units (SFU) for a given peptide were ≥ 200/106 PBMCs (dashed line). B. The 
stimulation index (SI) was determined by calculating by calculating the ratio between specific SFU and background SFU. A 
peptide-specific T cell response was considered positive when the SI was at least 2 (dashed line). Positive responses by both 
criteria are indicated by green (positive controls) and black bars. 
 
3.3.3.2 The effect of ERAP1 attenuation in target cells on cytotoxicity measured by 
HPV16-specific CD8 T cells 
Based on the results from the T cell memory screening, long-term T cell lines were generated by three 
weekly stimulations of PBMCs with antigen-presenting cells (APCs) of the respective donor pulsed 
with one of the peptides described in the previous section. One week after the last stimulation, CD8 T 
cells were purified by negative selection. These CD8 T cells were co-cultured with HLA-matched 
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tumor cells in a cytotoxicity assay. We employed the recently established VITAL-FR cytotoxicity 
assay (211, 212). This assay is a flow cytometry-based assay allowing the simultaneous co-culture of 
effector CD8 T cells with two target cell populations, due to different labeling of target cells either 
with CFSE or FarRed. Target cells were first labeled and then treated with an ERAP1-targeting siRNA 
pool or a control siRNA pool for 24h. Afterwards, target cells and CD8 T cells were co-cultured in 
different ratios (effector:target ratio) for 48h. As a background control, a HPV16-negative, HLA-
matched cell line was used. Detailed information of HLA types and HPV16 variants contained in the 
cell lines used in this study is summarized in Table 7.2 in the appendix.     
 Figure 3.27 shows the result of the cytotoxicity assays using the E781-91-specific T cell line 
generated from PBMCs of the HLA-A2-positive donor. As target cell lines, 866 and CaSki were used. 
The HLA-matched, HPV16-negative control cell line was C33A. The experiments revealed that CaSki 
transfected with the ERAP1-specific siRNA pool were killed better by E681-91-specific T cells than 
target cells treated with the siRNA control pool (Figure 3.27 A). In a repetition experiment, the same 
trend was observed, but the difference in killing was less pronounced, possibly due to the use of a 
different T cell line (data not shown). In contrast, no difference in killing was observed with 866 target 
cells (Figure 3.27 B). A much lower cytotoxicity was detected for the HPV16-negative control cell 
line (Figure 3.27 A and B). 
 
 
Figure 3.27: The effect of ERAP1 attenuation in target cells on cytotoxicity mediated by HPV16 E781-91-specific CD8 T 
cells. Vital-FR assay using HPV16 E781-91-specific CD8 effector T cells from a HLA-A2-positive donor. The HLA-A2-
positive and HPV16-positive cell lines CaSki (A) and 866 (B) were used as target cells, whereas the HLA-A2-positive and 
HPV16-negative cell line C33A (HPV16-) served as background control. 24h after siRNA transfection, target cells and 
titrated numbers of effector cells were incubated for another 48h and were then analyzed by flow cytometry. One 
representative experiment of two independent experiments is shown. The results are plotted as mean ± SD from at least 
duplicates. 
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Figure 3.28 illustrates the results from cytotoxicity assays using long-term T cell lines from 
the HLA-A24-positive donor generated with the peptides E769-76 and E690-99. As a target cell line, the 
HLA-A24-positive and HPV16-positive cell line FK16A was used. The HLA-matched HPV16-
negative control cell line was SNU1160. The experiments surprisingly revealed that FK16A cells 
treated with a control siRNA pool were killed better by E769-76-specific T cells than those treated with 
the ERAP1-targeting siRNA pool (Figure 3.28 A). In addition, E769-76-specific T cells were also 
cultured with SiHa target cells (HLA-A24-positive and HPV16-positive), which resulted in similar 
effects as with FK16A (data not shown). The same effect was obtained for E690-99-specific T cells 
(Figure 3.28 B). E690-99-specific T cells could not be used on SiHa, as the HPV16variant present in this 
cell line contains a mutation in the E690-99 epitope. In comparison, a much lower cytotoxicity was 
detected for the HPV16-negative control cell line (Figure 3.28 A and B). 
 
 
Figure 3.28: The effect of ERAP1 attenuation in target cells on cytotoxicity mediated by HPV16 E769-76-specific and 
E690-99-specific CD8 T cells. Vital-FR assay with HPV16 E769-76-specific (A) and E690-99-specific (B) CD8 effector T cells 
from a HLA-A24-positive donor. The HLA-matched and HPV16-positive cell line FK16A was used as target cells, whereas 
the HLA-matched and HPV16-negative cell line SNU1160 (HPV16-) served as background control. 24h after siRNA 
transfection, target cells and titrated numbers of effector cells were incubated for another 48h and were then analyzed by flow 
cytometry. One representative experiment of two independent experiments is shown. The results are plotted as mean ± SD 
from at least duplicates.  
In conclusion, these results revealed that killing of FK16A by E690-99- and E769-76-specifc T 
cell lines was inhibited by ERAP1 normalization. Cytotoxicity of an E781-91-specific T cell line 
towards 866 was not affected by ERAP1 attenuation. However, killing of CaSki cells by E781-91-
specific T cells was improved when ERAP1 was normalized to levels observed in HPV-negative 
keratinocytes. 
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4 Discussion 
HPV-induced malignancies are a major health problem worldwide. The development of therapeutic 
vaccination strategies is important to cure people already infected with high-risk types of HPV. 
However, the overall clinical success of therapeutic vaccines is so far limited. One reason may be 
immune evasion mechanisms employed by HPV. In this thesis, HPV16-mediated changes in antigen 
processing machinery (APM) component expression were systematically analyzed, since these may 
directly interfere with anti-tumor CTL immune responses. ERAP1 was found to be consistently 
overexpressed in HPV16-positive tumor cells, CIN lesions and cervical cancer. The immunological 
consequences of ERAP1 overexpression were investigated by mass spectrometry (MS) and in 
functional T cell assays.  
 
 
4.1 Expression of APM components in HPV-induced malignancies 
Correct processing and presentation of tumor-specific antigens by the APM is crucial for effective 
cytotoxic T lymphocyte (CTL) responses against malignant cells, and HPV-induced malignancies are 
no exception. Several changes in the APM have been observed in HPV-induced malignancies. For 
instance, Evans and colleagues reported that presentation of the HPV16-derived epitope E629-38 is 
dependent on TAP and TAP was expressed at low levels in a cervical carcinoma cell line (132). This 
study demonstrated for the first time in the context of HPV-induced malignancies that changes in the 
APM are correlated with functional consequences in anti-HPV CTL responses. Many studies 
presented further data on APM defects in cervical and head and neck cancer (81, 133, 134, 226, 228), 
but one has to bear in mind that only 20-30% of head and neck cancers are HPV positive (229, 230). 
Furthermore, these studies do not present a complete picture of the APM situation since the APM is a 
tightly regulated process that needs a coordinated interplay of its many components (see 1.1.4). For 
instance, the presentation of HLA class I strongly depends on TAP, which channels peptides from the 
cytosol into the ER, thereby providing the peptide supply for HLA class I. In the light of these issues, 
a systematic analysis of all APM components in many different HPV16-positive tumor cells, 
compared to a group of HPV-negative cells, was conducted in this thesis (see 3.1.1.1). 23 HPV16-
positive cell lines, including cervical cancer cell lines, head and neck squamous cell carcinoma 
(HNSCC) lines and cell lines transformed with the whole HPV16 genome were compared to 6 HPV-
negative cell lines for the expression of 20 APM-associated genes. Furthermore, the influence of IFNγ 
on APM component expression was analyzed (see 3.1.1.2). The presence of IFNγ is known to increase 
the expression of several APM components (67, 217, 218), thereby augmenting and altering antigen 
presentation. 
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 The qRT-PCR screen of constitutive APM component expression showed that the HPV-
negative group had a strikingly uniform gene expression and cell lines transfected (but not naturally 
transformed) with the HPV16 genome were similar to the HPV-negative group. In contrast, this screen 
revealed that calreticulin, ERAP1 and the immunoproteasome subunits PSMB8, PSMB9, PSMB10, 
PSME1 and PSME2 were significantly overexpressed in HPV16-positive tumor cells. Expression of 
APM components upon IFNγ treatment showed that all cell lines upregulated HLA-A, HLA-B, TAP1, 
TAP2, PSME8, PSME9 and PSME1 and almost all cell lines upregulated HLA-E, β2m, tapasin, 
ERAP1, ERAP2, PSMB10 and PSME2. As expected, gene expression of non-IFNγ-inducible genes, 
namely calreticulin, calnexin, PDIA3, PSMB5, PSMB6 and PSMB7, was not upregulated. Further, a 
mathematical approach to determine final expression levels after IFNγ treatment demonstrated that 
expression of APM components after IFNγ treatment was comparable between HPV-negative and 
HPV16-positive tumor cells. Taken together, these results suggest that the cell lines tested in this 
screen have no defect in IFNγ signaling. In previous studies, an overall responsiveness to IFNγ 
reflected by upregulation of IFNγ-inducible genes was typically observed in HPV-induced 
malignancies, but these studies only analyzed few APM components (132, 178, 226). In contrast, 
especially melanomas have often been found to be insensitive to IFNγ in order to avoid immune 
recognition (231, 232). Viruses target IFNγ signaling in order to evade the host’s immune system. 
Poxviruses, for instance, produce a protein that is secreted and binds to IFNγ in the extracellular 
matrix, thereby neutralizing its effects on host cells (233, 234). So far, HPV is known to perturb IFN 
type I signaling (IFNα, IFNβ and IFNκ). HPV16 E6 is able to inhibit IRF3 transactivation which 
hampers IFNβ induction (235). Further, HPB16 E7 blocks the translocation of the p48/IRF9 complex 
necessary for IFN translation in the nucleus (236). Recently, it was reported that IFNκ, which is 
mainly expressed in keratinocytes, is silenced by de novo methylation mediated by HPV16 E6 (129). 
However, IFNγ signaling as shown by us and former studies is functional in HPV-induced 
malignancies.          
 After the broad qRT-PCR screen, protein expression of selected APM components and cell 
lines was analyzed (see 3.1.2). The analysis of HLA class I surface expression showed that 56% of 
HPV16-positve cell lines had higher surface HLA class I expression than HPV-negative cells. The 
other HPV16-positive cell lines had similar levels to the control group. Only one cell line, UDSCC2, 
had very low HLA class I surface expression consistent with low mRNA levels observed during the 
qRT-PCR screen. HLA class I was upregulated upon IFNγ stimulation confirming observations from 
the qRT-PCR screen. In a previous study, a tissue microarray in cervical cancer was conducted and 
described a downregulation of total HLA class I in 24% and even a total loss of expression in 21% of 
cases (81). On the contrary, in this thesis a strong downregulation of HLA class I was only observed in 
the UDSCC2 cell line on the mRNA and on the protein level. Other studies also report a 
downregulation of HLA class I in cervical cancer or HNSCC (132, 134, 226, 228, 237). A difference 
of two of these studies compared to the approach in this thesis is the use of tumor stroma cells as an 
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internal control (228, 237). Also Evans and colleagues (132) used a different control, since they 
compared protein expression in cervical carcinoma cell lines to an immortalized B cell line. 
Conversely, we used HPV-negative keratinocytes as negative controls for screening our cell line 
collection.           
 Besides HLA class I expression levels, the protein expression levels of other APM 
components in HPV-induced malignancies were investigated. In contrast to the qRT-PCR approach, 
the proteins PSMB9, PSMB10, PSME1 and PSME2 were not upregulated in the majority of tested 
HPV16-positive cell lines. Protein expression of PSMB9 and PSMB10 after IFNγ treatment was 
similar between HPV-negative and HPV16-positive cell lines, which is consistent with the qRT-PCR 
results. Similarly, no overexpression on the protein level was observed for tapasin and calreticulin. 
These data suggest that the regulation of APM component expression is complex and includes 
posttranscriptional mechanisms. Indeed, several microRNAs have recently been identified that target 
APM genes confirming the presence of posttranscriptional regulation. For instance, PSMB8, PSMB10, 
TAP1 and HLA-B are proposed to be targeted by microRNA9 but the direct association of this 
microRNA with the mRNA of these components still needs experimental evidence (238). TAP1 is a 
direct target of microRNA346, which is induced during ER stress (239). Furthermore, a discordant 
mRNA/protein expression was often observed in human tumors for the non-classical HLA molecule, 
HLA-G. The reason for this phenomenon was again the involvement of several microRNAs (240, 
241). Recently, HPV-encoded microRNAs have been identified (242). No association of these with 
APM components has been found to date, but as HPV-encoded microRNAs are a novel discovery it is 
possible that more HPV-encoded microRNAs and more target genes will be identified in the future.
 In a study from 2008, HLA class I downregulation was significantly associated with the 
downregulation of other APM components: TAP1, TAP2, tapasin, PDIA3, PSMB8 and PSMB9 (81). 
Conversely, PSMB10, calnexin and calreticulin were reported to be normally expressed, which is 
consistent with the data of this study. Hasim and colleagues, however, provide experimental evidence 
for a downregulation of calnexin and calreticulin in cervical cancer (134). As we do not observe 
defects in HLA class I surface expression in this study it is not surprising that we do not find 
downregulation of the mentioned APM components.      
 In contrast, ERAP1 was found to be overexpressed in the majority of HPV16-positive cell 
lines on the protein and on the mRNA level. ERAP1 expression after IFNγ treatment was still elevated 
in HPV16-positive cell lines. Five of these cell lines (SNU703, SNU1005, 866 and 93VU147T) also 
had elevated levels of ERAP2. Other studies report that ERAP1 and ERAP2 expression is often 
discordant, and also the correlation of one or the other enzyme with surface HLA class I expression is 
controversially discussed (77-79). Overall, studies working with ERAP2 expression or function have 
to be regarded with caution, because it has recently been reported that there is an ERAP2 allele leading 
to nonsense-mediated mRNA decay, resulting in absence of ERAP2 protein expression in 25% of the 
population (59). In general, it appears that ERAP1 expression is more coordinated with HLA class I 
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expression, highlighting the pivotal role of this enzyme on the overall ligand supply of HLA class I 
(77, 243).           
 To further confirm the obtained results in cell lines, ERAP1 expression was analyzed in 
immunohistochemical stainings (see 3.1.3). The obtained data strengthened the data from the cell line 
screen and showed overexpression of ERAP1 in all three grades of CIN and in cervical cancer. In 
addition, immunohistochemistry complemented our data by showing that the expression of ERAP1 
was increasing with disease progression, being lowest in CIN I and highest in established cervical 
cancer. Histologically normal cervical epithelium was used as a control for these experiments. In 
contrast to our results, Mehta and colleagues reported a downregulation of ERAP1 in cervical cancer, 
but only in 15% of cases (81). They also found that downregulation of ERAP1 is an independent bad 
prognostic factor. As described above, the use of tumor stroma as internal control may in part explain 
these different observations. The Human Protein Atlas available from www.proteinatlas.org observed 
both overexpression and downregulation of ERAP1 in cervical carcinoma, indicating that both 
scenarios are possible (80). Studies from other tumor entities revealed that ERAP1 expression is 
considerably variable, ranging from low to high expression. Ovarian, breast and lung cancers tend to 
downregulate ERAP1, whereas colorectal adenocarcinoma, renal cell carcinoma, skin cancer and 
melanoma tend to have high ERAP1 expression levels (77, 78, 244). Discordance between mRNA 
expression and protein expression was also observed (244), again suggesting a complex regulation of 
ERAP1 expression controlled by transcriptional and posttranscriptional mechanisms.  
 Taken together, APM expression analyses revealed that the APM is often dysregulated in 
HPV-induced malignancies. However, findings differ between studies. This may be explained by the 
use of different protocols and techniques, ranging from immunohistochemistry of tissue to molecular 
analysis of cell lines. Furthermore, it is important to point out that the use of controls varies, although 
the APM is differentially expressed in different tissues and cell types (78). The strength of the screen 
conducted in this thesis is the use of multiple HPV-negative controls that all originate from 
keratinocytes, as well as the use of histologically normal epithelium in immunohistochemistry. The 
variable expression of ERAP1 in human tumors – either upregulated as observed in this study or 
downregulated as observed in some other studies – leads to the hypothesis of ERAP1 dysregulation 
being a possible tumor immune evasion mechanism. Since ERAP1 is a critical determinant of the 
HLA class I peptide repertoire, tumors could evade CTL detection by altered ERAP1 expression. In 
the case of ERAP1 upregulation, it is reasonable to presume that the presentation of one or many 
dominant tumor-associated antigens is reduced due to overtrimming. In fact, this phenomenon has 
already been observed in melanoma and colorectal carcinoma (83, 84). 
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4.2 Possible mechanisms leading to ERAP1 overexpression  
After the identification of ERAP1 overexpression in HPV-induced malignancies, we decided to 
investigate possible mechanisms that could cause this overexpression. In recent years, nonsynonymous 
single nucleotide polymorphisms (SNPs) within ERAP1 have gained attention. In the inflammatory 
diseases ankylosing spondylitis (AS), Behçet’s disease and psoriasis, a strong association of MHC I 
alleles (HLA-B27, HLA-B51 and HLA-C6:02, respectively) and ERAP1 SNPs was found (75, 245, 
246). Interestingly, SNPs within ERAP1 do not only predispose for certain diseases but can influence 
enzymatic activity and expression levels. Therefore, a genomic sequencing analysis was performed to 
identify SNPs in ERAP1 of one HPV-negative (NOK), 4 HPV16-positive ERAP1 high expressing cell 
lines (CaSki, 866, SNU17 and SNU703) and two HPV16-positive cell lines with similar ERAP1 
expression to HPV-negative cells (SiHa and FK16A). The nonsynonymous SNPs (residue positions: 
12, 127, 276, 349, 528, 725 and 730) found in the tested cell lines were all already described as 
naturally occurring SNPs of ERAP1.         
 Concerning ERAP1 expression, ERAP1 variants harboring 528K were reported to be higher 
expressed than variants harboring 528R. Similarly, ERAP1 with 730Q was expressed at higher levels 
than with 730E (74, 221, 246). In our cell lines, both 528K and 730Q were present in low and high 
ERAP1 expressing cell lines, indicating that ERAP1 overexpression in our cell lines is not due to these 
SNPs. In cervical cancer, Mehta and colleagues show that a homozygosity of 56E/127P or the 
56K/127R haplotype combined with any other haplotype reduces survival to 50% (82). Furthermore, 
heterozygosity at position 127 or heterozygosity of the 56E/127P haplotype was significantly 
associated with normal protein expression. Haplotype combinations that were reported to be associated 
with reduced overall survival were found in none of the analyzed cell lines in this study. 
Heterozygosity of ERAP1 at position 127 was found in NOK and SNU703, but SNU703 was 
associated with a high ERAP1 expression whereas NOK had a normal ERAP1 expression level. 
E56/127P in combination with another haplotype that was linked to normal expression according to 
Mehta et al. (82) was found in NOK, SNU703 and FK16A, among which only NOK and FK16A have 
normal expression levels. In summary, ERAP1 expression – especially overexpression – in our cell 
lines cannot be explained by SNPs.        
 Besides an association of SNPs and ERAP1 expression, several but not all SNPs have an 
influence on its enzymatic activity. From a structural point of view, it was reported that residue 127 is 
located near domain junctions in the peptidase M1 domain, residues 276 and 528 both near domain 
junctions in domain III, residue 349 in the active site and residues 725 and 730 in the substrate binding 
cavity (82, 247, 248). It has been shown that SNPs distal from the active site can also affect function 
of ERAP1 (249). The enzymatic cycle of ERAP1 is strongly dependent on conformational changes 
between its domains. ERAP1 has an “open” and a “closed” state (see 1.1.4.1) mediating substrate 
binding and product release. Residue 528 affects conformational changes of ERAP1 since it is located 
at the beginning of domain III near to the hinge region. On the other hand, residue 730, located in the 
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substrate binding cavity, has an impact on substrate length selection. Given these facts, it is likely that 
amino acid variations at these positions change enzymatic functions of ERAP1. The influence of 
ERAP1 SNPs on the enzymatic activity has been investigated in numerous studies. In general, 127P, 
276M, 575N and 730E had a small or no effect on the trimming activity in vitro (71, 248, 250). On the 
contrary, Evnouchidou and colleagues provided experimental evidence that 730E leads to highly 
decreased presentation of an HLA-B27 epitope in vivo (72). Higher trimming activities were attributed 
to 528K, 528K/575N, 725R and 725Q/730E (203, 251, 252) whereas poor trimming activities were 
reported for 349V, 528R and 725Q (251, 253). Conversely, 349V was reported to have higher 
trimming activities in the Seliger laboratory (244). Garcia-Medel and colleagues (251) describe that 
variants containing the 575N SNP have a poorer trimming activity, which is in conflict with the 
observation that a combination of 528K /575N renders ERAP1 very active. According to the body of 
research on the impact of ERAP1 SNPs, there is clear evidence for the association of ERAP1 variants 
with functional consequences. However, the exact impact of SNPs on ERAP1 is very complex, which 
is reflected by discrepancies between the studies. These differences are likely due to different 
methodological approaches. For instance, earlier studies analyzed functions of single SNPs whereas 
later studies used naturally occurring alleles of ERAP1. Also different assays and protein purification 
techniques were employed in the studies and may have resulted in the different observed outcomes. In 
our cell lines, SNPs that were reported to confer high trimming activities to ERAP1 and SNPs 
associated with low trimming activities were found in both ERAP1-overexpressing cell lines and cell 
lines with normal expression. The cell lines CaSki, SNU17, SiHa and FK16A contain only variants 
reported to have a higher trimming activity.       
 The dysregulated expression of ERAP1 in HPV-mediated lesions could also be caused by 
effects of the HPV oncogenes. HPV E6 and E7 are constitutively expressed in HPV-positive malignant 
cells and maintain their malignant phenotype. Besides manipulating the cell cycle, E6 and E7 also 
have intracellular targets associated with immune escape (125). E6 and E7 can hamper the IFN 
signaling cascade at multiple steps (129, 235, 236, 254) as described in section 4.1. Interestingly, the 
E7 oncoprotein also has multiple targets within the APM. On the one hand, there is evidence that E7 
inhibits both PSMB9 and TAP1 expression on the transcriptional level and on the other hand E7 also 
represses the promoter of the MHC I heavy chain (133). Therefore, we investigated whether E6 and 
E7 play a role in ERAP1 expression. To test this, HPV16 E6 and E7 were knocked down in CaSki 
cells using a siRNA approach (209). ERAP1 expression was assessed after 72h. However, the level of 
ERAP1 expression remained unchanged, suggesting that neither E6 nor E7 affect ERAP1 expression. 
It cannot be ruled out that other viral proteins play a role in this context.    
 Analysis of ERAP1 SNPs and knockdown of HPV16 E6 and E7 did not elucidate the reason 
why ERAP1 is overexpressed in HPV-induced malignancies. Other mechanisms on the transcriptional 
level, such as mutations or DNA modifications in the promoter region, may play a role. For instance, 
two ERAP1-deficient melanoma cell lines share a mutation in the promoter of ERAP1 and it has been 
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demonstrated that this mutation leads to reduced transcriptional activity. This study showed that 
mutations in the ERAP1 promoter exist in a disease associated context (244). Another study analyzed 
the mechanism underlying ERAP1 downregulation observed in 15% of cervical cancer (255). The 
authors found a complete or partial loss of heterozygosity in 50% of cases with ERAP1 
downregulation. Epigenetic changes, namely the DNA methylation status of ERAP1 was analyzed as 
well, but this did not contribute to dysregulated expression (134, 244). Unfortunately, the molecular 
background of ERAP1 upregulation in tumors has not been studied so far, but is reasonable to assume 
that mechanisms for overexpression may take place on similar molecular levels as those for 
downregulation.         
 Additionally, there are hints that ERAP1 expression can be regulated on multiple levels, since 
discordance between mRNA and protein levels was detected already in a previous study (244), as well 
as in this thesis. Thus, not only transcriptional but also posttranscriptional processes could account for 
ERAP1 overexpression. Recently, a novel immune evasion mechanism of human cytomegalovirus 
(HCMV) has been unraveled (69). The authors identified a viral microRNA (miR-US4-1) which 
inhibited ERAP1 expression during viral infection, thereby hampering HCMV-specific CTL 
recognition of infected cells. MicroRNAs are involved in almost all developmental and pathological 
processes since they are critical regulators of gene expression and have the potential to induce or 
inhibit expression of a particular gene. In cancer, overexpression of oncogenic microRNAs or loss of 
tumor suppressor microRNAs has gained much interest, because it was demonstrated that these 
changes are sufficient to promote cancer development in vivo (256). Cellular or HPV-encoded 
microRNAs that influence ERAP1 expression have not yet been discovered, but it is possible that 
microRNAs with either a cellular or a viral origin might play a role in ERAP1 expression. In the 
context of HPV-induced malignancies, there are studies on dysregulation of cellular microRNA 
expression as well on HPV-encoded microRNAs (242, 257, 258). Cellular microRNAs have been 
identified that are altered in HPV-induced malignancies and these are mostly involved in cell cycle 
control (257, 258). The first papillomavirus encoded microRNAs were described in 2013 (242) and 
predicted targets are involved in cell cycle, cell adhesion and oncogenesis. It remains to be 
investigated if posttranscriptional processes, such as microRNAs, play an important role in ERAP1 
upregulation. 
 
 
 
 
 
 
DISCUSSION 
114 
4.3 Possible consequences of altered ERAP1 expression 
4.3.1 ERAP1 functions besides antigen processing 
After the discovery of ERAP1 in 1999 (57), multiple cellular functions have been ascribed to this 
aminopeptidase (61, 243). In Figure 4.1, the roles of ERAPs in peptide trimming, cytokine receptor 
shedding, post-natal angiogenesis and blood pressure are illustrated. In this chapter, the functions of 
ERAP1 not related to antigen processing will be discussed.    
 ERAP1 mediates cytokine receptor shedding (259-261), including shedding of tumor 
necrosis factor receptor 1 (TNFR1), IL-6 receptor alpha subunit (IL-6Rα) and type II IL-1 decoy 
receptor (IL-1RII). For this function, ERAP1 is associated with the plasma membrane as a type II 
integral membrane protein. The enzymatic activity of ERAP1 is not necessary for TNFR shedding but 
it rather supports the activity of the TNFR1 sheddase. On the contrary, IL-1RII and IL-6Rα shedding 
is dependent on the catalytic activity of ERAP1. Shedding of these receptors is important in the 
regulation of innate and inflammatory responses. IL-1RII shedding attenuates the bioactivity of IL-1 
by binding the cytokine and preventing binding to its membrane-bound receptor and subsequent 
intracellular signaling. Similarly, TNFR1 shedding decreases TNF signaling. Shedded IL-6Rα, 
however, prolongs the half-like of bound IL-6, thereby augmenting its effects (262). Thus, ERAP1 has 
the ability to orchestrate immune responses by influencing cytokine signaling. In this thesis, ERAP1 
expression was studied in cell lysates and immunohistochemistry. In immunohistochemical stainings, 
ERAP1 expression was strongly cytoplasmic and in some cases also perinuclear in normal and 
malignant cervical tissue and CaSki cells. Thus, a predominant role in cytokine receptor shedding in 
HPV-mediated malignancies can be excluded in the light of the results presented herein.  
 ERAP1 also plays a role in post-natal angiogenesis (263, 264). During the process of neo-
angiogenesis, new blood vessels are formed from already existing vessels. This process is achieved by 
proliferation and migration of endothelial cells (ECs). ERAP1 is expressed in ECs after stimulation 
with vascular endothelial growth factor (VEGF) and mediates G1/S transition during EC proliferation 
and also spreading of ECs during vessel formation. As this function of ERAP1 is limited to ECs (265), 
ERAP1 overexpression in the HPV16-positive cancer cells is unlikely to have an effect on 
angiogenesis.          
 Furthermore, ERAP1 is involved in blood pressure regulation through the renin-angiotensin 
system. For this purpose, ERAP1 is secreted from cells and cleaves angiotensin II to angiotensin III 
and IV (57, 266), thereby preventing an increase in blood pressure. Secreted ERAP1 has the same 
enzymatic functions as ER-resident ERAP1, but it has a different glycosylation pattern, which is 
formed during secretion (267). However, it is improbable that ERAP1-mediated regulation of blood 
pressure poses an advantage for cancer cells. Thus, we did not investigate mechanisms associated with 
this ERAP function. 
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Figure 4.1: ERAPs have multiple functions. ERAP1 and ERAP2 exert functions in many physiological processes. A. 
ERAPs perform the final trimming of peptides in the ER so that they perfectly fit into the MHC I binding groove. B. Cell 
membrane-associated ERAPs are involved in the shedding of cytokine receptors. C. ERAPs regulate post-natal angiogenesis 
in endothelial cells. D. Secreted ERAPs play a role in blood pressure regulation. Taken from (61). 
 
4.3.2 ERAP1 functions related to antigen processing 
4.3.2.1 Effects of ERAP1 on levels of HLA class I surface expression 
It is known that aberrant expression or activity of ERAP1 can lead to suboptimal peptide supply for 
HLA class I and thereby leads to altered stability and surface expression of HLA class I complexes 
(73, 268, 269). A siRNA-mediated knockdown of ERAP1 was established (see 3.3.1) to elucidate the 
effect of ERAP1 expression at similar levels as in HPV-negative cells. Former studies following 
similar research questions in the context of other epitopes also chose siRNA- or shRNA-mediated 
knockdown approaches (48, 63, 83, 84, 270-272). A complete knockout of ERAP1 was not desirable, 
since ERAP1 knockout changes the whole nature of the epitope repertoire on the cell surface (273) and 
also does not reflect the situation in normal epithelial cells. In the absence of ERAP1, surface       
MHC I:peptide complexes are unstable, because they are mostly loaded with N-terminally extended, 
poorly binding peptides. This also leads to a reduced MHC I surface expression by 15% up to 80%, 
depending on the respective MHC I:peptide complex. However, in this study the aim was to mimic the 
physiologic situation in nonmalignant cells, which is given by a lower ERAP1 expression but not 
ERAP1 absence. Normalization of ERAP1 expression to a protein expression similar to normal levels 
was successfully established in several HPV16-positive cell lines (see 3.3.1.1).   
 The impact of ERAP1 attenuation on surface HLA-A2 and HLA-A24 surface expression was 
investigated (see 3.3.1.2). HLA-A2 is one of the most common HLA class I types in the Caucasian 
population (223) whereas HLA-A24 is most abundant in the Asian population (274). Previous 
DISCUSSION 
116 
assessments of surface MHC I presentation upon ERAP1 knockdown led to contradictory results. One 
study reported decreased surface expression of murine MHC I Kk by 23% and Ld levels by 44% (270). 
On the contrary, another study describes an increase of overall HLA class I surface expression in HeLa 
cells upon ERAP1 attenuation (63). In a more recent study, the effect in 5 human tumor cell lines was 
tested (272). The authors demonstrated that inhibition of ERAP1 expression affects human tumor cell 
lines differently with either a decreased, unchanged or increased HLA class I surface expression. This 
is possibly due to the differing levels of ERAP1, i.e. if they were reduced, normally or overexpressed 
in the respective cancer cell. Moreover, it has been recently observed that ERAP1 knockdown 
improves rejection of RMA cells in mice mediated by NK cells indicating that ERAP1 affects innate 
immune responses as well (275). In a follow up study, it was shown, as expected, that cells with 
reduced MHC I expression (approximately 50%) are more susceptible to NK killing (272). In the 
present thesis, ERAP1 knockdown affected HLA class I (HLA-A2 and HLA-A24) surface expression 
differently in 6 human HPV16-positive cell lines, which is in accordance with previous studies.   
HLA-A2 surface expression was significantly reduced by 34% in CaSki cells while the change in the 
other cell lines was not significant. Interestingly, a lowered HLA class I expression does not 
necessarily lower CTL responses as shown by James et al. (84). Presentation of the immunodominant 
colon carcinoma epitope GSW11 was enhanced in spite of an overall decreased MHC I expression 
upon ERAP1 attenuation. Different effects of ERAP1 knockdown on MHC I surface expression are 
certainly also dependent on MHC I and ERAP1 alleles. Indeed, the interplay of ERAP1 and MHC I 
molecules seems to be very complex, because it was recently reported for the first time that ERAP1 
polymorphisms can influence the surface expression of HLA class I depending on the HLA subtype 
(271). Haroon and colleagues further complemented previous findings by demonstrating that ERAP1 
suppression by siRNA only led to an increase in HLA class I surface expression in cells expressing 
certain HLA-B27 subtypes, which are associated with AS.  
4.3.2.2 Effects of ERAP1 on the epitope repertoire 
To fully understand the influence of ERAP1 on the peptide repertoire, it is important to know its 
enzymatic properties. The trimming preferences of ERAP1 have been analyzed in multiple studies. It 
was not possible to find a chemical determinant that renders a substrate good or bad, because ERAP1 
is able to hydrolyze many residues from the N-terminus of peptides and bind peptides with different 
C-terminal residues. However, a preference profile of ERAP1 for its substrates could be defined. First, 
ERAP1 is known to have a preference for longer peptides (10 up to 16 amino acids) whereas short 
peptides with 8 to 9 residues, which have optimal length for MHC I, remain mostly untouched (63, 
66). In vitro trimming assays showed that ERAP1 spared 8-mers or had strongly reduced trimming 
activities compared to longer peptides (63, 66, 67). In addition to in vitro trimming assays, there is 
experimental evidence in cells demonstrating that 8-mers are protected from ERAP1. For this reason, 
the aminopeptidase is often described to have the unique property to act as a “molecular ruler” (66). 
Further, ERAP1 prefers to bind peptides with a hydrophobic C-terminal residue such as isoleucine, 
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leucine or valine (66). At the N-terminus, ERAP1 shows highest catalytic activities towards 
hydrophobic amino acids such as leucine, methionine, phenylalanine, isoleucine and tyrosine (66, 
276). With this in mind, it is not surprising that altered ERAP1 expression and function has most 
profound immunological effects with certain HLA molecules, whose peptide binding motifs are 
particularly sensitive to ERAP1 trimming. 
Examples of autoimmune diseases 
The three autoimmune diseases ankylosing spondylitis (AS), Birdshot Chorioretinopathy and Behçet’s 
disease are associated with certain ERAP1 variants and HLA class I types. In an effort to unravel the 
pathogenesis mechanism of AS, a model of altered ERAP1 trimming activity was proposed. ERAP1 
variants in patients were shown to mostly have either lower or higher trimming activities compared to 
variants isolated from healthy people (73). This imbalanced ERAP1 activity results in both cases in 
aberrant HLA-B27:peptide complexes and presentation. It has been proposed that aberrant forms of 
HLA-B27 at the cellular surface may induce inflammatory immune responses mediated by Th17 cells 
and innate immune cells (268), ultimately resulting in the symptoms of AS.    
 Birdshot Chorioretinopathy is strongly associated with HLA-A29 and genetic studies revealed 
that ERAP1 and ERAP2 may be genetic risk factors. In fact, it has been demonstrated that the      
HLA-A29 peptidome is influenced by ERAP1 variants, suggesting that certain ERAP1 SNPs 
predispose for the disease by altering the peptidome (74). Follow up studies will have to elucidate the 
consequences of this altered expression and maybe also other pathogenic mechanisms that drive 
disease progression.           
 In addition, the ERAP1 locus has been identified in combination with HLA-B51 as a risk 
factor for Behçet’s disease, a systemic vasculitis (245). Recently, the peptidome of HLA-B51 was 
studied (277) revealing that ERAP1 shapes the peptidome of HLA-B51. Taken together, the 
involvement of ERAP1 in inflammatory diseases stresses its pivotal role in editing immune responses 
by antigen processing and influencing folding and stability of HLA class I:peptide complexes. One or 
both of these issues may have a strong impact on the pathogenesis of these inflammatory diseases 
(269).  
Examples of viral diseases 
There is experimental evidence that ERAP1 affects immune responses to viruses such as HIV and 
CMV. A striking example for this phenomenon comes from the HIV research field. HIV has a high 
mutation rate in order to be able to evade from the host’s immune system. The N-terminal region of a 
dominant epitope from the Gag protein is often mutated at one residue from alanine to proline. This 
residue change inhibits ERAP1 from trimming the precursor peptide and eventually suppresses the 
presentation of the dominant epitope, leading to CTL escape (68). This mechanism demonstrates how 
a virus-associated mutation exploits the specificity of ERAP1, because peptides with a proline (P) at 
position 2 (consensus motif: X-P-Xn) are poor substrates for ERAP1. These peptides are not 
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transported into the ER by TAP (278, 279) suggesting that they enter the ER as longer precursor 
peptides (motif: Xn-P-Xn) and are dependent on further trimming by ERAP1. For example, the murine 
MHC I molecule Ld harbors this motif. Indeed, the effect of ERAP1 deficiency on Ld expression is 
very strong, with a loss of surface expression of up to 80% (273). There also is experimental evidence 
that ERAP1 has an impact on CTL responses towards one peptide from LCMV (NP396-404) but not to 
another one (GP33-41) originating from the same virus (224). CTL responses against NP396-404 were 
strongly inhibited in ERAP1 knockout mice, whereas CTL responses against GP33-41 were not 
impaired. The authors from an elegant study analyzing the impact of different peptidases on the 
generation of the CMV epitope pp65495-503 reported that downregulation of ERAP1 strongly impairs 
presentation of this immunodominant epitope (48). As already mentioned in chapter 4.2, human CMV 
encodes for a microRNA that is targeting ERAP1 (69). Strikingly, CTL responses against 5 of 6 CMV 
epitopes (restricted to different HLA class I types) were inhibited by microRNA-mediated ERAP1 
attenuation. 
Examples in cancer 
Studies from recent years demonstrate the importance of a thorough analysis of epitope 
processing/presentation, which is indispensable for antigen-specific cancer immunotherapy. ERAP1 
has been shown to play a role in the presentation of different clinically important tumor-associated 
epitopes. A study on the melanoma epitope MART126-35 supports the hypothesis that ERAP1 can 
destroy tumor-associated epitopes. ERAP1 downregulation rescues MART126-35 presentation reflected 
by enhanced anti-tumor CTL responses (83). Similarly, the presentation of the potent colon carcinoma 
epitope GSW11 is strongly enhanced when ERAP1 is attenuated (84, 86). These findings fit to studies 
showing that melanoma and colorectal adenocarcinoma show elevated ERAP1 expression when 
compared to nonmalignant counterparts (see 4.1). It is, thus, not surprising that the development of an 
ERAP1-specific inhibitor is an attractive tool for enhancing immunotherapies and is currently ongoing 
(85, 86, 280, 281). However, the efficacy and of course toxicity of newly found inhibitors remains to 
be studied in vitro and in vivo. 
ERAP1 and HPV16-derived epitopes 
In the light of the concept of epitope destruction by ERAP1 overexpression in melanoma and colon 
cancer cells, we investigated the role of ERAP1 overexpression in the generation of HPV16 E6 and 
E7-derived epitopes. Our first approach was targeted mass spectrometry (MS) analysis of 17 HLA-A2-
restricted HPV16 E6 and E7 peptides in CaSki cells. These peptides were chosen because their MS 
detection was already established in the laboratory. The targeted MS approach was primarily designed 
to investigate absolute differences in presentation, i.e. to see whether there was a loss of peptides in 
ERAP1 overexpressing cells. With this approach we did not observe a loss of any of the 17 selected 
HLA-A2 HPV16 E6 and E7-derived peptides. As explained above, ERAP1 is strict in its length 
dependence. In this context, it has to be noted that half of the selected peptides were short 8- or 9-
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mers, which are expected to be protected from ERAP1-trimming due to its “molecular ruler” function. 
Thus, it is not surprising to see no effects on this group of peptides. Moreover, a recent study showed 
that there is a considerable proportion of the peptide repertoire that is not ERAP1-dependent (282). 
This may explain why we did not observe a difference in the presentation of the other half of the 
selected peptides in cells with attenuated ERAP1 expression compared to ERAP1-overexpressing 
cells.           
 Another approach to assess HPV16 epitope presentation is the generation of peptide-specific T 
cell lines and cytotoxicity assays. Peptide-specific functional T cells can sense even a small variance 
in peptide presentation. For T cell line experiments, our choice of peptides was limited, because we 
had to choose peptides that were shown to have strong memory responses in our donors. We were able 
to generate T cell lines against the HLA-A2-restricted 11-mer E781-91, the HLA-A24-restircted 8-mer 
E769-76 and the HLA-A24-restricted 10-mer E690-99. These peptides were not contained in the MS 
analysis. Given the length preferences of ERAP1 we expected to observe differences in epitope 
presentation only in experiments with the 10-mer and 11-mer. The HLA-A24-restricted 8-mer E769-76 
is likely too short to be prone to ERAP1 trimming. Furthermore, for HLA-A24 we had to use a target 
cell line that does not endogenously overexpress ERAP1 (FK16A) due to limited choice of HLA-A24-
positive HPV16-positive cell lines. ERAP1 expression levels in FK16A are comparable to HPV-
negative cell lines. Indeed, no enhanced killing of these cells after ERAP1 knockdown was observed. 
On the contrary, we observed reduced killing of FK16A cells in cytotoxicity assays using E769-76-
specific and E690-99-specific T cell lines when ERAP1 expression was attenuated (see 3.3.3.2). It is 
likely that the levels of ERAP1, when further knocked down in FK16A cells that express ERAP1 at 
low levels anyway, are no longer sufficient for proper epitope presentation.    
 In contrast, in the last experiment, employing a T cell line against the 11-mer E781-91 with 
naturally ERAP1-overexpressing CaSki as target cells, differences in killing were more likely to occur. 
Indeed, CaSki cells were killed better by this T cell line when ERAP1 expression was attenuated. 
Conversely, killing of 866 target cells (which also overexpress ERAP1) by the same E781-91-specific T 
cell line was not affected by ERAP1 attenuation. The difference in killing of these two target cell lines 
by the same T cell line may at least be partly explained by different ERAP1 alleles within these cells. 
As described in chapter 4.2, the enzymatic function of ERAP1 can be determined by SNPs. Thus, it is 
possible that ERAP1 variants in the CaSki cell line have, for instance, a higher binding affinity or 
trimming activity for E781-91, so that overexpression of the peptidase results in destruction of the 
peptide. Indeed, the ERAP1 alleles in CaSki cells only harbor SNPs that are associated with a higher 
trimming activity in the majority of studies. In addition, ERAP1 knockdown in CaSki cells had the 
strongest effect on HLA-A2 surface expression levels in comparison to other cell lines. Thus, there is a 
fundamental difference in CaSki cells compared to the 866 cell line considering ERAP1 alleles and the 
interplay with HLA-A2. The exact catalytic mechanism of ERAP1 is not known, but a “bind-trim-
release” mechanism model is suggested, involving high substrate on and off rates (83, 84). Based on 
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this model, ERAP1 hydrolyzes one amino acid at a time and releases its substrate. The released 
peptide has either the chance to bind to MHC I or it will bind to ERAP1 again and the next amino acid 
will be cleaved. Thus, MHC I and ERAP1 compete for the available peptide pool and this competition 
decides about the fate of a peptide. In case of a high affinity peptide, the peptide would bind stably to 
MHC I and is protected from further trimming. On the contrary, low affinity peptides briefly bind to 
MHC I and are released again, rendering them susceptible to another round of trimming by ERAP1 
before they are efficiently bound to the MHC I binding groove. Indeed, GSW11 and MART126-35, the 
peptides mentioned earlier to be strongly influenced by ERAP1, have poor binding affinities for   
MHC I, supporting the “bind-trim-release” mechanism (83, 84). Interestingly, the E781-91 epitope also 
has a weak binding affinity to HLA-A2 (227). It is thus very likely that this peptide is destroyed in 
ERAP1 overexpressing cells. As we worked with T cell lines from healthy donors, this indicates that 
the memory response was formed during an early stage of infection, which was subsequently cleared. 
In immunohistochemical stainings, we observed that ERAP1 expression increased with the disease 
stage. Thus, presentation of E781-91 may decrease with the disease stage while ERAP1 expression 
increases, leading to removal of a target of an existing memory response.    
 In conclusion, ERAP1 overexpression can hamper some HPV16-specific CD8 T cell 
responses and hence possibly represents a novel immune evasion mechanism of HPV-induced 
malignancies. 
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4.4 Summary and outlook 
Induction of potent antitumor-specific CTL responses is crucial to develop therapeutic anti-HPV 
vaccines. The efficacy of these CTLs against HPV-induced lesions or tumors is significantly 
determined by antigen presentation of the malignant cells. In the scope of this thesis, it was 
demonstrated that ERAP1 is upregulated in HPV16-positive tumor cells, CIN lesions and established 
cervical cancer. ERAP1 plays a key role in editing the HLA class I peptidome by generating but also 
destroying HLA-binding peptides. It was shown by targeted MS detection that ERAP1 overexpression 
has no major influence on the presentation of a panel of 17 HLA-A2 HPV16 E6 and E7 epitopes. 
However, T cell assays using other target peptides revealed that presentation of some HPV16-derived 
epitopes is influenced by ERAP1 expression levels. Remarkably, a T cell line against an 11-mer E7 
peptide showed increased killing upon ERAP1 attenuation in one HPV16-positive tumor cell line, 
indicating that destruction of this epitope may happen when ERAP1 is expressed at high levels. This 
implies that the overexpression of ERAP1 in advanced HPV disease stages can alter the presentation 
of HPV16-derived antigens. In conclusion, the results of this thesis highlight the importance of 
thoroughly studying the APM and the functional consequences of changes on the epitope repertoire 
and distinct epitopes. This analysis should always precede antigen choice of peptide-based anti-tumor 
immunotherapies, since the success of these therapies is strongly dependent on the presence of the 
exact peptide on target cells. The inhibition of ERAP1 might enhance the efficiency of 
immunotherapies in cases where clinically relevant epitopes are destroyed by the peptidase. 
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6 Abbreviations 
4-1BB tumor necrosis factor receptor superfamily member 9 (TNFRSF9), 
CD137 
A adenine 
AA amino acid 
ACN acetonitrile 
APC antigen presenting cell 
APM antigen processing machinery 
β2m β2-microglobulin 
bp base pairs 
BPV bovine papillomavirus 
BSA bovine serum albumin 
C cytosine 
C-terminus carboxyl-terminus 
°C degree Celsius 
CAD collision gas 
CALR calreticulin 
CANX calnexin 
CCR CC chemokine receptor 
CD cluster of differentiation 
cDNA complementary desoxyribonucleic acid 
CFSE carboxyfuorescein 
CIN cervical intraepithelial neoplasia 
CMV cytomegalovirus 
ConA concanavalin A 
Cq quantification cycle 
CTL cytotoxic T lymphocyte 
CTLA cytotoxic T lymphocyte associated antigen 
CXCR5 CXC motive chemokine receptor 
Da Dalton 
DC dendritic cell 
ddH2O double distilled water 
dH2O deionized water 
DMSO dimethylsulfoxid 
dNTP deoxynucleoside triphosphate 
DNA deoxyribonucleic acid 
DRiP defective ribosomal product 
dsRNA double stranded RNA 
DTT dithiothreithol 
E6-AP E6-associated protein 
EBV Epstein-Barr virus 
EC endothelial cell 
ECL enhanced chemiluminescence 
EDTA ethylenediaminetetraacetic acid 
EGF epidermal growth factor 
ELISpot enzyme linked immunospot 
ER endoplasmic reticulum 
ERAP endoplasmic reticulum aminopeptidase  
ERAAP endoplasmic reticulum aminopeptidase associated with antigen 
processing 
ESI electron spray ionization 
et al. et alii, at aliae, et alia 
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FA formic acid 
FACS fluorescence-activated cell sorting 
FAM fluorescein amidite 
FCS fetal calf serum 
FSC forward scatter 
FDA Food and Drug Administration 
FITC fluorescein isothiocyanate 
Foxp3 forkhead box p3 
G guanine 
Gag group-specific antigen 
GAG glycosaminoglycan 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
Gy Gray 
h hour 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV human immunodeficiency virus 
HLA human leukocyte antigen 
HNSCC head and neck squamous cell carcinoma 
HPRT1 hypoxanthine-guanine phosphoribosyltransferase 
HPV human papillomavirus 
HRP horseradish peroxidase 
HSPG heparan sulfate proteoglycan 
hTERT human telomerase reverse transcriptase gene 
ICOS inducible T cell co-stimulator 
ID inner diameter 
i.e. id est 
IFN interferon  
Ig immunoglobulin 
IL interleukin  
IL-1RII type II IL-1 decoy receptor 
IL-6Rα IL-6 receptor alpha subunit 
IP immunoprecipitation 
IPO8 importin 8 
IRAP insulin-regulated aminopeptidase 
IRF3 interferon regulatory factor 3 
iTreg induced regular T cell 
kb kilobase 
kDa kilo Dalton 
l liter 
LC-MS liquid chromatography-mass spectrometry 
LFA leukocyte function antigen 
LLO listeriolysin O 
LPS lipopolysaccharide 
M molarity 
MACS magnetic-activated cell sorting 
MAP mitogen-activated protein 
MDSC myeloid-derived suppressor cells 
MFI mean fluorescence intensity 
Mg magnesium 
MHC major histocompatibility complex 
min minute 
MIP-3α macrophage inflammatory protein 3α 
ml milliliter 
µl microliter 
ABBREVIATIONS 
143 
mM millimolar 
Mo-DCs monocyte-derived dendritic cells 
MPLA monophosphoryl lipid A 
mRNA messenger ribonucleic acid 
MS mass spectrometry 
MVA modified vaccinia virus ankara 
NK natural killer cell 
N-terminus amino terminus 
nano-UPLC-MS nano ultraperformance liquid chromatography mass spectrometry 
nm nanometer 
NP-40 nonyl phenoxypolyethoxylethanol 
nTreg natural regulatory T cell 
OD optical density 
ORF open reading frame 
OX40 tumor necrosis factor receptor superfamily member 4 (TNFRSF4), 
CD134 
P proline 
PAGE polyacrylamide gel electrophoresis 
PBMC peripheral blood mononuclear cell 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PDIA3 protein disulfide isomerase A3 
PFA paraformaldehyde 
PGK1 phosphoglycerate kinase 1 
pH pondus hydrogenii 
PHA phytohemagglutinin 
pHFK primary human foreskin keratinocytes 
pHK primary human keratinocytes 
PLC peptide loading complex 
PMSF phenylmethylsulfonylfluorid 
PPIA peptidylprolyl isomerase A 
pRB retinoblastoma protein 
PRR pattern recognition receptor 
PSMA proteasome subunit alpha 
PSMB proteasome subunit beta 
PSME proteasome activator subunit 
PV papillomavirus 
qRT-PCR quantitative real-time PCR 
RNA ribonucleic acid 
ROS reactive oxygen species 
RRP recurrent respiratory papillomatosis 
rpm rounds per minute 
RT room temperature 
RT-PCR real-time polymerase chain reaction 
SCC squamous cell carcinoma 
SCX strong cation exchange chromatography 
SD standard deviation 
SDS sodium dodecyl sulfate 
sec seconds 
SFU spot forming units 
siRNA small interference RNA 
SLP synthetic long peptides 
SNP single nucleotide polymorphism 
SSC side scatter 
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T thymine 
TCM central memory T cell 
TEM effector memory T cell 
TFH follicular helper T cell 
TAM tumor-associated macrophages 
TAP transporter associated with antigen processing 
Taq Thermus aquaticus 
TCR T cell receptor 
TFA trifluoroacetic acid 
TGF transforming growth factor 
Th helper T cell 
TNF tumor necrosis factor 
TNFR tumor necrosis factor receptor 
TOP thimet oligopeptidase 
TPP tripeptidyl peptidase 
Tris Tris(hydroxylmethyl)-aminoethane 
Treg regulatory T cell 
TYK2 tyrosine kinase 2 
U unit 
UPLC ultra performance liquid chromatography 
URR upstream regulatory region 
UV ultraviolet 
V Volt 
VEGF vascular endothelial growth factor 
VIN vulvar intraepithelial neoplasia 
VLA-4 very late antigen 4 
VLP virus-like particle 
W Watt 
WHO World Health Organization 
x times, -fold 
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7 Appendix 
Table 7.1: Quality control parameters for qRT-PCR. The quality control parameters employed by LinRegPCR and qBase 
plus are summarized below. 
LinRegPCR 
Correlation coefficient (R2) > 0.996 
Point included in linear regression ≥ 4 
Mean efficiency per amplicon Exclude wells without amplicon 
Exclude wells without plateau 
Exclude wells if outside 15% of group median 
qBase plus  
Replicate variability (Cq) < 0.5 
Reference target stability – geNorm M < 0.9 
Reference target stability – CV < 0.3 
Data exclusion criteria (Cq) > 40 
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Figure 7.1: PCR efficiencies of the qRT-PCR screen calculated by LinRegPCR. Individual calculated mean PCR 
efficiencies in the constitutive APM expression screening (A) and after IFNγ treatment (B). A Individual calculated PCR 
efficiencies that were used for the amplicon mean efficiency calculation. Each dot represents the PCR efficiency of a single 
reaction well. B Each dot represents the calculated mean PCR efficiency of the corresponding amplicon per cell line. The 
amplicon mean PCR efficiencies were calculated from triplicates of both the untreated and IFN-γ treated groups for each cell 
line. GAPDH = glyceraldehyde 3-phosphate dehydrogenase, PGK1 = phosphoglycerate kinase 1, IPO8 = importin 8, PPIA = 
peptidylprolyl isomerase A, TAPBP = tapasin, CANX = calnexin, CALR = calreticulin  
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Figure 7.2: Constitutive expression of MHC I associated genes on the mRNA level. Total RNA was purified from cells, 
reverse transcribed to cDNA and analyzed for APM component expression by qRT-PCR using TaqMan® probes. PCR 
reactions were run in triplicates. At least three of the following genes were used as internal reference: GAPDH, PGK1, PPIA 
and IPO8. Gene expression was calibrated to the NOK cell line. All quantitative qRT-PCR data were processed by 
LinRegPCR and data management was done by qbasePLUS 2. Blue bars represent data from HPV-negative cell lines. Data is 
plotted as ± SD.  
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Figure is continued on the following page 
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Figure 7.3: Constitutive expression of peptide loading complex associated genes on the mRNA level. Total RNA was 
purified from cells, reverse transcribed to cDNA and analyzed for APM component expression by qRT-PCR using TaqMan® 
probes. PCR reactions were run in triplicates. At least three of the following genes were used as internal reference: GAPDH, 
PGK1, PPIA and IPO8. Gene expression was calibrated to the NOK cell line. All quantitative qRT-PCR data were processed 
by LinRegPCR and data management was done by qbasePLUS 2. Blue bars represent data from HPV-negative cell lines. 
Data is plotted as ± SD. 
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Figure 7.4: Constitutive expression of proteasome associated genes on the mRNA level. Total RNA was purified from 
cells, reverse transcribed to cDNA and analyzed for APM component expression by qRT-PCR using TaqMan® probes. PCR 
reactions were run in triplicates. At least three of the following genes were used as internal reference: GAPDH, PGK1, PPIA 
and IPO8. Gene expression was calibrated to the NOK cell line. All quantitative qRT-PCR data were processed by 
LinRegPCR and data management was done by qbasePLUS 2. Blue bars represent data from HPV-negative cell lines. Data is 
plotted as ± SD. 
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Figure is continued on the following page 
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Figure 7.5: Constitutive expression of immunoproteasome associated genes on the mRNA level. Total RNA was 
purified from cells, reverse transcribed to cDNA and analyzed for APM component expression by qRT-PCR using TaqMan® 
probes. PCR reactions were run in triplicates. At least three of the following genes were used as internal reference: GAPDH, 
PGK1, PPIA and IPO8. Gene expression was calibrated to the NOK cell line. All quantitative qRT-PCR data were processed 
by LinRegPCR and data management was done by qbasePLUS 2. Blue bars represent data from HPV-negative cell lines. 
Data is plotted as ± SD. 
 
 
 
 
Figure 7.6: Primer positions used for ERAP1 sequencing. The ERAP1 gene (2826bp) was sequenced by GATC Biotech 
using at least five of the indicated primers. The positions of forward primers (F) are shown above and the positions of reverse 
primers (R) are shown below the line representing the ERAP1 gene. The primer sequences are given in the method section 
(2.1.10).  
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Table 7.2: Cell lines with their HLA type and designated HPV16 variant including nucleotide and amino acid 
exchanges in comparison to the HPV16 reference sequence. The first column indicates the cell line, the second its HLA 
class I type types, the third the identified HPV16 variant if the cell line is HPV16-positive and the last two columns 
nucleotide exchanges in the E6 and E7 open reading frame (ORF), respectively, that result in a missense mutation. Resulting 
amino acid changes are included in (). E6 and E7 mutations are taken from Dr. Stephanie Hoppe (194). HPV16 variant 
nomenclature is derived from Robert D. Burk (283). n.a. = not applicable 
Cell line HLA class I types HPV16 variant  Exchanges within 
E6 ORF 
Exchanges within 
E7 ORF 
2A3 A*01:01, -;  
B*15:07, - 
European Prototype 1 - - 
866 A*02:01, A*68:01; 
B*15:01, B*27:05 
African-2 G132T (R10I), 
C143G (Q14D in 
combi), G145T 
(Q14D in combi), 
C335T (H78Y) 
A647G (N29S) 
915 A*03:01, - ;  
B*14, -  
European Prototype 1 - - 
93VU147T A*03:01, -; 
B*07:02, - 
European Prototype 1 - - 
C33A A*02:01, A*11:01; 
B*07:02, B*44:02 
   
C66-3 A*02:01, A*30:02; 
B*18:01, B*35:03 
European Prototype 1 T350G (L83V) - 
C66-7 A*02:01, A*30:02; 
B*18:01, B*35:03 
European Prototype 1 T350G (L83V) - 
CaSki A*02:01, A*03:01; 
B*07:02, B*37:01; 
C*07, - 
European Prototype 2 A131G (R10T), 
T350G (L83V)  
- 
FK16A A*01:01, A*24:02; 
B*07:02, B*0801 
European Prototype 1 - - 
Goe A*01:01, - ; 
B*37:01, - 
European Prototype 1 - - 
HaCat A*31:01, -;  
B*40:01, B*51:01 
   
HPK1A  A*02:01, A*03:01; 
B*40:01,B*55:01 
European Prototype 1 - - 
Mar A*02:01, - ;  
B*27:02, -; 
C*02:02 ,- 
European Prototype 1 - n.a. 
MRIH196 A*02, A*03:01; 
B*07:02 , B*51:01 
European Prototype 1 T350G (L83V)  - 
NOK A*02:03, A*11:01; 
B*13:01, B*38:02 
   
RiSh A*24:02, A*26:01; 
B*35:03, B*51:08; 
   
SCC090 A*02:01, A*03:01; 
B*44:03, B*51:01 
European Prototype 2 A131G (R10T), 
T350G (L83V)  
- 
SCC152 A*02:01, A*03:01; 
B*44:03, B*51:01 
European Prototype 2 A131G (R10T), 
T350G (L83V)  
- 
SCC154 A*25:01, -;  
B*44:02, B*44:03 
Asian-American G145T (Q14D), 
C335T (H78Y), 
T350G (L83V), 
- 
SiHa A*24:02, - ; 
B*40:02, - ; 
C*03, -  
European Prototype 1 T350G (L83V), 
A442C (E113D)  
A645C (L28F) 
SNU1000 A*02:01, A*11:01; 
B*40:02, - 
European (Asian) T178G (D25E), 
T183G (I27R) 
A647G (N29S) 
SNU1005 A*24:02, - ;  
B*52:01, - 
European (Asian) T178G (D25E)  A647G (N29S) 
SNU1160 A*24:02, - ;  
B*13:01, - 
   
SNU1299 A*02:01, A*33:03; 
B*27:05, B*44:03 
Asian-American G145T (Q14D), 
C335T (H78Y), 
T350G (L83V), 
- 
SNU17 A*02:06, - ,  
B*48:01, - 
European (Asian) T178G (D25E)  A647G (N29S) 
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SNU703 A*02:01, A*02:06; 
B*35:01, B*40:06 
European (Asian) T178G (D25E)  A647G (N29S), 
UDSCC2  A*25:01, - ;  
B*18N  
European Prototype 1 - C712A (H51N) 
UMSCC47 A*01:01, A*23:01; 
B*37:01, B*45:01 
African-2 G132T (R10I), 
C143G (Q14D), 
G145T, G188C 
(E29Q), C285G 
(A61G), C335T 
(H78Y) 
A647G (N29S) 
 
 
Table 7.3: Blood donor characteristics and HLA types.  
 
Donor Gender Age HLA class I HLA Class II 
1 female 34 A*01:01, A*02:01; 
B*35:08, B*44:02; 
C*05:01, C*06:02 
DRB1*01:01, 
DRB1*04:03; 
DQB1*03:02, 
DQB1*05:01; 
DPB3*04:01; 
DPB4*04:02 
2 female 39 A*24:02, A*26:01; 
B*35:03, B*51:08 
DRB1*04:08, 
DRB1*13:01; 
DQB1*03:04, 
DQB1*06:03; 
DRB3*02:02; 
DRB4*01; 
DPB1*09:02, 
DPB1*15:01 
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Figure 7.7: Successful detection of HPV16 peptides E777-86 RTLEDLLMGT and E781-90 DLLMGTLGIV on CaSki 
cells by targeted LC-MS3 analysis in HLA-A2 IP samples. Samples were subjected to Seppak cartridge purification and 
subsequently to LC-MS3 analysis on a nanoAcquity UPLC-QTrap6500 platform. A. Extracted ion chromatogram for 
fragments: b5 (582.80/615.31), b7 (582.80/841.48) and b8 (582.80/988.51) for peptide E777-86 RTLEDLLMGT detected in the 
CaSki IP sample (pointing upwards) and its synthetic counterpart (pointing downwards). B. Extracted ion chromatogram for 
fragments: y6 (524.29/559.35), y7 (524.29/706.38), b8-H2O (524.29/799.40) and b9 (524.29/930.49) for peptide E781-90 
DLLMGTLGIV detected in the CaSki IP sample and its synthetic counterpart. C. MS3 spectrum for fragment b7 
(582.80/841.48) corresponding to the detected peptide E777-86 in the IP sample and its synthetic counterpart. D. MS
3 spectrum 
for fragment b8-H2O (524.29/799.40) corresponding to the detected peptide E781-90 in the IP sample and its synthetic 
counterpart. Only one MS3 spectrum per peptide is displayed for clarity reasons. 
 
